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Summary 
 
 
In recent years, genome wide association studies (GWAS) have established that 
common genetic variation plays an important role in complex brain disorders, such 
as autism spectrum disorder, schizophrenia and Alzheimer’s disease. However, as 
the vast majority of GWAS risk loci are located in poorly characterised non-coding 
regions, interpretation of GWAS data is difficult. As very few associations can be 
attributed to effects on protein-coding sequence, the majority of common risk loci for 
complex brain disorders are believed to operate through effects on gene regulation.   
 
In order to elucidate genetic risk mechanisms for complex brain disorders, it is 
important to establish in which cell types these risk loci are operating. Microglia are 
the primary immune cell of the central nervous system and are important regulators 
of brain function throughout life. As such, there has been growing interest in the 
potential role of microglia in brain disorders. One means of interpreting the function 
of the non-coding genome in a cell of interest is to measure the cell’s chromatin 
landscape. For example, the assay for transposase accessible chromatin with 
sequencing (ATAC-seq) maps regions of ‘open’ chromatin, which have the potential 
to regulate gene expression through binding of transcription factors.  
 
In this thesis, I use ATAC-seq to map open chromatin in adult ex vivo microglia, 2nd 
trimester foetal microglia, and in vitro human cell models of microglia. I then integrate 
this with complex brain disorder GWAS data to investigate whether gene regulatory 
processes in human microglia contribute to genetic risk for complex brain disorders. 
I find evidence that risk variants for late onset Alzheimer’s disease, autism spectrum 
disorder, bipolar disorder, major depressive disorder and schizophrenia are enriched 
within regulatory regions utilised by foetal and / or adult microglia, suggesting a 
primary role for this cell type in these conditions. Using the electrophoretic mobility 
shift assay, I further show that two single nucleotide polymorphisms associated with 
Alzheimer’s disease, and within regions of open chromatin in adult microglia, alter 
binding of protein from microglial nuclei.   
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1 General Introduction 
 
1.1 Definition of brain disorders 
 
The practical and theoretical core of this thesis centres on leveraging functional 
genomic data derived from a particular brain cell to interpret genetic data derived from 
patients with disorders of the brain. These disorders include schizophrenia, autism 
spectrum disorder, attention deficit hyperactivity disorder, late onset Alzheimer’s 
disease, bipolar disorder and major depressive disorder. For the purposes of this 
thesis, the terminology I will use to collectively describe these conditions is ‘complex 
brain disorders’, or simply ‘brain disorders’.  
 
At certain times during the text I use additional terms, such as psychiatric, 
neurodevelopmental or neurodegenerative, as a means to sub-characterise brain 
disorders; however, I acknowledge that these terms can be ambiguous and often 
mean different things in different settings. For example, in the latest release of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM), DSM-V, a 
neurodevelopmental disorder is defined as a disorder where psychopathological 
symptoms have a childhood or adolescent age of onset (1). As such, autism spectrum 
disorder and attention deficit hyperactivity disorder are characterised as 
neurodevelopmental disorders, but, schizophrenia is not on the basis that psychotic 
symptoms for schizophrenia (usually) first manifest in early adulthood (schizophrenia 
is classified as a psychotic disorder in DSM-V; 1). By contrast, in the scientific 
literature, schizophrenia is often cited as a neurodevelopmental disorder, due a 
variety of epidemiological, neurobiological and now genetic data suggesting a 
prenatal component to this condition (2–5). In this thesis, I will refer to schizophrenia, 
bipolar disorder and major depressive disorder as ‘psychiatric disorders’, autism 
spectrum disorder and attention deficit hyperactivity disorder as ‘neurodevelopmental 
disorders’ and Alzheimer’s disease as a ‘neurodegenerative disorder’. 
 
In the absence of robust biomarkers for these conditions, classification  continues to 
be based primarily on a descriptive psychological examination (6). The core 
diagnostic features for each of the brain disorders I consider in this thesis are as 
follows. 
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Autism spectrum disorder (ASD) is a developmental disorder with a childhood onset 
and is characterised by deficits in social communication and behaviour (7). 
Prevalence of ASD is estimated at ~1-1.5% worldwide and affects children and adults 
(8,9). In children with ASD, diagnostic features can include delayed speech 
development, the use of simple repetitive phrases rather than structured sentences 
when verbalising or being unresponsive when spoken to or asked to perform a task. 
Non-verbal communication can also be diminished such that individuals make little or 
no eye contact, and do not gesticulate normally, when interacting with others. 
Children with ASD also have difficulty understanding and forging relationships and 
prefer to play alone. Regarding behavioural abnormalities, activities are usually 
stereotyped and highly repetitive, such as hand flapping or rocking to-and-fro 
continuously. Play is also unimaginative such that toys or objects are repetitively 
organised by colour or size. ASD patients also demonstrate an intolerance to any 
alteration in their normal routine and can exhibit extreme distress when normal rituals 
are deviated from (10).  
 
Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder that 
affects 5% of children and adolescents worldwide (11) and is characterised by 
inattentiveness and hyperactive or impulsive behaviour. Suffers may be unable to 
focus on specific tasks for extended periods and they constantly lose interest and 
make careless mistakes. Persistent fidgeting, excessive talking and movement, and 
acting without thinking are also common features. Symptoms often result in social 
and disciplinary problems causing isolation from their peer group and educational 
underachievement (12). For an ADHD diagnosis to be given, symptoms must present 
before the age of 12 (and be continuous for at least 6 months), they must occur in at 
least two environmental settings (i.e. at school and at home) and considerably impact 
social and educational progress. Although symptoms can partially or fully recede in 
adulthood it is estimated that 2.5% of adults remain symptomatic (13). Before 
adulthood, ADHD is 4-times more likely to affect males, but this sex-bias normalises 
after adolescence (11).  
 
Bipolar disorder (BPD) is an episodic illness characterised by polarised alterations of 
mood, energy level and behaviour which manifest as periods of mania or depression. 
There are two major classifications of BPD: Bipolar I which involves at least one 
episode of mania, and BPD II which is characterised by at least one depressive 
episode and one hypomanic episode (i.e. a subthreshold period of mania; 14). During 
manic episodes, individuals with BPD are commonly hyperactive, have delusions of 
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grandeur and have a reduced need to sleep. In depressive episodes, patients 
become socially withdrawn, hypoactive and despondent. Psychosis is also a typical 
feature of BPD, most commonly during mania, but it can also occur during depression. 
Cognitive impairments are also sometimes seen, affecting executive function, 
attention and memory (15). BPD has a mean age of onset of ~20 years (16), and 
affects >1% of people worldwide (17).  
 
Late onset Alzheimer’s Disease (LOAD) is a progressive neurodegenerative 
condition. It is the most common form of dementia, accounting for 62% of all dementia 
cases in the UK (18). Relentless cognitive decline is a major symptom of the disease 
and, as the disease progresses, the severity of decline correlates with synapse and 
neuronal loss that begins first in the hippocampus before spreading widely throughout 
the brain (19–21). Symptoms in the early stages of the disorder include mild deficits 
in attention, problem solving and short-term memory that do not affect an individual’s 
independence. However, over time these symptoms worsen to such a degree that 
individuals lose the capacity to complete basic daily tasks, like washing and dressing. 
In the latter stages of the disease, physiological and motor deficits emerge, leaving 
sufferers incontinent and unable to walk or speak (22). On average, symptom 
progression lasts 7-10 years with death being the end result. The defining 
neuropathological features of LOAD are insoluble extracellular amyloid plaques and 
intracellular neurofibrillary tau tangles (23). 
 
Major depressive disorder (MDD) is a neuropsychiatric disorder characterised by 
episodes of depressed mood that last longer than 2 weeks which are not associated 
with an underlying health condition or stressful life event. Individuals with MDD can 
exhibit a marked reduction in their capacity to take pleasure in life and commonly 
experience feelings of worthlessness and guilt. As such, individuals with MDD are 20-
times more likely to die by suicide than the general population. Sleep and appetite 
disturbance, fatigue and social detachment are also typical symptoms (24). MDD is 
twice as likely to occur in females than in males (25) and affects 1 in every 6 adults 
making it the second highest contributor to disease burden worldwide (26,27). The 
median age of onset of MDD is 25; however, symptoms can emerge in mid-
adolescence (26). MDD is associated with periods of sickness and remission with 
episodes of illness ranging, on average, between ~3-7.5 months.  
 
Neuroticism is personality trait that describes the tendency of an individual to respond 
with negative emotion to daily experiences. Individuals high in neuroticism frequently 
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respond with disproportionate negativity to life challenges and are disposed to 
experience their environment (or situation) as being stressful or threatening. Feelings 
such as personal inadequacy or dissatisfaction with the world at large are commonly 
expressed (28). Neuroticism is of interest in neuropsychiatric research as it 
associates with conditions such as schizophrenia (29) and depression (30). 
 
Schizophrenia (SCZ) is a neuropsychiatric disorder that affects ~1% of the population 
(31). As the symptoms of SCZ are wide-ranging, and present heterogeneously, they 
are divided into three broad categories; namely, positive, negative and cognitive. 
Positive symptoms include thoughts or motivations that are additional to normal 
behavioural repertoire, such as auditory or visual hallucinations, which may cause an 
individual to lose their grasp of reality (32). Paranoid and delusional modes of thought 
often accompany hallucinations such that individuals have an unrealistic outlook and 
become convinced they are being pursued, controlled or persecuted. In contrast, 
negative symptoms are associated with reductive patterns of behaviour such that 
individuals become withdrawn, experience anhedonia or lack motivation (32). 
Cognitive dysfunction is also a core feature of SCZ with deficits in reasoning, 
information processing, planning and working memory being common (33,34). 
Cognitive symptoms usually manifest first during adolescence; however, diagnosis 
often does not take place until early adulthood upon presentation of the first psychotic 
episode (35,36). Often people with schizophrenia have disorganised speech and 
behaviour such that they fail to interact properly in social situations or at work, which 
can lead to long-term unemployment and social isolation.  People with schizophrenia 
have reduced life expectancy (37) and are more likely to commit suicide than the 
general population (38).  
 
Despite a century of research, definitive characterisation of the molecular events 
that cause the majority of these disorders remains elusive. As all of these disorders 
severely impair the cognition, behaviour and mood of those affected, they place a 
significant burden on health and social care systems worldwide.  
 
 
1.2 Genetics of complex brain disorders 
 
For many years, scientists have been interested in understanding how genetic 
variation between individuals contributes to complex brain disorders. Like the majority 
of human traits, many clinical disorders are heritable to some degree. Considering 
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the heritability of complex brain disorders, evidence from twin studies, which compare 
phenotype concordance between monozygotic and dizygotic twins, shows that a 
significant component of risk for most brain disorders is driven by genetic factors, (see 
table 1.1; 39,40). Indeed, in the case of schizophrenia, genetic inheritance is 
considered the strongest risk factor for the disorder (41,42).  
 
 
 
 
 
However, risk for complex brain disorders is not mediated by genes alone, but by a 
combination genetic and environmental factors. The theoretical rationale for studying 
the genetic component of these disorders is that genes, and the genome as a whole, 
are fixed and measurable entities, and far easier to quantify in an unbiased, objective, 
manner than an individual’s environmental experiences. Moreover, an individual’s 
genetic landscape provides the biological outline for the traits that will interact with 
the environment. It encodes the resilience and/or vulnerability an individual has for a 
particular disorder and, as such, makes it a logical place to look for clues regarding 
the underlying pathological mechanisms of these disorders (43).  
 
 
1.2.1 Early molecular genetic studies of brain disorders 
 
Early efforts to identify genetic risk variants for brain disorders relied principally upon 
genetic linkage and candidate gene association studies (44).  
 
Linkage studies are family-based studies that attempt to measure whether a disorder, 
and the alleles that cause it, co-segregate with known genetic markers that are 
situated throughout human chromosomes. As such, when co-segregation occurs 
Disorder Heritability estimate
Attention-deficit hyperactivity disorder 0.75
Autism spectrum disorder 0.80
Bipolar disorder 0.75
Late onset Alzhiemer's disease 0.60-0.80
Major Depressive disorder 0.37
Schizophrenia 0.81
Table 1.1 Heritability estimates of complex brain disorders
Adapted from table in (42) except late onset Alzhiemers disease source (40)
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consistently within a family pedigree, it implies that a particular genomic region is a 
candidate risk locus for that disorder. Notable successes of genetic linkage studies 
were the identification of APP, PSEN1 and PSEN2 as risk genes for early onset 
Alzheimer’s disease, a rare, more aggressive, form of the disease that affects 
individuals younger than 65 years (45–47). However, while linkage studies have been 
successful in identifying rare variants conferring strong effects on risk for certain 
(neurodegenerative) disorders (45,46) they have had limited success in identifying 
common risk variants for brain disorders (48). 
 
In candidate gene association studies, the frequency at which certain genetic variants 
occur is usually compared between individuals with a disorder (‘cases’) and 
unaffected controls, with higher frequency in cases being taken as evidence that the 
variant is associated with the disease (49). These studies typically investigate a 
limited number of genetic variants at a candidate gene locus in a small number of 
individuals (usually < 1000). Although candidate gene association analyses were 
thought to be better suited to identifying common variants conferring weak effects on 
disease risk than linkage analyses, they rarely produced results that could be 
replicated across studies (50). An exception to this was the identification of the APOE 
epsilon 4 allele as an important risk factor for late onset Alzheimer’s disease (51). 
Prior to genome-wide analyses, candidate genes were selected in a biased fashion 
based on imperfect biological assumptions. With the advent of genomic technology, 
and significant collaboration between research groups to pool genetic samples, a 
coherent representation of the genetic architecture of brain disorders emerged that 
explained why the design of earlier genetic studies proved, for the most part, 
inadequate. It is now apparent that, for most complex brain disorders, genetic risk is 
conferred by many common alleles that individually confer a small effect on risk as 
well as rarer alleles of potentially stronger effect. These findings will be discussed in 
the next sections.  
 
 
1.2.2 Rare genetic variation  
 
Rare genetic variation, typically defined as alleles with population frequencies less 
than 1%, can arise through small insertions or deletions of DNA sequence (indels), 
large structural alterations (copy number variants) or mutations at the base pair level 
(single nucleotide variants). Compared to common alleles, rare mutations are 
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considered to have arisen in recent ancestry (52). Disease-relevant rare mutations 
are the most difficult form of variation to detect due to extremely low allelic frequencies 
in the population and the large sample sizes required to detect them in multiple 
individuals. However, in recent years, exome, and whole genome sequencing 
technologies have made it possible to identify rare variants disrupting individual 
genes that occur more often in individuals with brain disorders than in unaffected 
controls.  
 
Copy number variants (CNVs) are typically defined as deletions or duplications of at 
least 1kb. Several rare CNVs have been linked to increased risk for complex brain 
disorders (53). To date, 11 CNVs have been robustly linked to schizophrenia risk 
including six deletions and five duplications with odds ratios from 2 to >50 (54,55). Of 
these risk loci, CNVs on chromosomes 1q21.1, 13q13.3 and at the NRXN1 locus 
have also been shown to increase ASD risk (56–58), suggesting shared pathways in 
certain psychiatric disorders. An increased rate of rare CNVs has also been observed 
in ADHD (59). However, CNVs appear to be less important in the aetiology of bipolar 
disorder (60) and major depressive disorder (61). Similarly, no CNVs have been 
robustly associated with LOAD, although duplication of the amyloid precursor protein 
has been linked with the early onset form of the disease (62). 
 
Rare single nucleotide variants (SNVs) are the most difficult form of genetic variant 
to identify. It is estimated that, on average, ~74 de novo SNVs occur each generation 
(63). De novo SNVs have the potential to be more deleterious than inherited variants 
as they have undergone less selection pressure (64). Trio-based studies, which 
compare the exomes of affected cases and their parents, are commonly used to 
detect rare SNVs that arise between generations, and recent reports have associated 
de novo SNVs with complex brain disorders such as schizophrenia and autism 
spectrum disorder (65–67). Indeed, several rare LOAD-associated SNVs have been 
identified in the gene encoding the myeloid cell surface receptor TREM2 that increase 
risk 2-4 fold (68–70). 
 
 
1.2.3 Genome-wide association studies  
 
With the development of microarray-based genotyping technology in the early 2000s, 
together with improved understanding of haplotype structure and frequencies in 
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human populations (71,72), it became possible to perform genome-wide association 
studies of complex traits. These typically involve genotyping thousands of single 
nucleotide polymorphisms (SNPs) across the genome in large numbers of cases and 
controls or in a population that varies on a quantitative trait (e.g. plasma lipid levels). 
The advantage of this approach is that it provides a global screen for common variant 
association with a trait, without knowledge of the functional variants or bias towards 
prior hypotheses of underlying biology. However, the multiple testing burden is such 
that only associations where P < 5 X10-8 (P < 0.05 Bonferroni-corrected for 1 million 
tests) are considered ‘genome-wide significant’. In order to detect association of small 
effect alleles at such low P-values, large sample sizes are required. For brain 
disorders, like for many other complex traits, these have been achieved through the 
formation of large international research consortia.  
 
 
1.2.4 Genome wide association studies of brain disorders  
 
In 2009 the Genetic and Environmental Risk in Alzheimer’s Disease Consortium 
(GERAD) and the European Alzheimer’s Disease Initiative (EADI) simultaneously 
published two GWAS, implicating novel genetic loci for late onset Alzheimer’s disease 
(LOAD) in PICALM, CLU and CR1 (73,74). Despite the fact that both studies were 
carried out on independent samples, they both implicated loci containing the CLU and 
APOE genes, suggesting that the GWAS methodology could provide robust genetic 
associations. Until that point, alleles at APOE were the only common variants robustly 
associated with LOAD due to unusually strong effects of the common e4 allele (75). 
In subsequent years, several independent consortia published their own GWAS, 
identifying 6 additional LOAD genome-wide significant risk loci (76–78). In order to 
increase the statistical power to detect common variants with smaller risk effects, 
these consortia pooled resources to launch the International Genomics of Alzheimer’s 
Project (IGAP). The IGAP’s most comprehensive GWAS meta-analysis to date, using 
data from a sample of 21,982 cases and 41,944 controls, reported genome-wide 
significant associations between LOAD and 25 loci (79). Promisingly, 20 loci of these 
loci had been identified in a smaller meta-analysis carried out in 2013 (80). Moreover, 
the 5 newly reported loci had fell just below the genome-wide significance threshold 
in the previous study, demonstrating the benefit of increasing GWAS sample size to 
capture more of the common variant signal.  
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GWAS have also identified high confidence common risk loci for schizophrenia and 
other psychiatric disorders. In 2014, the Psychiatric Genetic Consortium (PGC) 
published data from the colloquially termed ‘PGC2 study’ reporting genome-wide 
significant associations between schizophrenia and 108 independent loci (81). 
Candidate genes contained within these loci implicated genes involved in glutamate, 
dopamine and calcium channel signalling. More recently, Pardinas and colleagues 
combined PGC2 data with that from the ‘CLOZUK’ sample, identifying a total of 145 
genome-wide significant associations with schizophrenia (82). In recent years the 
PGC has published GWAS data for other psychiatric and neurodevelopmental 
conditions. Although the sample sizes collected so far do not match the level of those 
generated for schizophrenia, robust risk loci have been reported, including 16 
genome-wide significant risk loci in ADHD (83), 12 in ASD (83), 30 in BPD (84), and 
44 in MDD (85).  
 
 
1.2.5 Pathway analysis  
 
As complex brain disorders are highly polygenic, interpreting how genetic 
perturbations contribute to illness is challenging. Pathway analysis is an analytical 
aggregation method that determines whether specific biological annotations, such as 
system, cellular or molecular networks, are enriched for genetic risk loci, thus 
implicating these networks in risk for brain disorders (86,87). This method has been 
used extensively in brain disorder genetics research. For example, networks involved 
in the regulation of the immune response, endocytosis, cholesterol transport and 
protein ubiquitination have been reported to be enriched for LOAD GWAS risk 
variants (88). Similar analyses have been carried out leveraging rare schizophrenia 
risk loci. Using a case-control gene set enrichment analysis approach, Pocklington 
and colleagues reported that CNVs were enriched in genes associated with excitatory 
and inhibitory neurotransmission in people with schizophrenia compared to controls 
and in an exome sequencing study on schizophrenia trios, Fromer and associates 
reported that rare de novo mutations were enriched in genes associated with 
glutamatergic post-synaptic density proteins (65).  
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1.2.6 Limitations of genome wide association studies 
 
Although GWASs have had undoubted success in identifying genetic loci that impact 
risk in brain disorders, these successes are tempered by several limitations that make 
aspects of GWAS data interpretation difficult. 
 
For example, a limitation in terms of the interpretation of GWAS data is that assigning 
causality to any particular variant is problematic. This is due to the fact that GWASs 
are based on a heuristic methodology designed to measure genome-wide common 
variation by genotyping a relatively small number of SNPs. To understand GWAS 
methodology and why it is not possible to identify causal SNPs using GWAS data 
alone, it is necessary to understand two key evolutionary concepts. First, is a 
phenomenon called linkage disequilibrium (LD) which describes the tendency of 
SNPs in close spatial proximity to be inherited non-randomly. SNPs that are inherited 
together are described as being in LD and the genome is segregated into blocks of 
SNPs that are in LD. Second is that allelic variation within LD blocks in individuals 
from the same ethnic background (i.e. European) occurs at only a few critical SNPs; 
most alleles are identical. This makes it possible to ‘map’ common variation genome-
wide by genotyping only the critical SNPs (referred to as index, or ‘tagging’, SNPs) in 
each LD block. Moreover, as only a limited number of haplotypes (i.e. a unique sets 
of alleles) exist at these critical SNPs within each population, the remaining non-index 
SNPs can be imputed post-hoc using the human reference genome. These concepts 
are fundamental in GWAS design as they make it possible to measure common 
variation in an individual’s genome quickly and cheaply. The drawback is that as each 
LD block can contain >1000 SNPs, all of which could feasibly contribute to disease 
risk, it is not possible to conclusively distinguish functional risk-causing SNPs, from 
risk-associated SNPs (89). This means additional, epigenomic and/or fine-mapping 
analyses are required to attempt to identify SNPs that increase risk (89). 
 
A second challenge when interpreting GWAS data is that the large majority of risk loci 
fall in non-protein coding regions of the genome (90). This means that it is not 
immediately obvious through which gene(s) or cell type(s) risk variants are operating. 
However, it does strongly implicate the regulation of gene expression in the aetiology 
of brain disorders (see section 1.3.6). As such, functional annotation of GWAS data 
with genome-wide epigenetic data is needed to ascertain the regulatory functions 
impacted by these loci (91,92). 
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1.3 The regulation of gene expression 
 
Despite the fact that virtually all cell types in the human body contain the same genetic 
information, which is encoded in their DNA sequence, cells are morphologically and 
phenotypically diverse. Phenotypic diversity in cells, with the same underlying genetic 
template, is made possible by altering the regulatory architecture surrounding DNA. 
Complex networks of proteins, DNA elements and non-coding RNAs interact to 
determine the genes that are expressed in a particular cell type at a particular time. 
This control of gene expression is vital for the maintenance of cellular identity, but it 
also allows cells the flexibility to activate different groups of genes in response to 
changing environmental demands or at critical periods during their development.  
 
 
1.3.1 Mapping the human epigenome 
 
After the successes of Human Genome Project, it became apparent that only ~1% of 
the human genome encodes proteins. As such, there was a requirement to determine 
what the remaining 99% of the genome did. Whilst it was hypothesised that a crucial 
function of the non-coding part of the genome was to regulate gene expression, until 
that point, there had been no attempt to empirically confirm this on a genome-wide 
scale. The Encyclopaedia of DNA Elements project (ENCODE) project was created 
in 2003 to take on this challenge and its remit was to characterise, map and create a 
comprehensive repository of all the epigenetic features in the human genome (93,94). 
To achieve this, the consortium committed to developing new high throughout 
methods, technology and analysis strategies to streamline this process. Since its 
inception, the ENCODE project has produced seminal data highlighting the 
importance of chromatin organisation in the control of gene expression and, 
specifically, how discrete chromatin states (and molecular signatures) can 
functionally partition the genome in a cell-specific manner. Moreover, it was shown 
that by integrating cell-specific epigenomic data with GWAS data, that GWAS risk loci 
segregated in a non-random manner in DNA elements, or chromatin annotations, in 
cell types that are relevant to the GWAS phenotype, i.e. SNPs associated with 
Crohn’s disease, an auto-immune disorder, were enriched in open chromatin regions 
of immune cells (90). 
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In recent years, many groups have produced work exploring non-coding epigenomic 
phenomena. The work of ENCODE and similar groups, such as the US National 
Institute of Health Roadmap Epigenomics Mapping Consortium (REMC; 97,98), 
provided the foundation for this work which has advanced our understanding of the 
regulatory networks involved in the control of gene expression and how they 
contribute to disease. This section will describe the chromatin and DNA features that 
are involved in epigenomic control of gene expression and how they influence 
complex brain disorders. 
 
 
1.3.2 Chromatin and chromatin accessibility 
 
Chromatin is a complex of DNA, RNA and protein that is located in the nucleus of all 
human cell types, and it is the main constituent of chromosomes. The core structural 
element of chromatin is the nucleosome, and each nucleosome consists of a 147 
base pair section of DNA sequence that is coiled around 8 histone proteins. 
Nucleosomes are connected to one another via a short (~60bp) sections of DNA, 
called linker DNA, to form a repeating structure that resembles beads on a string. 
Each histone protein octamer is composed of two copies of the H2A, H2B, H3 and 
H4 histones, and these are bound on their external surface by a H1 linker histone 
(97,98). During cellular mitosis, chromatin tightly condenses such that it can be 
visualised microscopically. In order to regulate cellular gene expression, chromatin 
dynamically alters its physical state. Euchromatin, is relaxed, uncoiled, chromatin 
where histones are either well-spaced, or displaced entirely, exposing DNA to 
molecules (e.g. transcription factors; TFs) that regulate gene expression. By contrast, 
heterochromatin is tightly compacted, and histones are bunched together making 
DNA relatively inaccessible. Chromatin accessibility is a measure of the functional 
state of chromatin and is defined by the degree to which DNA is exposed. In any 
given cell type, accessible DNA constitutes ~2-3% of the entire genome (99). In order 
for a gene regulatory event to take place chromatin must be uncoiled and in the 
euchromatic state to allow regulatory molecules to interact with DNA. When 
chromatin is heterochromatic most regulatory molecules cannot get access to DNA 
due to phenomena such as steric hindrance (100,101).  
 
The assay for transposase-accessible chromatin using sequencing (ATAC-seq) is a 
popular method used to measure genome-wide chromatin accessibility (see figure 
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1.1; 102). This method takes advantage of the fact that euchromatin is sensitive to 
enzymatic cleavage. In the ATAC-seq assay, nuclei are extracted from a cell of 
interest and incubated with a hyperactive Tn5 transpose enzyme, which selectively 
excises exposed DNA from all the open chromatin regions of the genome. Crucially, 
the enzyme has been modified to carry adapter sequences such that, whilst excising 
the DNA, adapters are simultaneously inserted at the ends of the DNA fragments. 
These adapters act as barcodes for the DNA fragments so they can be recognised 
after pooled sequencing. Due to the high efficiency of the Tn5 enzyme, ATAC-seq 
has largely superseded alternative methods for measuring open chromatin regions, 
such as DNAse-seq (101). Once the DNA has been excised and barcoded, the DNA 
fragments are sequenced and the reads produced are aligned to a reference genome. 
The final read out of an ATAC-seq assay is a genome-wide set of ‘peaks’, 
representing sites of open chromatin that are potentially involved in the regulation of 
gene expression in the cell type of interest at the time the nuclei were extracted.  
 
 
 
 
 
As described in the following sections in this chapter, open chromatin regions may be 
located either near the transcription start sites of genes or in non-coding regions 
located far from genes. This provides information on the genes that are likely to be 
active, or poised in preparation to be activated, within a cell type and the regulatory 
elements that have the potential to influence gene expression in these cells. It is also 
possible to identify specific DNA recognition sequences that gene regulatory proteins 
bind to within these loci. This provides a picture of the DNA-protein interactions that 
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regulate gene expression in the cell of interest. Furthermore, when integrating 
chromatin accessibility data with other functional genomic data it is possible to make 
functional predictions of the pathologically relevant effects that genetic variation may 
have in particular tissues or cell types.  
 
 
1.3.3 Regulatory elements  
 
Regulatory elements are non-coding sections of DNA sequence that act as binding 
platforms for DNA binding proteins, and they are involved in the initiation or 
modulation of gene expression (see figure 1.1). Cell-specific gene expression is 
possible through exposure of unique sets of regulatory elements to transcriptional 
proteins and co-factors. This ensures that cells have a unique set of activated genes 
that cater to their environmental needs, and distinct regulatory control over the rate 
of expression of those genes. Regulatory elements can be located proximally or 
distally to the genes that they influence, and several types have been described in 
the literature including promoters, enhancers, silencers and insulators. However, I will 
only discuss promoters and enhancers in this section.  
 
 
 
 
 
Promoters are a type of regulatory element that are located proximal to the genes 
they influence and are necessary for RNA synthesis (see figure 1.1). Whilst all genes 
have at least one promoter situated upstream of the 5’ end of the gene, over 50% of 
genes have multiple, alternative promoters (103,104). The DNA sequence of a 
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promoter acts as a docking site for the transcription pre-initiation complex which, in 
turn, directs RNA polymerase II to the transcription start site of the gene to initiate 
mRNA production (105). Binding of RNA polymerase II is sufficient to drive low-level, 
basal transcription of RNA, so additional activator proteins that bind upstream of the 
core promoter, are required to modulate the rate of gene expression. Genes with 
alternative promoters can produce different protein isoforms by producing different 
mRNA transcripts thus contributing to phenotypic diversity (106,107). Moreover, 
alternative promoters from the same gene demonstrate tissue specificity (108,109) 
and have contrasting activity levels during development (110).  
 
Unlike promoters, enhancers are located distally to the genes they regulate. Typically 
a few hundred base pairs in length, enhancers also act as binding platforms for 
transcription factors and, in general terms, increase the rate of expression of their 
target genes (111). Enhancers interact with transcription start sites of promoters 
through chromatin looping; a biophysical phenomenon where sections of genomic 
sequence form loops to bring distant regulatory elements into close spatial proximity 
with their target gene(s) (see figure 1.1; 112). Typically, enhancers are more difficult 
to identify than promoters as they lack the universal sequence characteristics, such 
as CpG islands (113) or shared protein binding elements (105), that help distinguish 
promoters across tissue types. It is also difficult to accurately predict the genes that 
enhancers target, particularly as a single enhancer can modulate the activity of 
multiple genes. Chromosome conformation capture (3C) - based assays have been 
developed to map these long-range regulatory interactions, although such datasets 
are not yet available for all cell types (and none currently exist for microglia). 
 
Crucially, genetic changes that impact regulatory elements can contribute to variance 
in phenotypic traits and disease susceptibility between individuals. While only ~1% of 
the human genome encodes protein, up to 10% is evolutionarily conserved, 
suggesting that a significant portion of the non-coding genome is of functional 
importance (103).  
 
 
1.3.4 Transcription factors 
 
The term transcription factor (TF) is used to describe a protein that is involved in the 
regulation of gene expression. Transcription factors can influence gene expression 
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through direct interaction with DNA, or by binding indirectly to DNA as part of a larger 
protein complex. DNA binding transcription factors bind to DNA in a sequence specific 
manner, recognising short 4-12bp sections of DNA sequence called motifs (see figure 
1.2; 114). A motif can be interpreted as the DNA footprint for a DNA binding 
transcription factor. Some transcription factors, such as those that form the 
transcription initiation complex, are generically expressed and have the same function 
across cell types, whilst other TFs are cell type specific. However, it is also possible 
for the same transcription factor to influence expression of a distinct set of genes in 
different cell types (116).  
 
Cellular control of gene expression is critical in order to respond to internal and 
external stimuli and to balance two seemingly competing needs (A) the need to alter 
gene expression (e.g. at critical times during its developmental life cycle or to respond 
to environmental stimuli), which is particularly true for functionally dynamic cells such 
as microglia, and (B) the need to preserve a gene expression pattern, in order to 
maintain tissue homogeneity and cell identity (117).  
 
One mechanism that is proposed to underpin these processes in cells is enhancer 
selection. The human genome is predicted to have hundreds of thousands of 
enhancer regions (118). The method by which cells preferentially select a specific 
group of enhancers in order to confer cell identity and/or to react to an environmental 
stimulus has been a topic of some debate. A consistent finding across studies is that 
combinations of transcription factors interact in a context-specific manner, spatially 
and/or temporally, to drive enhancer selection. For example, the pioneer factors PU.1 
and C/EBP-a/-b interact in spatial context, to establish myeloid, and in particular 
macrophage, cell lineage (119). These pioneer factors, directly compete with histones 
for the DNA binding sites in heterochromatic regions (120). In macrophages, PU.1 
binds specifically at enhancer sites that also contain C/EBP factor binding sites and 
these factors act in combination to induce histone depletion, increase chromatin 
accessibility and increase the deposition of active chromatin modifications, such as 
H3K4Me1, at macrophage enhancers (121–123). Once enhancers are exposed, they 
can be primed, or activated, by additional transcription factors to modulate 
transcription in their target genes. This illustrates the interplay that occurs between 
histones, DNA and transcription factors to drive cell-specificity and regulate gene 
expression; however, other factors such as biochemical modifications on the surface 
of chromatin also play a critical role in these processes. 
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1.3.5 Chromatin modifications 
 
The surface of nucleosomes is decorated with chemical markers, referred to as 
chromatin modifications, that can disrupt the contacts between neighbouring 
nucleosomes to influence chromatin accessibility and recruit proteins which initiate 
key cellular processes such as DNA transcription, replication or repair. Chromatin 
modifications can be attached to histones or DNA and they demarcate the genome 
into distinct functional domains (124).  
 
Histone modifications (HM) are post-translational modifications that are covalently 
bound to the amino acids of histone proteins. Structurally, histones are predominantly 
globular, but they also have a freely protruding N-terminus tail to which the vast 
majority of HMs are attached. HMs can act to dynamically to alter the structure and 
function of chromatin by direct interaction with DNA, or by recruitment of chromatin 
remodelling proteins, to influence gene expression. HMs can be mapped to 
functionally annotate the genome and to predict the nature and activation status of 
the regulatory elements that they are proximal to (125,126). Two histone 
modifications commonly used to annotate the human genome are methylation of 
histone 3 lysine 4 (H3K4Me1-3) and acetylation of histone 3 lysine 27 (H3K27ac). 
Histone methylation is a reversible process that is facilitated by histone 
methyltransferases, which attach methyl groups to histones, and demethylases, 
which detach methyl groups. The methylation status of H3K4 is used to demarcate 
proximal and distal regulatory elements (127). For example, H3K4Me3 is associated 
with active transcription at promoters and gene bodies (128,129), whereas H3K4Me1 
correlates strongly with functional enhancers (130).  
 
Chromatin immunoprecipitation with sequencing (ChIP-seq) is the assay used to 
detect histone modifications. In this assay, genomic chromatin is fragmented then 
incubated with antibodies that target a histone modification of interest. Chromatin 
fragments associated with that modification are then immunoprecipitated and the 
DNA in each fragment is sequenced (131). Similar to the data produced in the ATAC-
seq assay, reads are aligned with a reference genome and regions where reads pile 
up (‘peaks’) indicate the genomic loci associated with that particular histone 
modification.  
 
As well as post-translational modifications to histones, the DNA itself can be adorned 
with epigenetic marks. DNA methylation is an epigenetic modification that is 
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associated with the repression of transcription in mammals. This process is heritable 
and is facilitated by a family of DNA methytransferases which catalyse the transfer of 
a methyl group to the 5th carbon of the cytosine ring in DNA. In regions where 
regulatory elements are silenced, DNA is often directly methylated, and the chromatin 
is closed and compacted, so transcription factors can’t access regulatory elements 
(132,133). 
 
One of the main benefits of chromatin-based assays such as ATAC-seq and ChIP-
seq is that they make it possible to functionally annotate the genome. This provides 
information on which regulatory elements (and which genes) are likely to be active 
within tissues or cell types, but importantly from the perspective of making sense of 
GWAS data, it provides information on the function of non-coding regions of the 
genome (134).  
 
 
1.3.6 Integration of genetic and epigenomic data 
 
A primary goal for groups working in brain disorder research is to identify the cell-
types and molecular mechanisms that are important in these disorders in order to 
identify potential targets for pharmacological intervention. One approach used to do 
this is to integrate GWAS data, which provides information on the loci associated with 
a particular brain disorder, with cell-specific epigenomic data which contains details 
on the regions that are active and inactive within a particular cell type, and what these 
regions do. Theoretically, this makes it possible to functionally annotate GWAS risk 
loci and potentially identify the cell-specific regulatory elements they may perturb.  
 
An example of this approach is a study by Fullard and colleagues, who measured 
chromatin accessibility of neurons and non-neurons across 14 distinct brain regions, 
and using a statistical method called stratified linkage disequilibrium score regression 
(described in section 2.2.4), integrated this with GWAS data from 3 complex brain 
disorders (SZ, ADHD and LOAD). They reported that neuronal open chromatin 
regions in the neocortex and striatum were enriched for SZ-associated common 
variants, with the hippocampus, nucleus accumbens and the superior temporal cortex 
being the regions most enriched (135). Pinpointing the specific SZ risk loci that 
operate in neurons in this manner demonstrates the benefit of functional annotation 
of GWAS data to draw biologically meaningful conclusions regarding the cell-types 
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(and brain regions) important in complex brain disorders. Indeed, ascertaining the 
cell-types that brain disorder risk variants operate in will be an important step toward 
unravelling the molecular aetiologies that drive these disorders.  
 
 
1.4 Microglia 
 
Microglia are the primary immune cell of the central nervous system (CNS) and in 
human adults constitute ~0.5-16% of the total brain cell population, depending on 
region (136). Microglia were first definitively characterized by del Rio-Hortega who 
catalogued their migratory and phagocytic properties as well as their distinctive 
ramified morphology (137). However, it is unlikely del Rio Hortega could have 
foreseen the diverse and complex range of functions microglia satisfy during the 
human life cycle. In recent years, it has emerged that microglia contribute significantly 
to critical processes such as immune surveillance, neurodevelopment and CNS 
homeostasis (138). As such, microglia are capable of responding to a wide range of 
environmental and internal stimuli and can tailor their gene expression profile to 
present the phenotype best suited to the conditions that they encounter in their local 
environment. This requires epigenomic activation of specific enhancers and 
transcription factors (139–141). Moreover, as our understanding of microglial function 
has grown, there has been increasing interest in their role in the neuropathology of 
complex brain disorders (142).  
 
 
1.4.1 Microglia ontogeny and turnover 
 
For many years the developmental origin of microglia was unclear. Their emergence 
early on in brain development suggested they derived from an embryonic progenitor, 
whilst their phenotypic and antigenic similarity to myeloid cells found in the peripheral 
tissues implied that they are derived from circulating blood monocytes (143). 
However, recent lineage-tracing studies in transgenic mice have driven the current 
consensus view that microglia arise from a unique, and transient RUNX1+/c-
Kit+/CD45- erythromyeloid progenitor population in the embryonic yolk sac (143,144). 
Once the circulatory system has been established, these cells begin to infiltrate the 
neuroepithelial tissues of the primitive brain and upregulate microglia lineage-specific 
transcription factors (Pu.1 and Irf8) before finally migrating, and proliferating, in CNS 
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parenchyma. Importantly, due to the formation of the blood brain barrier, this microglia 
progenitor population remains distinct from the main pre-natal haematopoietic 
reservoir in the foetal liver, which is the primary source of proliferating peripheral 
myeloid cells until the development of the bone marrow (144–146).  Although fate 
mapping studies of a similar nature have still to be carried out in humans, 
immunohistochemical studies do hint at a similar human microglial developmental 
trajectory (147–149).  
 
Once the blood brain barrier has been established, it is hypothesised that, in normal 
physiological conditions, microglia remain isolated from the peripheral myeloid cells 
that circulate in the blood (150,151). Evidence supporting this comes from studies in 
parabiotic mice which show that when the circulatory systems of genetically identical 
animals are combined, whilst peripheral myeloid cells derived from both animals were 
found in the vasculature, only host microglia were found in the brain of each mouse 
(144,150,152,153). As a consequence of this, and in order to maintain adequate brain 
coverage in homeostatic and immune activated conditions, microglia are long-lived, 
compared to peripheral myeloid cells (154), and self-renewing (150).  
 
In certain experimental circumstances, bone-marrow derived myeloid cells can enter 
brain parenchyma. For example, when the myeloid cell lineage-determining 
transcription factor Pu.1, or the cell surface receptor Csf1r, are genetically depleted 
in mice, peripherally engrafted bone-marrow derived cells from donor animals can 
infiltrate the brain of recipient mice (155–157). Although these engrafted cells are 
morphologically similar and express similar cell surface markers, they are 
transcriptionally and functionally distinct from microglia, despite the fact that they 
inhabit the same environmental niche in the brain (156,157). Findings such as this 
has led to speculation that future exploitation of this engraftment mechanism could 
lead to the use of peripheral, bone-marrow derived cells to treat brain disorders 
(156,158,159). Indeed, brain engraftment of bone-marrow derived macrophages has 
been shown to alleviate the symptoms of autism and Rett syndrome in mouse models 
(160,161).  
 
The impact that ontogeny has on the intrinsic phenotypic repertoire of microglia, and 
myeloid cells generally, remains an open question in the field, however it will be 
important to clarify whether or not microglia are uniquely vulnerable to brain disorder-
associated insults and/or may be uniquely targeted for therapeutic benefit (162). 
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1.4.2 Microglia’s immunological functional repertoire  
 
Microglia have two primary functions in the central nervous system: to provide 
immunological defence and to maintain a relatively constant homeostatic balance. In 
the absence of an infectious or immune insult, microglia maintain the homeostatic 
equilibrium of the brain parenchyma. In these conditions, microglia have a ramified 
morphology and they constantly extend and retract their processes to survey, and 
‘sample’, their local microenvironment for chemical or proteinaceous stimuli that could 
elicit a context-specific response (163–165). Similar to macrophages in the peripheral 
tissues, microglia act as the principal responders of the innate immune system by 
monitoring the parenchymal landscape for biochemical signals. These signals can be 
brain-derived, alerting microglia to cellular waste or apoptotic cells marked for 
phagocytic removal, or they can arise from external sources, such as infectious 
organisms, initiating an innate immune response. When exposed to a response-
inducing stimulus, microglia retract their processes, adopt an amoeboid morphology, 
and alter their gene expression profile to provide the tools required to resolve the 
situation. 
 
As the first line of defence for the innate immune system, microglia have an array of 
receptors on their cell surfaces through which to detect invading pathogens. For 
example, microglia carry a family of transmembrane molecules called toll like 
receptors which recognise a wide array of pathogen-specific ligands, such as 
lipoproteins, on the surface of bacteria, viral RNA, and chemokines released by other 
immune cells such as INF-g (166). Once detected, the transcription factor nuclear 
factor-kB is activated which orchestrates the upregulation of pro-inflammatory genes 
to increase the production of pro-inflammatory cytokines (i.e. TNF-a, IL-1, IL-6, IL-12, 
IFN-a;b), chemokines (monocyte chemotactic protein-1, CXCL9-10) and free radicals 
(nitric oxide) to alert, and recruit, neighbouring microglia (and T-helper cells) to the 
threat, and efficiently eliminate the pathological disturbance. Microglia’s antigen 
presenting capacity is also significantly increased which alerts cells of the adaptive 
immune system, such as T-cells and B-cells to the threat. However, a drawback of 
this swift and aggressive response is that some of the chemicals produced by 
microglia as part of this response, such as nitric oxide (167,168), are neurotoxic so 
have the potential to collaterally damage surrounding neurons. Microglia have also 
been associated with a range of anti-inflammatory, activation states (M2a, M2b, M2c) 
whereby arginase is released, and the presence of specific interleukins can (A) 
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induce tissue repair via expression of neurotrophic factors, (B) promote the release 
of the neuromodulators (Il-4, Il-10 and TGF-b) to inhibit neighbouring cells from 
releasing pro-immune factors or (C) induce a phagocytotic profile to remove dead 
cells and cellular debris (169–172).  
 
However, the nomenclature surrounding microglia activation states has been 
questioned recently. The terms M1 and M2 derive from studies in peripheral 
macrophages and are used to describe their polarised pro- and anti-inflammatory 
activation states. Although this terminology has been widely adopted in the microglia 
literature, it has been criticised for being too simplistic. Moreover, as much of the 
evidence to support this work was carried out in microglial cell cultures in vitro, which 
cannot model the complex interactions that occur in vivo, there is little evidence that 
these binary activation states occur in vivo. Indeed, microglia are often exposed to 
competing stimuli simultaneously in vivo, which leads to co-expression of pro- and 
anti-inflammatory factors (173–176). This has led to calls for new, unbiased, 
classifications for states of microglia activation based on transcriptomic and/or 
epigenomic profiles (177).  
 
 
1.4.3 Microglia’s brain architectural functional repertoire  
 
In addition to their immunological and homeostatic roles, microglia are also involved 
in refining neuronal circuitry and modulating synaptic function throughout life. Indeed, 
as microglia emerge from the yolk sac at the same time as the birth of early neurons, 
microglia’s role in neural refinement is thought to be particularly important in the 
developing brain where extensive rewiring of the nervous system takes place 
(178,179).  
 
As the predominant phagocytic cell in the brain, microglia have been implicated in the 
removal of developing, and mature neurons, in regions of the brain where 
neurogenesis takes place. This can be a passive process whereby non-activated 
microglia simply engulf and clear the remains of apoptotic neurites (180), or microglia 
may drive neuronal apoptosis via the release of reactive oxygen species, nerve 
growth factor or tumour necrosis factor (181–183). Microglial control of neurogenesis 
is particularly important during CNS development where they control the rate of 
turnover of neural precursors. For example, activated microglia have been shown to 
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colonise the interface between ventricular and subventricular zones in the pre-natal 
developing cortex in human, macaque and mouse and, in macaque, microglia 
consume and phagocytose neural progenitor cells developing in these proliferative 
zones (184). Furthermore, pharmacological deactivation, or elimination, of microglia 
increased the number of neural progenitor cells in the proliferative zones, indicating 
that microglia have a critical role in restraining neuronal production. Microglial control 
of neurogenesis continues into adulthood where they have been shown to eliminate 
apoptotic neural progenitor cells in mice (185).  
 
Similarly, microglia have a pivotal role in sculpting the connections between neurons 
in a process called synaptic pruning, in which neuronal activity and the complement 
system are also involved (186). Complement is a group of proteins that the innate 
immune system uses to tag apoptotic cells or foreign bodies for removal. These tags 
are recognized by microglia which, in turn, engulf and remove tagged elements from 
the microenvironment. For example, in the developing mouse visual system (P5-
P10), the complement factors C1q and C3 are widely expressed and they co-localise 
at immature, or weakly signalling, retinal ganglion cell synapses to tag them for 
removal. Crucially, when retinogeniculate synaptic density was measured in C1q and 
C3 KO mice there was excess synapses in KO animals compared with controls. 
Excess cortical neuronal connectivity has also been reported in C1q knockouts (187), 
and microglia have been shown to actively engulf synapses in the mouse 
hippocampus (188). Moreover, microglia are the primary cell type in the brain that 
express the CR3 receptor and the C3-CR3 interaction is required for synaptic 
engulfment and elimination of C3 tagged synapses (189). Other factors have been 
implicated in microglial mediated synaptic pruning. For example, during 
neurodevelopment, fractalkine (CX3CL1) is expressed by neurons (190) and it has a 
chemotactic influence on microglia and may act to attract microglia to weak synapses 
(191–193). Microglia are the only cells in the CNS to expresses the fractalkine 
receptor (194,195) and mice lacking the receptor have increased neuronal 
connections in the hippocampus compared to wild-type mice (188). Similarly, the 
cytokine IL-33, expressed by astrocytes, has been shown to increase microglial 
engulfment of developing synapses in mouse thalamus and spinal cord via activation 
of the microglial cell surface receptor 1L1RL1. IL-33 KO mice have excessive 
excitatory synapses (196). Furthermore, when the microglial immune receptor 
triggering receptor expressed on myeloid cells 2 (TREM2) is genetically deleted, the 
CA1 region in the hippopcampi of mice has increased excitatory neurotransmission 
and synapse density compared to wild-type littermates (197).   
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As well as synaptic removal, it has been postulated that microglia are also involved 
in synapse formation and modulation. In young adult mice lacking microglia, learning-
associated spine formation and behavioural task scores, have been reported to be 
significantly reduced compared to wild-type animals (198). Microglia also have a role 
in modulating the activity rate of synapses.  For example, in zebrafish, microglia have 
been shown to preferentially interact with highly active neurons to attenuate their 
activity in a contact-dependent manner (199). It has been proposed that microglia 
identify neurons with high activity levels through the P2RY12 receptor that detects 
ATP released after neuronal activation (200). 
 
Microglia are also reported to interact with oligodendrocytes in the brain and support 
myelinogenesis. For example, after a demyelination event, microglia clear fatty debris 
from the injury site and secrete factors to modify the surrounding extracellular matrix 
and recruit oligodendrocyte precursor cells which support myelin regeneration (201).   
 
 
1.4.4 Microglia and brain disorders 
 
As scientific interest has grown, and a fuller understanding of the range of 
physiological processes that microglia are involved in in the brain has emerged, 
research into the role that microglial dysregulation plays in the aetiology of complex 
brain disorders has also developed (202). Indeed, many studies have reported a link 
between microglial function and the pathophysiology of late onset Alzheimer’s 
disease. For example, microglia are consistently shown to engulf, proliferate and 
accumulate around amyloid plaques in patients with the disease (203,204) and the 
proportion of activated microglia in the brain increases as the disease advances 
(23,205). The amyloid plaque burden in the brain is an established biomarker for the 
disorder and one proposal is that inefficient clearance of these plaques by microglia 
leads to plaque build-up, which, over time, triggers a chronic inflammatory response 
that leads to synaptic and neuronal degeneration (206). However, debate is ongoing 
around whether microglia are assuming a protective role in this process and merely 
being overwhelmed when attempting to clear the plaques or whether they have a 
direct role in neurodegeneration by releasing cytotoxic factors that damage 
surrounding neurites (207). Genetic evidence also strongly implicates microglia 
function in LOAD pathogenesis. For example, the majority of genes implicated by 
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LOAD GWAS, including CD33, ABI3, and PLGC2, are preferentially expressed by 
microglia, and pathway analyses implicate immune and microglia-specific gene 
networks with increased risk. Common variants in the microglia lineage determining 
transcription factor PU.1 have been associated with reduced risk for LOAD (208) 
whilst rare variants in TREM2, encoding an extracellular myeloid cell receptor are 
associated with increased risk. Moreover, a study leveraging gene expression data 
from post-mortem brain tissue in a LOAD case-control sample identified genes 
related to immune networks, and specifically, microglial networks, as being 
associated with LOAD pathophysiology (209).  
 
Microglia have also been hypothesised to be important in the pathophysiology of 
psychiatric and neurodevelopmental disorders. For example, it has been postulated 
that excessive synaptic pruning occurring during adolescence or early adulthood 
increases schizophrenia risk, and recent work implicates microglia (and the 
complement system) in this process (210). For example, Sekar and associates 
reported that a proportion of the common variant SZ risk is driven by structural alleles 
of the complement component C4 gene such that a higher copy number of the C4A 
long form (C4AL) haplotype is associated with increased C4 expression and 
increased SZ risk (211). C4 is released by neurons and it activates another 
complement molecule in the brain, C3, which is secreted by microglia. When 
activated, C3 tags synapses for elimination and promotes phagocytic engulfment of 
synapses by microglia (186,189,212). In a recent induced pluripotent stem cell study, 
SZ patient-derived (SPD) microglia had increased uptake of synaptic material, and 
SPD neurons grown in co-culture had reduced spine density, when compared to cells 
derived from healthy controls (213). Increased C3 deposition on SPD neurons was 
also reported to correlate with a higher copy number of C4AL genotype. As low spine 
density is a common neuropathological feature reported in the post-mortem brain of 
SZ patients (214), this work has led to the proposal that increased C4 release in SZ 
patients with more copies of C4AL increases activation of C3 that, in turn, promotes 
pathologically increased synaptic engulfment by microglia. Intriguingly, clinical 
studies suggest that the antibiotic minocycline, which inhibits microglial activation 
(215), may alleviate the negative (and potentially positive) symptoms associated with 
schizophrenia (216,217). Minocycline has been shown to decrease microglial 
engulfment of synapses in vitro (213). 
 
Synaptic dysfunction has also been linked to the pathophysiology of ASD (218,219). 
For example, de novo CNVs identified in individuals with ASD have been shown to 
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contain genes that converge on synaptic networks (220) and neuroimaging studies 
have reported white matter overgrowth in cortical areas associated with social 
communication (221). Given microglia’s role in synaptic removal and/or maturation 
during neurodevelopment their role in ASD aetiology has been investigated. Post-
mortem studies have shown that microglia are more ramified, have larger cell bodies 
and are more densely populated in the cortex of ASD patients compared to age-
matched controls. Moreover, a post-mortem cortical transcriptomic differential 
expression analysis between 107 ASD cases and controls reported upregulation of 
genes associated with microglia activation (M1) and the type I interferon response, 
with the M2 activation state module negatively correlated with the expression of 
synaptic transmission genes (222). Rare genetic variants in CX3CR1 gene, which 
encodes a fractalkine receptor expressed by myeloid cells, has also been associated 
with increased risk of ASD (and schizophrenia) (223). In Cx3cr1 deficient mice, 
excitatory synapses in the hippocampus are structurally immature (188,224,225) and 
mice exhibit repetitive and reduced social behaviours analogous to ASD phenotypes 
in humans (188,225), leading authors to speculate that this could be caused by 
delayed microglial colonisation of the brain during a key neurodevelopmental period 
(188,226,227).  
 
 
1.5 Aims 
 
In this thesis, my primary aim was to investigate whether gene regulation in human 
microglia contributes to genetic risk for complex brain disorders. To do this I 
measured the open chromatin profile of adult ex vivo microglia (chapter 2), in vitro 
human cell models of microglia (chapter 3) and cryopreserved microglia extracted 
from the 2nd trimester human foetal brain (chapter 4) and integrated these data with 
GWAS data for complex brain disorders. Finally, using an electrophoresis mobility 
shift assay, I aimed to investigate how allelic variation at two LOAD risk-associated 
loci, that overlap adult ex vivo microglial open chromatin sites, impacts DNA-protein 
interactions in microglia (chapter 5).     
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2 The open chromatin landscape and common variant 
disease heritability in human ex vivo microglia 
 
 
2.1 Introduction 
 
Although GWASs have been successful in associating multiple genomic loci with risk 
for complex brain disorders, it is generally unclear in which cells risk variants are 
active. Given that the majority of brain disorder susceptibility variants fall within 
intronic or intergenic regions that do not code for protein, risk variants are likely to 
impact processes that regulate gene expression in disease-relevant cell types (90). 
As described in chapter 1.3.2, the gene regulatory profile of a cell is partly determined 
by the biophysical state of chromatin that surrounds specific regulatory elements. 
Interactions between regulatory elements and transcription factors, that influence 
gene expression, are permissible in regions where chromatin is open and the DNA is 
exposed. As such, each cell-type has a unique set of accessible regulatory elements 
that have the potential to be activated and these elements dictate a cell-type’s 
function and identity. This is important when considering the impact that a risk variant 
may have in a particular cell type as, if the variant falls within in an inactive region, it 
can have no impact on the function in that particular cell type. Understanding how 
individual brain cell types contribute to the burden of risk for complex brain disorders 
is important to understand their underlying aetiologies. 
 
Chromatin-based assays can identify cell-specific regulatory elements and make it 
possible, when integrated with GWAS data, to test for enrichment of GWAS risk loci 
within such annotations. For example, in a recent study by Tansey et al., GWAS 
summary statistics were integrated with H3K4Me3 ChIP-seq data derived from 
neurons and glia extracted from human post-mortem tissue (228). The authors 
demonstrated that, whilst schizophrenia SNP heritability was enriched at promoter 
sites common to both cell types, when testing for enrichment at promoters that were 
specific to either cell type, only promoters in neurons were enriched. This implies that 
neurons contribute more to the common genetic load of schizophrenia than glia in 
adult brain.  
 
Genetic evidence strongly implicates microglia function in the pathogenesis of late-
onset Alzheimer’s disease (LOAD). For example, the majority of genes implicated by 
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LOAD GWAS, including SPI1, CR1, CD33, ABI3, and PLGC2 (79,80,229), are 
preferentially expressed by microglia, and pathway analyses implicate immune and 
microglia specific gene networks with increased risk (209). Rare variation in TREM2, 
which encodes an extracellular myeloid cell receptor, is also associated with 
increased risk for LOAD (229). Moreover, environmental insults that putatively 
increase microglial activation, such as maternal immune activation, have also been 
associated with increased risk of schizophrenia and autism (230–234). Despite these 
findings, the role that microglia have in the aetiologies of these disorders is unknown. 
As such, I sought to investigate the causal relationship between common variant 
genetic risk for complex brain disorders and dysfunction in microglial regulatory 
regions. 
 
 
2.1.1 Aims 
 
In this chapter, using a statistical technique called stratified linkage disequilibrium 
score regression (sLDSC), I test whether SNP heritability, measured in a panel of 
complex brain disorder GWAS, is enriched in genomic open chromatin sites derived 
from human adult ex vivo microglia. I then run a second analysis substituting the 
microglia data for open chromatin regions derived from human adult neurons to 
ascertain whether any SNP heritability enrichment I measure in microglia annotations, 
is specific to microglia or common across brain cell types. Finally, I further partition 
the microglial annotation into microglial open chromatin sites that contain individual 
transcription factors to determine whether brain disorder SNP heritability is enriched 
in open chromatin sites that contain specific factors involved in the regulation of gene 
expression. This work was included as part of a recent publication (235). 
 
 
2.2 Methods 
 
2.2.1 Accessing publicly available datasets 
 
ATAC-seq data derived from adult human ex vivo microglia, which were extracted 
from fresh surgically resected brain tissue (236), were obtained from the database of 
Genotypes and Phenotypes repository (dbGaP) using the study accession code 
phs001373.v1.p1.  For comparison, ATAC-Seq data derived from adult human 
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neurons extracted from frozen ventrolateral prefrontal cortex (135) were downloaded 
from the European Bioinformatics database quoting the study accession code 
PRJINA380200.  
 
 
2.2.2 Sequencing, QC and bed file preparation 
 
In total, 12 single-end human ex vivo microglia fastq files (corresponding to 12 
biological replicates) and 10 paired-end human vlPFC neuronal fastq files 
(corresponding to 5 biological replicates) were downloaded. The sequencing depth 
of each file set ranged between 28.3-45.6 million and 20.3-43.6 million reads 
respectively. For quality control, FastQC (237) was run separately on all fastq files 
and MultiQC (238) used to collate the FastQC output. As all files passed the quality 
control measures, no files were excluded from the analyses. Next, single-end and 
paired-end fastq files were aligned to the human genome using Bowtie2 (239), and 
the average alignment rates were 98.3% for the microglial files and 99.0% for the 
neuronal files. Mitochondrial reads were removed from all files using Samtools (240). 
For peak calling, MACS2 (241) was run using either the BAM parameter for single-
end files or BAMPE parameter to handle paired-end reads, and an FDR of < 0.05 was 
set as the threshold. Duplicate reads were ignored by MACS2 during the analysis by 
default. The final output from the peak calling process is a peak file. Diffbind (242) 
was used to obtain consensus peak files that retained high confidence open 
chromatin regions for each cell type, with the consensus setting at 0.66, in order to 
retain peaks that were observed in at least 2/3rds of all donor files for each cell type. 
 
 
2.2.3 De novo motif enrichment analysis 
 
HOMER motif analysis (243) was used to test enrichment of transcription factor 
binding motifs in the adult microglia open chromatin peak set. First the microglia peak 
file was annotated using the annotatePeaks.pl command. This provides 
additional information for each peak, such as whether it occurs over a promoter or an 
intergenic region, and is required for motif analysis. For the motif analysis, the 
annotation file was used to run the findMotifsGenome.pl command. As HOMER 
motif analysis is a differential motif discovery algorithm, it first creates a set of 
background sequences with which to compare the regions in the annotation file. This 
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background set was selected at random from the specified genome (hg19), and the 
size (-size given) and GC content of these sequences were chosen to match the 
regions provided in the microglial peak file. Then both the background and microglial 
open chromatin regions were queried for nucleotide stretches of specified lengths (-
len 14,12,10,8) and these were tested for enrichment of particular sequences 
using cumulative binomial distributions. Sequences that are enriched in microglial 
open chromatin regions were then compared for similarity to a database of known 
transcription factor motifs and reported if the p-value was < 0.05. Two files are 
produced by homer, containing the enrichment scores for either known, or de novo 
transcription factor motif locations. As I am interested in the discovery of novel motifs, 
only the de novo results are reported here.  
 
 
2.2.4 Stratified linkage disequilibrium score regression 
 
Stratified linkage disequilibrium score regression (sLDSC) is a statistical method 
designed to estimate the proportion of SNP heritability associated with a trait in the 
population. It also makes it possible to partition the genome by functional category 
and to test whether SNP heritability associated with a trait is attributable to certain 
functional categories more than others. SNP heritability in this context is defined as 
the proportion of genetic variance in a trait explained by all SNPs, as opposed to 
SNPs that reach the genome-wide threshold for significance. To partition heritability, 
sLDSC requires a GWAS summary statistics file and an annotation file that contains 
genomic coordinates for the functional partition. sLDSC exploits the predicted 
relationship that exists between the association statistics of a set of GWAS index 
SNPs and local linkage disequilibrium surrounding each index SNP for a polygenic 
trait, i.e. this relationship predicts that, on average, index SNPs with high LD r2 scores 
are more likely to tag SNPs with higher association statistics than SNPs with low r2 
scores. As such, using a linear regression model, sLDSC generates an estimate of 
the proportion of SNP heritability that is captured by a given set of index SNPs, 
including any heritability explained by non-assayed SNPs within the haplotype block 
that each index SNP tags, as well as correcting for systematic biases.  
 
To calculate the GWAS SNP heritability associated within microglial or neuronal open 
chromatin sites, an annotation file was generated by using bedtools to intersect either 
the microglial, or neuronal consensus peak file with the SNPs contained in the 1000 
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genomes reference panel. This assigns a 1 or 0 to each SNP depending on whether 
or not it overlaps an open chromatin region. Next, using the lsdc.py script and 
plink files provided, the latter containing genotype data from 329 European 
ancestry reference genomes, LD scores for all SNPs with a minor allele frequency 
>5% were taken by measuring the correlation between SNPs in 1cM windows in the 
plink files. However, only LD scores for SNPs that were located in both the GWAS 
summary stats file and the annotation file were retained for the next stage in the 
analysis. Next, again using the lsdc.py script, heritability was partitioned by 
functional category by regressing the c2 association statistics for each GWAS index 
SNP present in the annotation file against each SNP’s local LD score. This produced 
a single regression co-efficient representing the per-SNP heritability for that functional 
category (note that this assumes uniform per-SNP heritability for all SNPs in the 
category). Finally, the total SNP heritability for the category (h2) was calculated by 
multiplying the regression coefficient by the total number of SNPs in the category and 
an enrichment score was produced. The significance of SNP heritability enrichment 
was tested by generating a further 200 SNP heritability regression coefficients from 
random, equally sized, blocks of SNPs. This provided a normal distribution of 
regression coefficients and made it possible to calculate a z-score for the SNP 
heritability coefficient of the functional annotation of interest relative to the normally 
distributed coefficients. This score includes a correction for the baseline model which 
includes 53 annotations representing intrinsic heritability that is attributable to 
common genomic signatures across cell types such as promoters proximal to 
housekeeping genes, shared chromatin features and evolutionarily conserved 
regions (244). As these annotations are common between cell types, they would 
inflate the heritability score if not accounted for in the analysis. Z-scores were 
transformed and reported as p-values, with significance taken as p < 0.05.  
 
 
2.3 Results 
 
2.3.1 De novo motif enrichment analysis 
 
Table 2.1 shows the results for the de novo motif enrichment analysis in human ex 
vivo microglial open chromatin regions. The highest ranked motif was Spi1, which 
was significantly enriched in ex vivo microglial open chromatin sites compared to a 
random set of background regions (target = 32.34%, background = 7.97%; p-value = 
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1 x 10-8874). Spi1 is a mouse gene that encodes the transcription factor Pu.1. Pu.1 is 
a myeloid lineage determining transcription factor and both it, and its human homolog 
PU.1 (that is encoded by the gene SPI1) bind to the same transcription factor motif. 
Pu.1 is critical to microglial development and differentiation such that microglia are 
absent in mice lacking the Spi1 gene (146).   
 
 
  
 
 
Moreover, both interferon regulatory factor 8 (IRF8) and Runt-related transcription 
factor 1 (RUNX), the third and sixth ranked motifs respectively, were significantly 
enriched in microglial open chromatin regions over the background (IRF8, target = 
9.45%, background = 2.37%, p-value = 1 x 10-2271; RUNX, target = 24.77%, 
background = 17.66%, p-value = 1 x 10-578). Both factors are critical regulators of 
microglial differentiation (144,146,245). Therefore, the transcription factor motif 
profile of the adult ex vivo microglial open chromatin regions is consistent with what 
one would expect for a functional annotation derived from a myeloid cell.  
 
Rank Motif % of Targets % of Background p-value
1 Spi1 32.34 7.97 1 x 10-8874
2 BORIS 11.62 1.58 1 x 10-4950
3 IRF8 9.45 2.37 1 x 10-2271
4 Sp5 13.58 8.08 1 x 10-623
5 CEBPE 12.43 7.25 1 x 10-606
6 RUNX 24.77 17.66 1 x 10-578
7 BATF 8.23 4.43 1 x 10-499
8 DCE 21.19 15.06 1 x 10-484
9 E2F2 21.18 15.99 1 x 10-337
10 nMyc 13.59 9.41 1 x 10-333
11 NFY 10.93 7.28 1 x 10-315
12 MafA 24.66 19.41 1 x 10-301
13 ETV5 22.33 17.21 1 x 10-300
14 CREB1 7.88 5.2 1 x 10-233
15 NRF1 5.77 3.6 1 x 10-209
16 IRF5 4.2 2.43 1 x 10-198
17 USF2 5.06 3.14 1 x 10-188
18 MEF2A 3.21 1.87 1 x 10-147
19 GFY 1.31 0.58 1 x 10 -123
20 Rfx1 1.31 0.61 1 x 10 -112
Table 2.1. Motif enrichment analysis in human ex vivo  microglia OCRs
% of Targets (proportion of microglial open chromatin sites containing specified motif); % of 
Background (proportion of randomly selected backgroun regions containing specifed motif); OCRs 
(open chromatin regions).
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2.3.2 Enrichment of brain disorder GWAS SNP heritability in human ex vivo 
microglial open chromatin regions  
 
To test for enrichment of SNP heritability in ex vivo microglial open chromatin sites, 
sLDSC was run using GWAS SNPs from 7 brain disorder traits: attention deficit 
hyperactivity disorder (246) Alzheimer’s disease (80), autism spectrum disorder (83), 
bipolar disorder (84), major depressive disorder (85), neuroticism (247), and 
schizophrenia (248). A GWAS of wearer of glasses or contact lenses (WGL; 
downloaded from http://www.nealelab.is/uk-biobank/) was used as a negative control. 
 
 
 
 
 
SNP heritability associated with LOAD was significantly enriched in ex vivo microglial 
open chromatin regions (P = 0.013), but this did not survive Bonferroni correction for 
the 8 tests run (see table 2.2). SNPs within these sites captured 50.47% of the total 
common variant heritability explained by the Alzheimer’s disease GWAS SNPs which 
is an enrichment >43 times over and above the heritability explained by the sLDSC 
background annotations. By contrast GWAS SNP heritability associated with the 
remaining 6 complex brain disorders, and the negative control, was not significantly 
enriched in microglial open chromatin sites. 
 
 
 
 
GWAS SNPs (%) h2 (%) h2 SE (%) Enrichment Enrichment SE p-value cor. p-value
ADHD 1.17 4.92 4.25 4.21 3.64 0.492 1.000
ASD 1.17 2.82 5.27 2.42 4.51 0.620 1.000
BPD 1.17 4.03 3.32 3.45 2.84 0.936 1.000
LOAD 1.17 50.47 17.24 43.20 14.76 0.013 0.104
MDD 1.17 4.11 4.10 3.53 3.51 0.998 1.000
NEUROTICISM 1.17 -1.01 1.80 -0.87 1.53 0.097 0.776
SCZ 1.17 2.59 2.10 2.22 1.75 0.977 1.000
WGL 1.17 12.49 8.89 10.69 7.61 0.347 1.000
Table 2.2. Enrichment of brain disorder GWAS SNP heritability in human ex vivo  microglial OCRs
SNPs (proportion of GWAS SNPs contained in SNP reference panel); h2 (SNP heritability); h2 SE (SNP heritability standard error); Enrichment (enrichment 
of SNP heritability in microglial OCRs); Enrichment SE (enrichment of SNP heritability standard error); cor. p-value (Bonferonni corrected p-value for 8 
tests); OCRs (open chromatin regions); ADHD (attention deficit hypractivity disorder); ASD (autism spectrum disorder); BPD (biploar disorder); LOAD (late 
onset Alzheimer's Disease); MDD (major depressive disorder); SCZ (schizophrenia); WGL (Wearing glasses or lenses)
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2.3.3 Enrichment of brain disorder GWAS SNP heritability in human 
ventrolateral prefrontal cortex neuronal open chromatin regions 
 
 
Table 2.3 shows the sLSDC results testing for enrichment of SNP heritability 
associated for the 7 brain disorder GWASs, and 1 negative control GWAS, in open 
chromatin regions derived from adult ventrolateral prefrontal cortical neurons. 
 
 
 
 
 
In contrast to the ex vivo microglial sLDSC results, SNP heritability associated with 
LOAD was not significantly enriched at the P < 0.05 threshold in neuronal open 
chromatin regions (P = 0.096, enrichment = -10.07). However, SNP heritability for 
bipolar disorder (P = 0.024, enrichment = 9.42), schizophrenia (P = 5.59 x 10-5, 
enrichment = 9.67) and neuroticism (P = 2.90 x 10-3, enrichment = 7.88) were 
significantly enriched within these regions, with enrichment of SNP heritability for 
schizophrenia and neuroticism remaining significant after Bonferroni correction for 8 
tests.  
 
 
2.3.4 Enrichment of Alzheimer’s disease GWAS SNP heritability in human ex 
vivo microglial open chromatin regions containing specific transcription 
factors 
 
Due to such large proportion of Alzheimer’s disease SNP heritability being attributable 
to open chromatin regions in ex vivo microglia (<50%), see section 2.3.2, I tested 
whether this heritability could be partitioned further, i.e. to open chromatin regions 
GWAS SNPs (%) h2 (%) h2 SE (%) Enrichment Enrichment SE p-value cor. p-value
ADHD 1.01 8.34 4.04 8.24 3.98 0.103 0.824
ASD 1.01 10.10 5.22 10.04 5.16 0.100 0.800
BPD 1.01 9.53 3.01 9.42 2.98 0.024 0.192
LOAD 1.01 -10.20 12.70 -10.07 12.54 0.096 0.768
MDD 1.01 2.70 3.45 2.67 3.41 0.660 1.000
NEUROTICISM 1.01 7.98 1.85 7.88 1.83 2.90 x 10-3 0.023
SCZ 1.01 9.67 1.74 9.54 1.72 5.59 x 10-5 4.47 x 10-4
WGL 1.01 8.57 7.00 8.47 6.91 0.544 1.000
Table 2.3. Enrichment of brain disorder GWAS SNP heritability in human vlPFC neuronal OCRs
SNPs (proportion of GWAS SNPs contained in SNP reference panel); h2 (SNP heritability); h2 SE (SNP heritability standard error); Enrichment (enrichment 
of SNP heritability in microglial OCRs); Enrichment SE (enrichment of SNP heritability standard error); cor. p-value (Bonferonni corrected p-value for 8 
tests); OCRs (open chromatin regions); ADHD (attention deficit hypractivity disorder); ASD (autism spectrum disorder); BPD (biploar disorder); LOAD (late 
onset Alzheimer's Disease); MDD (major depressive disorder); SCZ (schizophrenia); WGL (Wearing glasses or lenses)
 35 
containing specific transcription factor motifs. For each of the 20 motifs identified in 
the de novo motif enrichment analysis (see section 2.3.1), a separate peak file was 
generated that included only those peaks in the original ex vivo microglia peak file 
that contained the specific motif. A peak file comprising of open chromatin sites that 
contained none of the 20 motifs was also generated as a negative control. The results 
are shown in table 2.4. 
 
 
 
 
 
LOAD SNP heritability was significantly enriched in ex vivo microglial open chromatin 
regions containing one of 3 transcription factor motifs at the P < 0.05 threshold; 
namely, Spi1 (P = 0.013), CEBP-e (P = 0.035) and RUNX (P = 0.033). Open 
chromatin sites containing these factors explained 29.08%, 13.80% and 20.67% of 
LOAD common variant heritability, which corresponds to 65-fold, 69-fold and 55-fold 
enrichments, respectively. No other set of transcription factor containing open 
chromatin sites was significantly enriched for Alzheimer’s disease SNP heritability at 
Motif h2 (%) h2 SE (%) Enrichment Enrichment SE p-value
Spi1 29.08 11.94 65.49 28.90 0.013
BORIS 7.60 6.95 63.29 57.88 0.401
IRF8 4.67 4.58 34.33 33.74 0.411
Sp5 3.07 7.08 12.96 29.90 0.834
CEBP-ε 13.80 6.12 68.74 30.47 0.035
RUNX 20.67 8.30 55.43 22.27 0.033
BATF 5.70 5.10 47.29 42.30 0.352
DCE 11.76 7.70 33.87 22.14 0.423
E2F2 7.18 8.71 20.51 24.91 0.89
nMyc 3.73 5.82 15.61 24.41 0.997
NFY -2.19 4.65 -12.46 26.44 0.317
MafA 10.64 7.69 29.14 21.05 0.418
ETV5 9.25 7.63 24.97 20.60 0.704
CREB1 13.50 6.00 104.91 46.60 0.256
NRF1 1.30 5.09 11.49 44.76 0.848
IRF5 5.95 3.59 87.84 52.95 0.114
USF2 5.72 3.91 65.94 45.00 0.22
MEF2A 5.98 3.57 134.13 80.09 0.091
GFY 1.82 1.32 8.24 60.29 0.856
Rfx1 2.10 1.65 113.93 89.77 0.263
No TF 1.44 2.91 32.91 66.59 0.708
Table 2.4. Enrichment of LOAD GWAS SNP heritability in human 
ex vivo  microglial OCRs containing specific transcription factors
h2 (SNP heritability); h2 SE (SNP heritability standard error); Enrichment (Enrichment of SNP heritability in 
micoglial OCRs); Enrichment SE (Enrichment of SNP heritability standard error); OCRs (open chromatin regions); 
LOAD (late onset Alzheimer's disease)
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the P < 0.05 threshold, including the negative control set that contained no 
transcription factor motifs (No TF). No set of microglial open chromatin sites tested 
were significantly enriched for LOAD SNP heritability after Bonferroni correction for 
21 tests.  
 
 
2.4 Discussion 
 
Establishing how common genetic risk variation impacts individual cell types in the 
brain is vital to improve our understanding of the causal mechanisms of complex brain 
disorders (90).  
 
The localisation of >50% of the total LOAD SNP heritability to adult ex vivo microglial 
open chromatin regions shown here (see table 2.2) implies that microglial specific 
gene regulatory processes mediate LOAD genetic risk mechanisms in some way, and 
that these processes account for more than half of the common variant liability for the 
disease. Moreover, given that the LOAD risk signal was not replicated in neuronal 
open chromatin sites (see table 2.3), these results add to growing body of evidence 
that the innate immune system and, myeloid cells specifically, are involved in LOAD 
pathophysiology. For example, LOAD SNP heritability has been shown to be enriched 
in myeloid cells extracted from peripheral blood (monocytes and macrophages; 246), 
and LOAD susceptibility alleles have been reported to be enriched for monocyte-
specific cis-eQTL effects (251). The results presented here are the first to directly link 
LOAD common variation to gene regulatory function in microglia (the primary myeloid 
cell of the brain), however, as microglia and peripheral blood myeloid cells share 
many gene regulatory features, it is still unclear whether microglia are the key disease 
mediating cell-type or whether peripheral myeloid cells contribute in some way.  
 
Having established that SNP heritability was enriched in microglial open chromatin 
sites, I investigated whether this enrichment could be localised to open chromatin 
regions containing motifs for specific transcription factors. Whilst distinct cell types 
share many transcriptional regulators that control common cellular processes, a 
significant proportion of the gene regulatory landscape is distinguishable between cell 
types, particularly the enhancer landscape (157,252). In the motif-specific sLDSC 
analysis, LOAD SNP heritability was significantly enriched in open chromatin sites 
containing motifs for 3 transcription factors (see table 2.4).  All 3 of these transcription 
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factors are prominently expressed in myeloid cells (245,253,254). For example, Spi1 
is a haematopoietic pioneer factor and it has been shown to determine both the 
constitutive and signal specific enhancer landscape in macrophages (microglia are 
the macrophage of the brain; 251,252). Common missense mutations in the SPI1 
gene are associated with LOAD (79), and PU.1, the transcription factor encoded by 
SPI1, has been reported to be present in the cis-regulatory elements of LOAD-
associated genes in myeloid cells (monocytes and macrophages), suggesting that 
SPI1 modulates LOAD risk via regulation of LOAD-associated genes (208).  
 
Interestingly, in a gene expression study carried out by Olmos-Alonso et al. on post-
mortem tissue comparing LOAD cases and non-symptomatic controls (257), 
expression of Spi1, Runx1 and CCAAT-enhancer-binding protein-a (CEBP-a), which 
binds to same core transcription factor motif as CEBP-e, were shown to be 
upregulated in the temporal cortex in LOAD cases. These factors are key regulators 
of the colony stimulating factor 1 receptor (CSF1R) pro-mitogenic pathway that acts 
to increase microglial proliferation which, the authors show, positively correlates with 
progression of the disease. Olmos-Alonso et al., also demonstrate that inhibition of 
the CSF1R in an Alzheimer’s disease mouse model (APPsew/PSEN1dE9) leads to a 
reduction in microglial proliferation, a reduction in expression of all three factors (Spi1, 
Runx1 and Cebp-a) and, crucially, short-term memory recovery and improved 
performance in exploratory and problem solving tasks designed to measure AD-like 
cognitive deficits (257). As such, the results presented in this chapter links polygenic 
common variant risk associated with LOAD to microglial specific gene regulatory 
networks that have potential therapeutic validity. Moreover, from a methodological 
perspective, the data presented here demonstrates the utility in integrating GWAS 
summary statistics with cell specific functional annotations as a means to draw 
meaningful, and more precise, conclusions about common variation in a cellular 
context that is not possible using GWAS data alone.  
 
Given that microglia function has been suggested to play a role in several psychiatric 
disorders (258,259), the lack of SNP heritability enrichment in microglial open 
chromatin sites for all psychiatric disorders included in the analysis (see table 2.2) is 
of interest. If microglia do have a role in the neuropathology of these disorders, these 
results imply that this will be generally mediated by factors other than common genetic 
variation. Infection and chronic stress during critical neurodevelopmental periods, 
both of which stimulate immune, and microglial activation, increase risk for 
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schizophrenia and autism (258) suggesting that environmental effects on microglia 
may be important in the aetiology of these disorders. In addition, rare genetic variants 
in the CX3CR1 gene, which encodes a fractalkine receptor expressed by myeloid 
cells, has also been associated with increased risk of ASD (and schizophrenia) (223). 
 
There were several limitations to this study. Firstly, the tissue preparation protocols 
for the microglial and neuronal datasets differed. For example, ex vivo microglia were 
extracted from live patients and processed within a few hours of extraction (157,236) 
whereas neurons were extracted from frozen post-mortem tissue obtained from brain 
banks (135). As these data derived from publicly available sources, it was not possible 
to control for any confounding effects caused by differing protocols  that may have 
impacted the results presented (260). Secondly, the SNP heritability estimates 
calculated by sLDSC are based on an additive model. This assumes that the effects 
of all observed SNPs contribute to heritability in an additive manner, and that each 
SNP effect is independent from the effects of all other SNPs. Whilst this may be the 
case for a majority of risk SNPs, it is an oversimplification as it does not take into 
account of non-additive, epistatic interactions between SNPs which are difficult to 
measure accurately (244). Thirdly, although the proportion of SNP heritability 
attributed to each microglial open chromatin annotation is relatively large (>50% and 
~14-29% in non-transcription factor, and transcription factor specific open chromatin 
sites respectively), it should be noted that the SNP heritability captured by sLDSC 
explains only 6.1% of total heritable component of LOAD. Whilst this may indicate 
that common variation makes only a small contribution to the overall genetic liability 
for LOAD, it is likely, at least partly, an artefact of the relatively low sample size of the 
LOAD GWAS (80) compared to other brain disorder GWAS such as schizophrenia 
(82). Fourthly, it has been reported that there is a correlation between lowering the 
proportion of SNPs included in an LDSC analysis and a reduction in the accuracy of 
its results (244,261). As such, it is not recommended to run sLDSC when <1% of the 
reference panel of SNPs is represented in the functional annotation of interest  (as 
this may result in sLDSC model misspecification; 
https://groups.google.com/forum/#!topic/ldsc_users/Mm0zN8ijsiE). As the total 
proportion of reference panel SNPs included in the microglial and neuronal analyses 
were 1.17% and 1.01% respectively (see tables 2.2 and 2.3), which is approaching 
the recommended threshold for the sLDSC model, these results should be interpreted 
with caution. However, as the proportion of SNPs included in an sLDSC analysis is a 
function of the genomic coverage of the cell-specific functional annotation, i.e. the 
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open chromatin regions of the microglial/neuronal genome, the number of SNPs 
included in the sLDSC analyses was outwith my control.  
 
2.4.1 Future Work 
 
Whilst this work provides better cellular and molecular resolution with respect to 
GWAS risk loci, it does not provide direct evidence showing whether or not 
transcription factors are bound at these locations, and more importantly whether the 
binding of these factors is actually altered by common risk alleles. Future work should 
seek to address these questions. For example, computational techniques exist to 
measure occupancy at transcription factor motifs using ATAC-seq data (262). These 
methods detect dips in read coverage in open chromatin regions of relatively high 
read coverage, called transcription factor footprints, which represent the locations 
within peaks where transcription factors are bound. This occurs as the tn5 
transposase enzyme normally cleaves DNA (relatively) indiscriminately throughout 
the entire nucleosome free region but is prevented from doing so when a transcription 
factor is present. Consequently, there is a reduction of read ends being cut at that 
locus. As transcription factor footprinting is sensitive to the depth at which ATAC-seq 
libraries are sequenced, this type of analysis was not possible in this study using the 
Gosselin et al. ex vivo microglial data (236) as the data were not sequenced deeply 
enough. As such, future analyses should consider increasing the sequencing depth 
to make transcription factor footprinting possible. ChIP-seq data could also be 
generated to measure genome-wide occupancy of specific transcription factors in 
microglia. However, this technique requires a relatively high number of input cells; 
therefore, due to the poor availability of primary microglia, ChiP-seq data derived from 
microglia are currently only available for one human transcription factor (SPI1; 235). 
 
Given that microglia are a phenotypically dynamic cell type, and that phenotype-
specific gene expression may require the open chromatin landscape of microglia to 
change, it is possible that GWAS risk loci operate in specific cellular contexts, such 
as particular microglial activation states. In a recent study measuring the open 
chromatin landscapes of T-cells after exposure to 13 different cytokine cocktails in-
vitro (which elicit specific immune related activation states), autoimmune GWAS 
SNPs were shown to be enriched in open chromatin sites in T-cells polarised toward 
a specific cellular state (263). For example, inflammatory bowel syndrome associated 
GWAS SNPs were in enriched in open chromatin regions of T-cells skewed toward a 
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Th1 phenotype, whereas arthritis associated risk SNPs were enriched in open 
chromatin regions of T-cells pushed toward the Th2 phenotype. A similar analysis 
assessing the open chromatin landscape of microglia across differing activation 
states and testing for enrichment of LOAD GWAS SNPs across open chromatin sites 
in these distinctly activated cells, could provide insight into the specific microglial 
functions that underpin LOAD aetiology.  
 
 
 
2.4.2 Concluding remarks 
 
By integrating brain disorder genetic association data with functional annotation data 
from a specific brain cell type, I provide evidence that a substantial proportion of 
common variant genetic risk for LOAD operates through gene regulatory processes 
in microglia, thereby strengthening the case that microglia are involved in LOAD 
pathophysiology. Furthermore, I provide evidence that variants contributing to 
polygenic risk of LOAD are enriched within open chromatin sites containing specific 
microglial transcription factor binding sites, thus suggesting tangible molecular targets 
for future mechanistic and/or translational studies. 
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3 The open chromatin landscape of in-vitro human cell 
models of microglia  
 
 
3.1 Introduction 
 
Access to fresh human brain tissue for brain disorder research is extremely limited. 
As such, procurement of human tissue mainly derives from frozen post-mortem 
sources (264). Brain samples that can be obtained from living patients tend to derive 
from individuals with existing brain pathology, such as epilepsy or tumour, so there is 
a risk that data generated using such tissue will be confounded by the effects of 
disease. When fresh tissue is available, it is possible to extract primary microglia for 
analysis; however, they downregulate many microglial-specific genes within a few 
hours of being removed from the brain (236,265,266), which severely limits their 
utility. As such, much of our knowledge regarding human microglial function is based 
on data that have been extrapolated from animal models. 
 
Animal models have provided exceptional insight into specific aspects of microglial 
function in health and disease. For example, the use of transgenic mice made it 
possible to map the fate of early microglial precursors during early development, 
establishing the embryonic yolk-sac as the location of microglia origin (144,146), and 
determining the critical factors that drive microglia differentiation and maturation in 
mice (i.e. PU.1, Irf8 and IL-34; 145,146,267). This work has directly informed the 
differentiation strategies used to derive microglia-like cells from induced human 
pluripotent stem cells (268). Similarly, mouse-derived immortalised microglial lines, 
such as BV2 cells, have been used to study neurodegenerative disease. For 
example, Ab uptake has been shown to be impaired when BV2 cells are transfected 
to overexpress the LOAD risk gene CD33 (which has increased expression in LOAD 
patients), implying that CD33 mediates microglial clearance of Ab, and that this 
mechanism may be relevant to AD risk in humans (269).  
 
Immortalised microglial cell lines have several benefits over primary microglia, 
including that they are freely accessible, easily maintained and propagate in an 
unrestricted manner (270). However, the legitimacy in using animal-derived 
immortalised microglial lines has been questioned for several reasons. First, as the 
immortalisation process often employs a retrovirus to introduce oncogenes to the 
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microglia genome (271), differences in cell morphology and adhesion have been 
reported when comparing immortalised lines to primary microglia (272). Indeed, the 
highly proliferative nature of immortalised lines does not accurately represent the 
microglial in vivo state (268).  Secondly, immortalised microglia have a tendency to 
dedifferentiate and lose microglial specific features (270,273). For example, BV2 cells 
have been shown to have functional differences when compared to primary and ex 
vivo human microglia (265,274,275). For these reasons, there is a critical need to 
establish a reliable and renewable human microglial cell model. 
 
One area of promise in relation to the generation of human-derived cell lines for use 
in the study of brain disorders is in the implementation of induced pluripotent stem 
cell (iPSCs) technology. iPSCs are generated from somatic cells, such as skin cells 
(fibroblasts), that are reprogrammed to express genes which elicit a pluripotent state 
in the cells. Then, using a cocktail of factors and cytokines pluripotent cells can then 
be skewed toward a specific cellular fate (276). Compared to primary brain cells, iPSC 
lines provide similar benefits to animal cell lines, such as their accessibility and 
capacity to be cultured for extended periods; however, a key additional benefit in 
relation to complex brain disorders is that iPSC lines can be derived from patients 
with disease-specific genetic backgrounds. This makes it possible to compare cellular 
phenotypes between affected cases and control individuals and use gene editing 
technology in these cells to test hypotheses regarding the genes and molecular 
mechanisms predicted to drive these disorders. Several protocols have been 
published recently describing how to generate microglia from induced pluripotent 
stem cells (iPSCs) derived from human fibroblasts (268,277–279). Whilst the precise 
methodologies used across these studies differ in terms of the specific cytokines and 
incubation times used to generate iPSC-derived microglia (iPSC_MG), and whether 
or not additional brain cell-types were added in co-culture, they all claim to generate 
viable myeloid cells with microglia-like properties. However, as transcriptomics was 
used as the primary global indicator to measure iPSC_MG in all of these studies, it 
has yet to be established whether the open chromatin landscape of microglia derived 
from iPSCs recapitulates that of primary microglia, despite the fact that a cell’s 
enhancer landscape better predicts cell identity than its transcriptomic profile (252). 
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3.1.1 Aims 
 
In the work described in this chapter, I aimed to generate three novel ATAC-seq 
datasets from human cell culture lines. The first two lines were iPSCs harvested at 
distinct developmental time points during the myeloid iPSC differentiation process. 
These lines were iPSC macrophage precursors (iPSC_MΩpre), which are 
differentially antecedent to microglia and the terminally differentiated iPSC microglia 
(iPSC_MG). The third cell line was a human microglial line immortalised using the 
simian virus 40 (SV40). Motif enrichment and principal component analyses were 
then used to compare the open chromatin landscapes of all three cell lines to the 
landscapes of human ex vivo cells of myeloid and lymphoid lineage taken from the 
brain and circulatory system. Primarily, I aimed to establish whether the iPSC_MG 
microglial cell line can adopt a chromatin accessibility profile similar to that seen in 
human ex vivo microglia.  
 
 
3.2 Methods 
 
 
3.2.1 Accessing publicly available datasets 
 
To compare the open chromatin landscapes of the iPSC lines to microglia ex vivo 
open chromatin sites, the chromatin accessibility data from the Gosselin and 
colleagues study was again used (see section 2.2.1 for repository and cell preparation 
details; 280). A second in vitro microglial open chromatin dataset from the same 
repository was also included. These in vitro cells were derived from the ex vivo 
microglial population as described in section 2.2.1 but, before ATAC-seq took place 
(280), the cells were first cultured and maintained in medium (Dulbecco’s Modified 
Eagle Medium with 5% FBS and 20ng/ml Interleukin-34) for 7 days to assess the 
impact of environmental conditions on microglia phenotype. Additionally, due to the 
functional similarity of myeloid cells deriving from the brain and peripheral circulatory 
system, chromatin accessibly datasets extracted from a suite of peripheral blood cell 
populations (myeloid and lymphoid), were obtained for comparison (252). Data were 
produced for the peripheral blood datasets by Corces and colleagues by blood 
extraction from patients and separated into its individual components using Ficoll to 
create a cell density gradient under centrifugation. Cells were then cryopreserved 
(90% FBS + 10% DMSO) in liquid nitrogen until required for ATAC-seq. The cell types 
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included in the analysis were monocytes, CD8 T cells, CD4 T cells, natural killer cells 
and B cells. These data were downloaded from the GEO via accession code 
GSE74912.  
 
 
3.2.2 Processing induced pluripotent stem cells 
 
Undifferentiated iPSCs were generated from the commercially available Kolf2 cell line 
(HipSci - http://www.hipsci.org/). These iPSCs derived from dermal fibroblasts taken 
from a male of European descent aged between 55-59 years. The iPSC differentiation 
procedure was undertaken by my colleague Aurelian Bunga using the protocol 
published by Haenseler and colleagues with slight modifications (268).  A brief 
description of the iPSC_MΩpre and iPSC_MG differentiation protocol he used is as 
follows. To promote the formation of embryoid bodies, ~3 million human-derived 
iPSCs were seeded into plate wells and covered with mTeSR1 media supplemented 
daily with bone morphogenic protein 4, vascular endothelial growth factor and stem 
cell factor. After 4 days, embryoid bodies were re-plated and incubated in X-VIVO15 
media with macrophage colony stimulating factor (M-CSF), interleukin-3, glutamax, 
penicillin, streptomycin and b-mercaptoethanol, which was replenished every 7 days. 
After ~1-month, iPSC_MΩpre emerged. To obtain iPSC_MG, the iPSC_MΩpre were 
incubated in advanced DMEM/F12 supplemented with N2, granulocyte/macrophage 
colony stimulating factor (GM-CSF) and interleukin-34 (IL-34) for 7-14 days. Both 
iPSC_MΩpre and iPSC_MG were extracted at their appropriate differentiation stages, 
strained, cryopreserved in Hibernate E (Gibco) and stored at -80oC until required for 
ATAC-seq.  
 
 
3.2.3 Immortalised human microglia – SV40 
 
Immortalised microglial cell lines are widely available for a range of species including 
human. The benefits of using an immortalised line it is easier to culture than an iPSC, 
or primary culture line (as it has been modified to evade normal cellular senescence) 
and it provides an unlimited and relatively consistent cell source. The human 
microglia SV40 cell line (SV40s; Applied Biological Materials) was used in this study 
to test whether its open chromatin landscape was similar to that measured in ex vivo 
microglia. SV40s were derived from primary human microglia and immortalised by 
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transduction and serial passaging with recombinant lentiviruses carrying simian virus 
40 large T antigen (281).   
 
The cell processing procedure for the SV40s was as follows. When cell seeding was 
required, 1-2 cryovials of SV40s were obtained from in-house stocks cryopreserved 
in liquid nitrogen at -180oC. To defrost the cells, the cryovials were placed in a 37oC 
water bath for ~2 minutes. All cryopreserved SV40s were of low passage number (2-
5 passages). For the general cell maintenance and passaging, T75 flasks were pre-
coated with collagen (5µg of collagen per cm2) then incubated for 60 minutes at room 
temperature. The collagen was then removed, and the flasks washed 3 times with 
phosphate-buffered saline (PBS). Defrosted cells were then carefully added to the 
collagen coated flasks and incubated in Pirigrow III (Applied Biological Materials), 
supplemented with 10% fetal bovine serum (Sigma) and 2mM L-glutamine (Sigma), 
with a 5% CO2 level and the temperature set at 37°C. Cell culture media was changed 
every 2-3 days and cells were passaged when 80-100% confluent. First the media 
was extracted from the flasks and, to dissociate the cells, 3ml of Accutase 
(ThermoFisher) was added to each flask, gently swirled to cover all cells, then flasks 
were incubated for 3 minutes at 37oC. Once the cells had detached, 3ml of media 
was added to neutralise the Accutase and the cell suspension was centrifuged at 
1000rpm in a 15ml Falcon tube for 1 minute. The supernatant was removed, and the 
cell pellet was resuspended in the desired volume of supplemented Pirigrow III media.  
Finally, the cell suspension was seeded into new collagen coated flasks. This process 
was repeated until cells were required for ATAC-seq. 
 
 
3.2.4 ATAC-seq library preparation 
 
Cells were pelleted (SV40s) as described in section 3.2.3, or defrosted (iPSC_MG 
and iPSC_MΩpre) in a water bath at 37oC for 2 minutes, and then pelleted, before 
being transferred into Eppendorf tubes. The ATAC-seq library preparation process 
was identical for each of the SV40, iPSC_MG and iPSC_MΩpre cell lines and 
followed the OMNI-ATAC protocol (282). Nuclei were isolated by resuspending the 
cell pellets in 50μl cold cell lysis buffer (0.1% IGEPAL (Sigma), 0.1% Tween-20 
(Sigma), and 0.01% digitonin (Sigma)). Isolated nuclei were washed in wash buffer 
(0.1% Tween-20), pelleted then resuspended in transposase solution (25ul 2x TD 
buffer, 2.5ul Tn5 transposase (100nM final; Illumina), 16.5ul PBS, 0.5ul 1% digitonin, 
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0.5ul 10% Tween-20, 5ul H2O) and incubated for 30 minutes at 37oC. The DNA library 
was isolated and cleaned, using the DNA Clean and Concentrator-5 Kit (Zymo) and 
snap frozen at -20oC in 20µl of elution buffer. When I was ready for the next stage in 
the process, DNA was defrosted on the bench and amplified for 5 cycles of PCR (Bio-
rad S-1000) using the parameters outlined in table 3.1. Importantly, during all PCR 
and qPCR stages, the primers used for each sample consisted of a generic forward 
primer (Ad1) and a unique reverse primer (Ad2). These were kept consistent for each 
sample throughout the protocol.  
 
 
 
 
 
As the total number of amplification cycles required was sample dependant, in order 
to calculate the number of additional PCR amplification cycles required to generate 
an adequate DNA library for each sample, 5µl of each pre-amplified sample was 
aliquoted from the PCR products and added to a 30-cycle qPCR reaction (Applied 
Biosystems StepOnePlus) using the parameters described in table 3.2.  
 
 
 
  
PCR amplification Volume (µl) Temp (C) Time 
25µM Primer Ad1 (Nextera) 2.5 72 5min
25µM Primer Ad2 (Nextera) 2.5 98 30sec
Master mix (2x NEBNext) 25
Transposed DNA 20 98 10sec
63 30sec
72 1min
Table 3.1. PCR reaction protocol
50µl reaction Cycling conditions
Then 5 cycles of:
Hold at 4 (C)
qPCR amplification Volume (µl) Temp (C) Time 
25µM Primer Ad1 (Nextera) 3.75 98 30sec
25µM Primer Ad2 (Nextera) 0.5
Master mix (2x NEBNext) 0.5 98 10sec
25x SYBR Green in DMSO (ThermoFisher) 0.25 63 30sec
Pre-amplified sample 5 72 1min
18.2Ω water 5
20µl reaction Cycling conditions
The 5 cycles of:
Hold at 4 (C)
Table 3.2. qPCR reaction protocol
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To ascertain the number of additional cycles of PCR required for each sample, a 
graph depicting the relative fluorescence intensity of each qPCR reaction against cell 
cycle number was generated and the number of cycles it took for the qPCR reaction 
to reach 1/3 of the maximum relative fluorescence intensity was calculated. This 
number corresponds to the number of additional PCR cycles required for each 
sample, which was between 5-6 cycles. DNA fragments were then isolated and 
cleaned, as described above, using the DNA Clean and Concentrator-5 Kit (Zymo).  
 
In order to extract DNA fragments of a specific length, representing transposase-
mediated insertion of sequencing adapters into either one or two nucleosomes, DNA 
was size-separated by gel electrophoresis. A 2% agarose solution was made by 
dissolving agarose (Sigma) in 0.5X TBE (Tris-borate-EDTA; Thermo Fisher), and 
then ethidium bromide was added (1:100) to the solution. Ethidium bromide makes it 
possible to visualise DNA when it is exposed to ultraviolet light. The solution was then 
heated to until boiling point, and carefully added to a sealed gel-cast. A gel-comb was 
added across the cast to create wells in the gel, and the gel was left to set for 60 
minutes. Once the gel had set, a 100bp DNA ladder (New England Biolabs) was 
added to the right- and left-most wells of the gel. PCR products, pre-mixed with 10X 
loading dye (Orange G) were then added to the gel, one sample per well, leaving a 
gap of one well between all ladder and sample wells to prevent cross-contamination. 
The gel was electrophoresed at 100V for 20-25 minutes such that the increments in 
the DNA ladder had separated sufficiently to identify DNA between the range of 175-
400bp. Amplicons of this size range were selected using a scalpel under ultraviolet 
light and DNA extracted from the gel using the ZymocleanTM Gel DNA Recovery Kit 
(Zymo).  
 
To prepare for sequencing, the ATAC-Seq library was quantified using the Qubit 2.0 
Fluorometer (range 0.48-1.04ng/µl) and the average fragment length of the DNA in 
each sample was measured (range 307bp) using the Agilent high sensitivity DNA 
chip. DNA was pooled to a final molarity of 10nM in 30µl of elution buffer (Zymo) 
sequenced using an in-house Illumina HiSeq 4000 system (sequencing performed by 
Dr Joanne Morgan).  
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3.2.5 Sequencing, QC and bed file preparation 
 
Paired-end 75-base sequencing was carried out on the 3 SV40, and 6 iPSC cell line 
ATAC-seq libraries using the Illumina HiSeq 4000. Sequencing files were de-
multiplexed then sequencing adapters and poor-quality reads were removed using 
Trim Galore (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/), 
resulting in 18 cleaned fastq files which contained either the forward or reverse reads 
for one the 9 ATAC-seq libraries sequenced. In addition, a total of 15 single end and 
52 paired end ATAC-seq fastq files were downloaded from the public repositories 
respectively (see section 3.2.1). These corresponded to a panel of open chromatin 
datasets derived from cells of the brain and circulatory systems. In total, data from 7 
additional cell-types were included in the analysis.  
 
 
 
 
 
The downstream processing of the fastq files was identical to that described in section 
2.2.2. As before, FastQC (237) was used for quality control and MultiQC (238) used 
to collate the FastQC output. All files passed the quality control measures. Fastq files 
were aligned to the human genome (hg19), using Bowtie2 (239), and mitochondrial 
reads were removed from all files using Samtools (240). MACS2 (241), was used for 
peak calling, duplicate reads were ignored, and the FDR threshold for peak 
significance was set to <0.05. In total, 50 unique peak files were generated and 
unique peak files for each cell type were combined to create a consensus peak file 
using Diffbind (242). The consensus threshold was set to 0.66, in order to retain high 
confidence peaks that were observed in at least 2/3rds of all donor files for each cell 
type. The quality measures for all files included in the analysis are summarised in 
table 3.3. For peak visualisation, technical replicate bam files for each cell type were 
Cell Type No. of Replicates Replicate Type Read Depth (M) Alignment Rate (%) Peak No. (K) Study
SV40s 3 Technical 104.1 - 140.8 98.4 169.6 This study
iPSC MG 3 " 109.4 - 173.0 97.1 211.1 "
iPSC MΩpre 3 " 202.0 - 360.2 97.1 249.6 "
MG ex-vivo 12 Biological 28.3 - 45.6 98.3 100.6 Gosselin et al., (2017)
MG in-vitro 3 ' 32.2 - 51.4 98.2 122.3 "
CD8 5 Biological 30.6 - 122.8 62.8 33.2 Coerces et al., (2016)
CD4 5 ' 55.0 - 127.4 62.2 34.3 "
NK cells 6 ' 27.4 - 124.8 56.8 35.1 "
Bcells 6 ' 50.0 - 184.2 65.4 30.8 "
Monocytes 4 ' 15.2 - 97.8 71.1 22.1 "
Table 3.3. Cell type specific open chromatin data included in the chapter 2 analyses
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merged using Samtools (240) and peaks were visualised using the integrative 
genome viewer (IGV; 281). 
 
 
3.2.6 Motif enrichment analysis 
 
Homer motif enrichment analysis (243) was run on the iPSC_MG, iPSC_MΩpre and 
SV40 cell consensus peak files to ascertain whether motifs enriched in the open 
chromatin regions of these cell culture lines were similar to the motifs measured in 
the ex vivo microglial open chromatin regions  generated in section 2.3.1. The Homer 
parameters were set exactly as specified in section 2.2.3. 
 
 
3.2.7 Principal component analysis 
 
Principal component analysis (PCA) is an unsupervised statistical method used to 
transform multi-dimensional data. It provides a means to summarise complex 
datasets to identify patterns in the data, or relationships between samples, that may 
exist but would otherwise be difficult to distinguish (284). To approximate the similarity 
between the open chromatin landscapes of the 3 cell culture lines I generated and 
the open chromatin datasets of the ex vivo and in vitro cells that I downloaded, a PCA 
was run using the Diffbind package (242). To run the PCA, a file containing the bam 
file and peak file locations for all 50 samples shown in table 3.3 were produced, which 
included metadata relating to each sample, such as the cell-types from which the 
individual datasets were derived and unique replicate identification numbers. Peak 
files that were included in the analysis were individual peak files for each sample, 
rather than the consensus peak files. The peak file list was then read into Diffbind 
using the dba() with the minOverlap parameter set to 0.66 which ensured that 
only peaks present in 2/3rds of the individual peak files which derive from the same 
cell type were retained. Next, a raw count matrix was generated using the 
dba.count() command, with the score parameter set to DBA_SCORE_READS. This 
produces a read count for every peak that was retained in the dba() call for every 
sample, regardless of whether the peak is present in the sample or not. If the peak is 
not present within a particular sample, it is assigned a read count value of 0. As such, 
every retained peak across all 50 samples is represented, and assigned a read count 
value, in each individual sample. Finally, PCA was run, and a plot produced 
(dba.plotPCA()), using log2 normalised read counts.  
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3.3 Results 
 
 
3.3.1 De novo motif enrichment analysis 
 
The iPSC_MG cell line open chromatin regions were significantly enriched for Spi1 
(target = 22.35%, background = 7.99%; p-value = 1 x 10-6897), CEBP-a (target = 
11.17%, background = 6.65%; p-value = 1 x 10-971) and PU.1-IRF (target = 2.68%, 
background = 1.29%; p-value = 1 x 10-406) transcription factor binding motifs 
compared to background sites (see table 3.4). All of these factors are involved in 
myeloid fate commitment (144,146).  
 
 
 
 
 
Similarly, in iPSC_MΩpre cell line open chromatin sites, Spi1 (target = 32.83%, 
background = 11.14%; p-value = 1 x 10-12757), CEBP-a (target = 12.65%, background 
Rank Motif % of Targets % of Background p-value
1 Fra1 20.97 6.83 1 x 10-7388
2 Spi1 22.35 7.99 1 x 10-6897
3 BORIS 7.63 1.77 1 x 10-3842
4 Zfx 6.82 3.35 1 x 10-1013
5 CEBPA 11.17 6.65 1 x 10-971
6 EGR2 8.87 5.07 1 x 10-869
7 MED 8.25 4.64 1 x 10-849
8 RUNX2 8.22 4.66 1 x 10-828
9 HINFP 7.74 4.32 1 x 10-812
10 TEAD4 12.98 8.55 1 x 10-771
11 Sp5 14.92 11.18 1 x 10-457
12 PU.1-IRF 2.68 1.29 1 x 10-406
13 DCE 22.55 18.58 1 x 10-349
14 MafA 21.78 17.90 1 x 10-342
15 Ascl2 10.30 7.76 1 x 10-290
16 FOXL1 8.24 6.08 1 x 10-262
17 SpiB 4.14 2.68 1 x 10-248
18 JUND 5.19 3.57 1 x 10-236
19 NFkB-p65 2.53 1.47 1 x 10-222
20 MEF2B 0.91 0.40 1 x 10-171
Table 3.4. Motif enrichment analysis in human iPSC microglia OCRs
% of Targets (proportion of microglial open chromatin sites containing specified motif); % of 
Background (proportion of randomly selected background regions containing specified motif); 
OCRs (open chromatin regions)
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= 7.19%; p-value = 1 x 10-1417) and PU.1-IRF (target = 5.88%, background = 2.87%; 
p-value = 1 x 10-962) motifs were significantly enriched compared to background open 
chromatin regions (see table 3.5). Crucially, in both iPSC lines Spi1 was either the 
most, or second most, significantly enriched motif reported, concordant with the ex 
vivo microglia motif enrichment analysis where Spi1 was the most significantly 
enriched motif.  
 
 
 
 
 
Table 3.6 shows the de novo motif enrichment analysis results for open chromatin 
regions derived from the SV40 microglia cell line. Of the 20 motifs shown, the highest 
ranked myeloid cell specific motif was CEBP-a, which was the fifth most significantly 
enriched motif in SV40 microglial open chromatin sites compared to a background 
set of open chromatin sites (target = 13.50%, background = 9.86%; p-value = 1 x 10-
392).  
 
Rank Motif % of Targets % of Background p-value
1 Spi1 32.83 11.14 1 x 10-12757
2 BORIS 6.23 1.60 1 x 10-3030
3 BATF 11.59 5.64 1 x 10-1979
4 CEBPA 12.65 7.19 1 x 10-1417
5 PU.1-IRF 5.88 2.87 1 x 10-962
6 Sp1 5.41 2.82 1 x 10-745
7 Zfp161 5.39 2.94 1 x 10-646
8 RUNX1 11.74 8.05 1 x 10-624
9 ZNF519 6.07 3.58 1 x 10-574
10 DCE_III 10.05 7.18 1 x 10-424
11 E2F3 4.28 2.63 1 x 10-345
12 MafK 13.66 10.66 1 x 10-338
13 Mef2d 2.31 1.38 1 x 10-200
14 DCE_II 27.33 24.32 1 x 10-184
15 MAFK 12.44 10.33 1 x 10-175
16 GCM1 9.55 7.80 1 x 10-154
17 SPIB 6.86 5.64 1 x 10-102
18 MGA 6.80 5.69 1 x 10-84
19 Nfe212 11.67 10.33 1 x 10-73
20 Zfp809 10.86 9.60 1 x 10-68
Table 3.5. Motif enrichment analysis in human iPSC MΩ precursor OCRs
% of Targets (proportion of microglial open chromatin sites containing specified motif); % of 
Background (proportion of randomly selected background regions containing specified motif); 
OCRs (open chromatin regions)
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CEBP-a is a pioneer transcription factor that drives myeloid cell lineage commitment 
through preferential enhancer selection during myeloid differentiation (285). As for ex 
vivo microglial open chromatin sites (discussed in section 2.3.1), the RUNX1 motif 
was also significantly enriched in the SV40 open chromatin regions over the 
background (target = 6.22%, background = 4.03%; p-value = 1 x 10-311), and was the 
10th ranked motif reported. However, in contrast to the ex vivo microglia motif 
enrichment results, there was no enrichment for motifs binding the myeloid lineage 
determining transcription factors Spi1 or IRF8. Indeed, when inspecting peaks over 
the SPI1 promoter of the ex vivo and in vitro microglial cell lines (see figure 3.1), there 
is a distinct peak present in all lines except the SV40s implying that chromatin is 
closed and that SPI1 is likely not expressed in the SV40 line.   
 
 
Rank Motif % of Targets % of Background p-value
1 Fra1 27.64 7.06 1 x 10-11345
2 BORIS 8.23 1.85 1 x 10-3550
3 TEAD4 14.82 9.56 1 x 10-807
4 ERG 18.00 12.90 1 x 10-609
5 CEBPA 13.50 9.86 1 x 10-392
6 EBF 21.64 17.15 1 x 10-388
7 Sp5 7.42 4.79 1 x 10-380
8 Zfp161 7.92 5.24 1 x 10-368
9 Zic3 6.34 3.99 1 x 10-357
10 RUNX1 6.22 4.03 1 x 10-311
11 Zic3 15.44 12.23 1 x 10-261
12 IRF1 1.63 0.73 1 x 10-244
13 ETV1 12.67 9.89 1 x 10-233
14 SOX10 21.96 18.68 1 x 10-197
15 Zfp691 27.78 24.26 1 x 10-191
16 c-Jun 6.41 4.68 1 x 10-176
17 BARHL2 20.70 17.69 1 x 10-175
18 Foxo1 20.73 17.74 1 x 10-172
19 Gfi1 7.85 6.02 1 x 10-159
20 NFkB-p65 2.37 1.43 1 x 10-153
% of Targets (proportion of microglial open chromatin sites containing specified motif); % of 
Background (proportion of randomly selected background regions containing specified motif); 
OCRs (open chromatin regions)
Table 3.6. Motif enrichment analysis in human SV40 microglia OCRs
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Common to all motif analyses is enrichment of generic transcription factor motifs such 
as Fra1 and BORIS. In humans FRA1 encodes a leucine zipper protein that forms 
part of the AP-1 transcription factor unit that regulates cell proliferation and 
differentiation (286) whilst BORIS is a paralog of CTCF, the latter of which encodes 
an 11 zinc finger protein that can act as a transcriptional activator or repressor (287). 
As both factors bind the same motif and are expressed in a mutually exclusive 
manner, (CTCF is widely expressed across tissues whereas BORIS is expresses 
mainly in gametes) it is likely these motifs bind CTCF (288,289). 
 
 
3.3.2 Principal component analysis  
 
Figure 3.2 depicts a plot of the first two principal components of the PCA 
undertaken for the ATAC-seq data from the 50 samples (10 cell types) included in 
the analysis. The first two principal components explained 85% of the total variance 
in the data. The first principal component, which captured 77% of the variance, 
generally separates 8 of the cell lines based on the environmental conditions from 
which the cells derived, with the trend, when moving from left to right on the plot, 
shifting from in-vitro to ex vivo cells. However, two ex vivo cell types derived from 
peripheral blood [i.e. the monocyte (lavender) and B cell (purple) samples] do not 
follow this trend and cluster with the cells that were processed in vitro. This may be 
Figure 3.1. ATAC-seq peaks in adult ex vivo, and cell lines of, human 
microglia. Representative genomic tracks showing 27kb surrounding the 
promoter of the myeloid lineage determining transcription factor SPI1. X-axis, 
genomic location; Y-axis, auto-scaled read counts. Adult ex vivo MG (Adult ex 
vivo microglia); iPSC_MG (induced pluripotent stem cell derived microglia); 
iPSC_MΩpre (induced pluripotent stem cell derived macrophage precursor);  
SV40 MG (Simian virus 40 large T antigen immortalised microglia).
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due to the fact these cells were cryopreserved after they were extracted and may 
have been more sensitive to the cryopreservation process than other ex vivo blood 
cells (NK-cells, CD8 T cells and, CD 4 T cells) processed in the same manner.  
 
   
   
 
 
 
The second principal component captures 8% of the variance in the data, and 
horizontally separates myeloid cells from lymphocytes at 0.0 on the y-axis, indicating 
that the PCA has clustered cells in a biologically relevant manner and that distinct cell 
types can be delineated based on differences in their open chromatin profiles.  
 
The iPSC_MG, iPSC_MΩpre and SV40 samples all cluster more closely with the ex 
vivo and in-vitro microglial samples and the blood monocyte samples (lavender), than 
the lymphoid cells samples (B cells, CD4 T cells, CD8 T cells, Mk cells), suggesting 
that all three cell lines have open chromatin landscapes more similar to myeloid cells 
than lymphoid cells. Similar to the result in the motif enrichment analysis reported in 
section 3.3.1, of the three cell lines I generated for the analysis, the open chromatin 
landscape of the SV40 cells (yellow) appears to recapitulate the landscape of the ex 
vivo microglia cells (orange) the least, as they cluster furthest from the ex vivo 
microglial samples. When comparing the similarity of the iPSC cell lines to the ex vivo 
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Figure 3.2. Principal component analysis plot of open chromatin site read counts derived 
from 10 cell lines. Ex-vivo MG (ex-vivo microglia); In-vitro MG (in-vitro microglia); iPSC_MG
(induced pluripotent stem cell microglia; iPSC_MΩpre (induced pluripotent stem cell 
macrophage precursors); SV40_MG (SV40 immortalised microglia; Monocyte (blood 
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microglia, the iPSC_MG cells cluster more closely with the iPSC_MΩpre cells and 
with monocytes derived from peripheral blood than with the ex vivo microglia. This 
implies that the final stage of the iPSC differentiation protocol, has not been 
successful in generating a line that recapitulates the open chromatin profile of adult 
microglia.  
 
 
3.4 Discussion 
 
Given the difficulty in obtaining primary human brain cells there is an unmet need to 
manufacture a human-derived cell line that is relatively easy to generate and 
maintain, and which, as closely as possible, can recapitulate microglial function in-
vivo. The rationale for this chapter was to measure, and compare, the open chromatin 
landscapes of 3 human-derived cell culture lines of putative myeloid origin, and to 
assess how these landscapes corresponded to the open chromatin landscapes of ex 
vivo cells at equivalent stages of myeloid cell development from the brain and 
circulatory system.  
 
Considering the iPSC lines, the motif enrichment analysis confirmed that these lines 
do have an open chromatin landscape consistent with what would be expected of a 
cell from the myeloid lineage. For example, open chromatin sites in both the 
iPSC_MG and iPSC_MΩpre cell lines contained motifs for key myeloid lineage 
determining transcription factors such as Sfpi1 and CEBP-a (see tables 3.3 and 3.4), 
suggesting that the iPSC differentiation protocol is capable of producing cells of 
myeloid lineage. However, as the motif enrichment profiles of both iPSC lines were 
similar, and these resembled the profile of ex vivo microglia, see table 2.1, it was not 
possible determine if the iPSC_MG and iPSC_MΩpre were distinct in order to (A) 
ascertain if the final stage of the iPSC differentiation protocol was successful and that 
iPSC_MGs did differentiate further to become more microglial-like than iPSC_MΩpre 
and (B) assess to what extent the open chromatin landscape of the iPSC_MG line 
resembled that of the ex vivo microglial cells. The PCA analysis was performed in an 
attempt to answer these questions.  
 
As the IPSC_MGs and iPSC_MΩpre samples clustered tightly with one another in the 
PCA analysis plot (see figure 3.2) and also cluster more closely with blood monocyte 
samples than with samples from ex vivo microglia, the implication is that the open 
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chromatin landscape of the iPSC_MGs more closely resembles that of cells derived 
from an earlier stage of the myeloid cell differentiation process (i.e. monocytes or 
macrophage precursor cells) than ex vivo microglia. This may reflect a limitation of 
the culture media in that the balance of factors within it may be insufficient to simulate 
the environmental conditions of the adult brain. Indeed, the fact that samples from 
both iPSC-derived lines cluster more closely with the in vitro microglia (which were 
shown to downregulate their microglial specific genes when placed in culture; 280), 
than the ex vivo microglia on PC2, supports this.  
 
Microglial phenotype is shaped by the local microenvironment which includes 
physical and chemical interactions with neighbouring brain cells. Given the exquisite 
sensitivity of microglia to signals from other cell types, the fact that the iPSCs were 
not generated in co-cultures containing other cells could also explain why the open 
chromatin landscape of the iPSC_MGs does not recapitulate that of the ex vivo 
microglia. For example, neurons have been shown to maintain the adult homeostatic 
phenotype, and have an immunosuppressant effect on microglia through direct 
interaction between neuronal membrane bound factor CD200 and its target receptor 
CD200R expressed by microglia (290). Interleukin-34, a cytokine produced 
predominantly by neurons in the brain (267) also interacts with microglia to promote 
microglial differentiation and homeostasis (267,291).  
 
Astrocytes also influence microglial phenotype via the activity of interleukins. 
Interleukin 33, which is released by synapse-associating astrocytes during post-natal 
neurodevelopment, has been shown to induce a synaptic engulfment phenotype in 
microglia via the IL1RL1 receptor in the thalamus (292). Conversely, interleukin-10 
that is released by activated microglia during neuroinflammation, stimulates 
astrocytes to release TGF-b which, in turn, acts to reduce microglial activation and 
homeostatically resolve the neuroinflammatory process (293). Moreover, it has been 
reported that in order for microglia to sustain the typical ramified morphology 
associated with their homeostatic phenotype, they must be simultaneously exposed 
to TGF-b, GM-CSF and M-CSF which are all released by astrocytes in the brain (294).  
Intriguingly, in the study from which the iPSC protocol used here was partly derived 
(268), a co-culture differentiation strategy was adopted and iPSC_MGs were 
differentiated in the presence of neurons. In their principal component analysis 
comparing gene expression profiles of various iPSC-derived and primary cell types, 
Haenseler and colleagues demonstrated that iPSC_MG cells co-cultured with 
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neurons were distinct from iPSC_MΩpre cells and a iPSC_MG incubated in 
monoculture of iPSC_MΩpres with microglia medium (268). Therefore, although it is 
not possible to make a direct comparison between studies as different functional data 
were used to assess cell similarity, the data presented by Haenseler and collegues 
suggests that a co-culturing methodology may recapitulate the brain 
microenvironment better than using an iPSC monoculture strategy.  
 
Considering the PCA results for the SV40 cells, all three samples cluster far from both 
the ex vivo microglia and the two iPSC lines suggesting that this line recapitulates the 
open chromatin landscape of ex vivo adult microglia the least out of all three cell lines. 
The lack of enrichment (and potentially expression) of the critical microglial lineage 
determining transcription factor Spi1 in the SV40 line (see table 3.5 and figure 3.1) 
suggests that the SV40 line has an altered gene regulatory profile when compared to 
the ex vivo microglia and iPSC-derived lines. This may be due to artefacts introduced 
during the immortalisation process and/or dedifferentiation that may have occurred in 
this cell line during culture (270,273). Indeed, in a recent study by Melief and 
colleagues comparing the gene expression profile of primary microglia to a suite of 
microglial cell culture lines, genes commonly identified as microglial-specific, and 
used as indicators for microglial specificity (CX3CR1, P2Ry12, MERTK, GAS6, 
PROS1 and GPR34), were shown to be expressed at extremely low levels, or be 
undetectable, in SV40 cells when compared to primary microglia (275). As such, the 
results presented here are consistent with previous work. 
 
There were several limitations of this study. First, only one biological replicate was 
used for each of the three cell culture lines generated. For the iPSC lines, this was 
due to the lack of cell availability, which was outside my control; however, in the case 
of the SV40 cells, I decided not to commit any further time or resources to this line 
once it was established that the motif analysis failed to find enrichment of Spi1. 
Having used only one biological replicate for each cell line, it is not possible to rule 
out that the findings reported here are due to specific batch effects introduced during 
cell culturing or the ATAC-seq laboratory protocol. A second limitation is that due to 
the differing iPSC-differentiation protocols used between this study and comparative 
microglia iPSC studies, any differences or similarities reported between the studies 
may be due to artefacts introduced using different methods. Third, as an iPSC’s 
phenotype resembles that of a cell from an early stage in its developmental life cycle, 
the comparison between iPSC_MG cells and ex vivo microglia, which have been 
extracted from adults, may not be as appropriate as comparing IPSC_MG to primary 
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foetal microglia. Indeed, several iPSC microglial studies use foetal microglia as the 
main ex vivo dataset for comparison and report transcriptomic similarities between 
iPSC_MG and primary foetal microglia (268,278,295). However, one study reports a 
transcriptomic similarity between iPSC_MG and both adult and foetal primary 
microglia, suggesting that aspects of adult primary microglia phenotype can be 
recapitulated in iPSC_MG cells (277).  
 
 
3.4.1 Future Work 
 
Due to the highly dynamic nature of microglia, and the strong influence that other 
brain cell types have on the microglial phenotype, future work should consider 
generating iPSC-derived microglial lines in co-culture with multiple cell types, such as 
using a triple culture approach involving astrocytes and neurons. As yet, no triple-
culture iPSC-derived microglia protocol has been published which is perhaps due to 
the fact that the factors required to differentiate non-microglial cell types can also 
compromise microglial function (e.g. Hanseler et al. omitted key neuronal supplement 
B27 from neuronal media for this reason; 263).  
 
One alternative in vitro model is the cerebral organoid, which is a multicellular, three-
dimensional structure resembling a cross-section of the embryonic human brain 
(296). Like iPSCs, cerebral organoids are generated from stem cells that, through the 
precisely timed application of Matrigel (components of extracellular matrix) and 
specific growth factors, are pushed toward a CNS fate. Organoids are considered a 
more physiologically relevant model than traditional 2D cell culture as their self-
organisational properties promote spatial cell-cell interactions that more accurately 
recapitulate the in vivo environment. As such, organoids have been shown to contain 
mature neurons (and astrocytes) with functional synapses after 6 months growth 
(297,298). Regarding microglia, until recently, the consensus view was that organoid 
tissue could only generate cell lines that derived from ectodermal tissue, and as 
microglia derive from the mesoderm, organoids were not suitable for the study of 
microglial function. However, a recent study by Ormel and colleagues produced a 
method to generate mesodermal tissue within human organoids such that microglia 
were shown to emerge from mesodermal progenitors, develop ramifications and 
express critical factors including PU.1, IRF8 and RUNX1 and cell surface markers 
such as TREM2, CX3CR1 and CD11b (299). Moreover, microglial processes were 
shown to interact with functional synapses in organoids, and synaptic debris was 
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detected in microglial vesicles implying that organoid microglia modulate and prune 
synapses in a similar fashion to in vivo microglia.  
 
Whilst organoids do not entirely recapitulate the environmental conditions of the 
human brain, culturing microglia in 3D models provides a means to circumvent the 
critical issue in 2D models where microglia removed from the brain downregulate their 
microglial-specific genes when placed in culture conditions (157,265,280), as 
organoids are capable of intrinsically producing the factors that interact with microglia 
cell surface receptors to maintain their identify (i.e. CSF1 and Il-34). Several studies 
have emerged in recent years using organoids to model complex brain disorders. For 
example, Mariani et al. generated telencephalic organoids derived from individuals 
with ASD, who also displayed a macrocephaly phenotype, and healthy controls (300). 
Using a combination of cellular, transcriptome and RNA interference analysis Mariani 
et al., demonstrated that that there was an overproduction of GABAergic neurons and 
progenitor cells in organoids from ASD individuals and that this was driven by 
increased expression of the transcription factor FOXG1, supporting the hypothesis 
that an imbalance between excitatory and inhibitory neuronal activation states 
contribute to ASD aetiology (301).  
 
 
3.4.2 Closing remarks 
 
By comparing the open chromatin landscape of iPSC-derived microglial models, to 
that of ex vivo microglia and in vitro cells of the brain and circulatory system, I have 
established that the open chromatin landscape of iPSC_MG cells generated in 
monoculture (and following the Haensler et al. protocol), is more similar to that of cells 
antecedent to macrophages in the myeloid differentiation process (i.e. macrophage 
precursor cells or peripheral monocytes) than ex vivo adult microglia. I also 
demonstrate that the open chromatin landscape of SV40 cells does not recapitulate 
that of adult ex vivo microglia in line with previous work. In the next chapter, I will 
consider the open chromatin landscape of cryopreserved microglia extracted from the 
human foetal brain. 
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4 The open chromatin landscape of FACS sorted 
cryopreserved foetal microglia 
 
4.1 Introduction 
 
Producing novel functional genomic data from primary human brain tissue, and 
integrating it with robust genetic associations, will be essential to enhance our 
understanding of how non-coding genetic variation contributes to the onset and 
progression of complex brain disorders. Of particular importance will be determining 
the developmental and cellular contexts in which risk variants are active.  
 
A prominent theory regarding the aetiologies of psychiatric disorders, particularly 
schizophrenia, ASD and ADHD, is that at least some of the perturbations that drive 
the onset of symptoms in later life occur during prenatal brain development 
(302,303). Evidence from epidemiological and animal studies have shown that 
maternal environmental insults, such as immune activation, during this period can 
increase the risk for schizophrenia and autism in offspring (230–234), and has led to 
the suggestion that synergistic effects between environmental stimuli and genetic 
susceptibility variants during this critical period can lead to the expression of 
disease-relevant endophenotypes (304). Microglial colonisation of the foetal brain 
occurs before neurogenesis and neural migration levels have reached their peak 
(305), which has led to the hypothesis that microglia have a pivotal role in shaping 
neuronal development (178,306). As described in chapter 1, microglia control key 
neurodevelopmental processes such as synaptic pruning and apoptosis (178,188). 
Furthermore, evidence across many complex brain disorders implicates the immune 
system as a key contributor to their genetic liability. As microglia are the 
predominant immune cell in the brain, it is plausible that non-coding risk variants 
that operate in microglial regulatory regions during this critical period of 
neurodevelopment could directly impact risk for a disorder, or synergistically 
operate via the environment to do so. 
 
Several groups have recently integrated brain disorder GWAS data with functional 
information derived from human foetal brain tissue to shed light on early 
neurodevelopmental risk mechanisms for these conditions. For example, O’Brien 
and associates, mapped expression quantitative trait loci (eQTL) operating in the 2nd 
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trimester human brain, finding these to be enriched for common genetic risk 
variants for ADHD, bipolar disorder, and schizophrenia (307). Furthermore, de la 
Torre Ubieta and colleagues used ATAC-seq to measure chromatin accessibility in 
different regions of the mid-gestation human cerebral cortex, reporting that common 
variants associated with schizophrenia and ADHD were enriched in open chromatin 
sites in the germinal zone (associated with neural progenitor cells) but not enriched 
in those from the cortical plate (containing more mature neuronal cells; 292). 
However, a major drawback with these studies is that they could not determine how 
specific cell types contribute to the risk burden as their analyses were carried out on 
mixed populations of cells from bulk tissue. As gene regulatory processes such as 
chromatin accessibility, transcription factor expression and posttranslational 
modifications can be cell-type specific, genetic risk variants in non-coding regions 
could be regulated differently in distinct cell types. It is therefore of crucial 
importance to map cell-specific gene regulation in the developing human brain.  
 
 
4.1.1 Aims 
 
There is a current lack of functional genomic data derived from cells of the human 
foetal brain. Based on the hypothesis that foetal microglia mediate some of the 
genetic risk for brain disorders, the aim of this chapter was to produce a novel 
dataset that captured the open chromatin landscape of ‘microglia’ extracted from 
second trimester foetal human brain tissue for integration with genetic data. To do 
this, I extracted CD11b+ cells from cryopreserved foetal brain cell suspensions using 
fluorescence activated cell sorting, and then mapped regions of open chromatin in 
extracted cells using ATAC-seq. In a similar manner to the partitioned heritability 
analysis in chapter 1, I tested foetal microglial open chromatin regions for 
enrichment of risk SNPs from a panel of brain disorder GWAS to ascertain whether 
risk for these disorders might be conferred through altered gene regulation in foetal 
microglia.  
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4.2 Methods 
 
4.2.1 Samples 
 
Human foetal brain tissue from elective terminations of pregnancy was provided by 
the Human Developmental Biology Resource (HDBR) (http://www.hdbr.org). The 
age (in post-conception weeks (PCW)) and sex of the 3 samples used in this study 
are shown in table 4.1 (information provided by the HDBR). 
 
 
 
 
 
4.2.2 Foetal tissue dissociation 
 
Human foetal brain samples arrived as a single intact hemisphere that was 
immediately weighed (range 12.98-18.45g) and the meninges carefully removed. To 
homogenise the tissue, a scalpel was used for gross dissection and the dissected 
tissue was added, in batches if required, to a dounce homogeniser until the volume 
of tissue reached approximately 1cm below the fill line. Hibernate-E (Gibco) was 
added to the douncer until the fill line of was reached, and then 6 strokes of pestle A 
were applied to the douncer, followed by 6 strokes using pestle B. The homogenate 
was then transferred to a 50ml Falcon tube. This process was repeated until all tissue 
was homogenised. The total volume of the homogenate was then adjusted to ~45ml 
by adding Hibernate-E. For storage, 1ml aliquots of the tissue homogenate, 
containing 6% DMSO (Sigma), were taken and transferred into cryovials (Griener). 
Each vial was inverted 5 times to mix and all vials were cryopreserved in a Nalgene 
Mr Frosty container containing isopropanol which gradually cools the homogenate at 
a rate of -1oC/minute. Cryovials were kept at -80oC until required for further 
processing. Prior to cryopreservation, approximate cell counts were taken for each 
sample and these ranged from ~35-45 million cells per ml. 
Sample ID PCW Sex Hemisphere Date received
14404 19 M Right 17/10/2018
14473 17 M Left 21/11/2018
14611 15 F Right 06/02/2019
Table 4.1. Human foetal sample information
Sample ID (Sample identification number); PCW (post conception weeks); Sex (sex of 
foetus); Hemisphere (Brain hemisphere received for analysis).
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4.2.3 Fluorescence activated cell sorting (FACS) 
 
Fluorescence activated cell sorting (FACS) is a flow cytometry method that allows 
the separation of individual cell populations from a heterogenous mixture of cells 
based on cellular light scatter and fluorescence characteristics. During this process, 
mixed cells passing through the sorter are hydrodynamically focussed to shuttle 
past a laser beam in a steady stream, one cell at a time. As cells are moved through 
the sorter’s interrogation point, light from the laser is transmitted onto each cell and 
the scattering patterns of the deflected photons are used to measure the size and 
structural complexity of the cells (309). Cells can be further distinguished based on 
fluorescence characteristics. To facilitate this, antibodies that recognise a target 
feature on the outer membrane of a cell of interest are pre-labelled with fluorescent 
compounds called fluorophores, and then incubated with the mixed cell population. 
As the antibody should only bind to the cell of interest, when mixed cells pass the 
laser, electrons in the fluorophore are excited into higher orbitals by high energy 
photons in the laser light. Given that electrons in high orbitals are unstable, the 
electron quickly returns to its ground state and emits lower energy light, or 
fluoresces, as it does so. The light that the fluorophore emits can be used to 
distinguish fluorescently labelled cells from non-labelled cells. A range of 
fluorophores are available with different excitation and emission spectra which 
makes it possible to sort multiple cells types during one FACS experiment. 
 
In preparation for FACS, 10-15 Eppendorf tubes were filled and incubated overnight 
(under rotation) with FACS buffer (0.5% bovine serum albumin, 2mM EDTA and 
PBS, pH 7.2). The following morning, 3 cryovials of dissociated cryopreserved foetal 
cells were placed in a 37oC water bath and rapidly defrosted. The approximate cell 
number at the start each assay was 105-135 million cells. To accord with the 
recommended antibody dilution and maximum cell input recommended by the 
antibody supplier (1:50 for up to 10 million cells), defrosted cells were split evenly 
between 11-14 pre-coated Eppendorf tubes and centrifuged at 3200rpm for 5 mins 
at 4oC. Identical centrifuge parameters were used throughout this protocol. The 
supernatant was removed from each tube and the cell pellets retained. Cells were 
then resuspended and washed in FACS buffer and centrifuged. After the 
supernatant was removed, cell pellets were resuspended in FACS buffer and 
incubated with antibodies targeting the myeloid cell surface receptor CD11b, for 10 
minutes. The CD11b antibodies were pre-conjugated to the fluorophore APC 
(CD11b-APC; Miltenyi Biotech 130-110-612) for detection by FACS. The final 
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dilution of antibody in FACS buffer was 1:50. Cells were again washed in FACS 
buffer, centrifuged and the supernatant was removed. All cells were then pooled in 
3ml of FACS buffer and placed in a pre-chilled FACS tube.  
 
Cells were sorted on a FACS Aria III cell sorter using 100µm nozzle with the tube 
temperature set to 4oC. No compensation was required as only one fluorophore was 
used during sorting. Cells were sorted at a rate of ~20 million per hour for a 
maximum of 3 hours.  
 
 
4.2.4 FACS gating 
 
The gating strategy that was used for sorting CD11b+ cells is depicted in figure 4.1 
and was a 3-stage process.  
 
 
 
 
 
Figure 4.1: Representative gating strategy for sorting 
cryopreserved foetal cells by CD11b-APC fluorescence. 
Top left side scatter area (SSC-A) against forward scatter 
area (FSC-A). Top right forward scatter height (FSC-A) 
against forward scatter area. Bottom left and right APC 
fluorescence (CD11bAPC-A) against side scatter area. Black 
dots either cellular debris or cell doublets. Red dots cell 
doublets. Blue dots, individual foetal brain cells with low APC 
fluorescence and deemed CD11b-. Pink dots individual foetal 
brain cells with height APC fluorescence and deemed 
CD11b+. Inclusion gates shown in black outline.
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Firstly, cells were sorted on forward scatter area (FSC-A) and side scatter area 
(SSC-A) (see figure 4.1 P1); the former estimates the size of each cell and the latter 
the structural complexity of the cells (i.e. their granularity). Due to the high cell input 
level it is not possible to see clustering of distinct cell types based on these 
parameters. However, this gate was used primarily to omit cellular debris, indicated 
in black and located at the bottom left hand side of the plot, and cell doublets, also 
indicated in black but located to the right, and upper right-hand side of plot A. To 
further enhance the doublet exclusion criteria the area scaling parameter of the 
sorter was used, which when set, produces a forward scatter height (FSC-H) and 
FSC-A correlation value for cells of the same size. Singlet cells would be located in 
a diagonal smear between 45o and 90o. In figure 4.1 P2, cells in blue were 
considered singlets and included in sorting, whereas red cells were considered 
doublets, or clumps of cells, and excluded from the sort. 
 
The final gate was set based on the CD11b-APC fluorescence level. Two distinct 
clusters of cells were seen when CD11b-APC fluorescence level was plotted 
against SSC-A (see figure 4.1 P3): a large dense cluster with low APC fluorescence 
(CD11b- cells), indicated in blue, and a small sparsely distributed cluster with 
relatively high APC fluorescence (CD11b+ cells), indicated in pink. Although the 
threshold distinguishing CD11b+ from CD11b- cells was arbitrarily set, it was set 
conservatively to exclude as much of the large CD11b- population as possible.  
 
FACS sorted, CD11b+ cells were collected in FACS buffer, and once the sorting 
process was complete, all CD11b+ cells were centrifuged, the supernatant removed, 
and the cells immediately used for ATAC-seq library preparation. 
 
 
4.2.5 ATAC-seq library preparation 
 
ATAC-seq library preparation for the FACS sorted CD11b+ cells followed the OMNI-
ATAC protocol (282), exactly as described in 3.2.4.  
 
 
4.2.6 Sequencing, QC and bed file preparation 
 
Paired-end 75 base sequencing was carried out on all 6 foetal brain derived microglial 
ATAC-seq libraries using the Illumina HiSeq4000. Sequencing files were de-
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multiplexed, and then sequencing adapters and poor-quality reads were removed 
using Trim Galore (www.bioinformatics.babraham.ac.uk/projects/trim_galore/). In 
total, 12 fastq files were generated, each containing either the forward or reverse 
reads for a particular ATAC-seq library. The sequencing depth of each file was 
between 70-114 million reads. For quality control, FastQC (237) was run separately 
on all fastq files and MultiQC (238) used to collate the FastQC output. All files passed 
the quality control measures. 
 
After quality control, read pairs for all samples were matched and aligned to the 
human genome (hg19; average alignment score >80%), using Bowtie2 (239) and 
mitochondrial reads were removed using Samtools (240). For peak calling, MACS2 
(241) was run using BAMPE to handle paired-end reads and the FDR set to < 0.05 as 
the threshold for peak significance.  Duplicate reads were ignored by MACS2 during 
the analysis by default. The final output from the peak calling process is a peak file. 
 
In total, 6 unique peak files were obtained, corresponding to two technical replicate 
files for each of the 3 biological donors. Using these, I carried out a series of steps to 
obtain a single bed file that contained high confidence open chromatin regions 
operating in foetal microglia (CD11b+ cells) that are not shared with other cells of the 
foetal brain. Initially, to improve the signal to noise ratio, technical replicate bed files 
for each donor were merged using Bedtools (310). Diffbind was then used to create 
a single consensus bed file by retaining peaks that were present in at least 2 of the 3 
merged donor files (242). Next, to select open chromatin regions that are not shared 
with other cells of the developing human brain, the consensus file was intersected 
with an ATAC-seq peak file generated using bulk human foetal brain tissue (provided 
by my colleague Dr. Manuela Kouakou) and overlapping regions were removed 
(bedtools intersect -v). Finally, in order to retain only high confidence open 
chromatin regions within this ‘microglia-specific’ peak set, the file was intersected 
(bedtools intersect -wa) with a file containing genomic regions that are 
evolutionarily conserved in mammals, which was obtained from the 29 mammals 
project repository (https://www.broadinstitute.org/mammals-models/29-mammals-
project-supplementary-info; 300). This final set of 35,466 peaks was used for all 
further analyses and will henceforth be referred to as 'conserved foetal microglia open 
chromatin regions’. Peaks were visualised as described in section 3.2.5.  
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4.2.7 Functional enrichment analysis 
 
The online tool Genomic Regions of Enrichment Annotations (GREAT; 301) was 
used to test whether genes in proximity to conserved foetal microglia open 
chromatin regions are enriched within particular biological categories. GREAT 
functions by assigning all genes a basal regulatory domain that consists of a 
proximal domain (5kb upstream and 1kb downstream of the gene TSS) and a distal 
domain (1Mb upstream or downstream of the TSS) and calculates the enrichment of 
regulatory regions (provided by the user) within these domains using a binomial test 
that corrects for variability in gene regulatory domain size. GREAT was accessed 
(http://great.stanford.edu/) and run on May 23rd 2019, using the conserved foetal 
microglia open chromatin regions file and the whole human genome (hg19) as 
background. 
 
 
4.2.8 De novo motif enrichment analysis 
 
De novo motif enrichment analysis was used to test enrichment of transcription 
factor binding motifs within conserved foetal microglia open chromatin peak set. The 
HOMER package was used for this analysis as described in chapter 2.2.3. 
 
 
4.2.9 Testing enrichment of risk variants for brain disorders within conserved 
foetal microglia open chromatin regions 
 
SNPs within conserved foetal microglia open chromatin regions constituted 0.24% 
of the total SNPs contained within the 1000 genomes reference panel. As this 
proportion of SNPs within the functional annotation is below the recommended 
minimum of 1% for stratified LD score regression (sLDSR), an alternative method to 
test risk SNP enrichment within these sites was sought. 
 
GARFIELD (GWAS analysis of regulatory or functional information enrichment 
with LD correction; 313)) is a software package designed to test for enrichment of 
GWAS risk variants in functional categories. Whereas sLDSR tests the enrichment 
of SNP heritability within functional annotations (i.e. the proportion of genetic 
variance in a trait explained by all SNPs), GARFIELD tests for enrichment of SNPs 
associated with the trait at specific p-value thresholds, by comparing these to an 
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independent set of SNPs matched for minor allele frequency, distance to the 
nearest transcription start site, number of linkage disequilibrium proxies and GC 
content.   
 
To identify SNPs that overlapped regulatory regions for the GARFIELD analyses, 
custom annotation files were created. SNP information was provided with the 
GARFIELD software and was derived from the UK10K sequence data (314). 
Bedtools (310) was used to intersect SNP base positions with open chromatin 
regions derived from the ATAC-seq experiments, and each SNP was annotated 
with a 1 or 0 to indicate whether or not it fell within an open chromatin region. 
GWAS summary statistics were prepared using the garfield-create-input-
gwas.sh script provided to retain only the base position and trait-associated p-
value information for each SNP. GARFIELD required four additional files, all 
provided with the software, for the analyses. These included two LD tag files, 
derived from the UK10K study, that contain LD information for each SNP at two 
different thresholds (r2 >= 0.1 and r2 >= 0.8). To reduce the set of GWAS variants 
included in the analysis to a more computationally tractable independent set of 
SNPs, the lower LD r2 threshold was used for a process called greedy pruning. This 
involved partitioning the genome into 1Mb windows, and for each window, 
sequentially removing SNPs with r2 value > 0.1 relative to the most significant trait-
associated variant and retaining the next most significant independent SNP (with r2 
< 0.1 being taken as an approximate measure of SNP independence) until a pruned 
set of independent SNPs was obtained. The higher threshold was used as the 
inclusion criteria for SNPs overlapping a functional region, i.e. a SNP was 
considered overlapping if it, or one of its LD proxies within 500kb (r2 >= 0.8), was 
located within the open chromatin region. Finally, files to match variants by minor 
allele frequency and distance to the nearest transcription start site were included, 
the latter to correct for bias driven by local gene density. GARFIELD was applied to 
7 GWAS of brain traits described in section 2.3.2. A GWAS of wearer of glasses or 
contact lenses (WGL; 249) which includes a similar number of genome-wide 
significant variants, but which does not appear to involve the immune system, was 
also tested as a negative control. To allow testing of traits with relatively low 
numbers of identified genome-wide significant SNPs, I tested enrichment of variants 
associated with traits at two P-value thresholds: P < 1 X 10-5 and P < 1 X 10-8. 
Statistical significance was calculated using a generalised linear model and 
enrichment relative to matched SNPs reported as an odds ratio. Empirical P-values 
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that survive Bonferroni-correction for 16 tests (8 traits at two GWAS P-values = P < 
0.00313) are highlighted.  
 
4.2.10 Overlap of open chromatin regions in conserved foetal and conserved 
adult microglia 
 
To statistically test the overlap of open chromatin regions in conserved foetal and 
conserved adult microglia open chromatin regions, I performed a two-tailed Fisher’s 
exact test using bedtools (310). The bedtools fisher command was run using 
the conserved foetal and adult microglial files, and the chromosome sizes of the 
genome the peaks were called from was also specified (hg19). Chromosome sizes 
are required to complete the Fisher’s exact test contingency table and estimate the 
total number of possible intervals from which the peak intervals contained within 
each file could have derived. This makes it possible to estimate the number of 
intervals across the genome that are contained in neither peak file, which is 
required to complete the test contingency table.  
 
 
4.3 Results 
 
4.3.1 Characterisation of foetal microglial-specific ATAC-Seq peaks 
 
Whilst the quality control procedures and data cleaning steps described in the 
methods (section 1.2.8) were designed to extract artefacts in the data (particularly 
contamination from other, non-microglia, brain cell types), it was important to further 
test that the FACS process was successful in isolating microglia. The online tool 
GREAT was therefore used to test whether genes that are proximal to identified 
open chromatin regions are enriched within particular biological categories of 
relevance to immune cells. 
 
Figure 4.2. shows GREAT biological process terms that were most significantly 
associated with the foetal CD11b+ cell open chromatin regions. Five of the 12 most 
significantly enriched terms describe immune functions, including the regulation of 
myeloid leukocyte mediated immunity and macrophage differentiation. As these 
terms are immune cell-specific, and no non-immune brain cell-specific biological 
processes were reported (i.e. neuronal or oligodendrocyte specific processes), 
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these results suggest that the FACS process was successful in purifying CD11b+ 
cells from the mixed foetal brain cell population. 
 
 
 
 
 
Considering the de novo motif enrichment results shown in table 4.3, foetal 
microglia open chromatin regions were significantly enriched for the myeloid fate 
determining factor Spi1 (target = 2.59%, background = 1.43%; p-value = 1 x 10-305; 
(146,315). Similar to the GREAT analysis results in table 4.2, no transcription factor 
motifs specific to non-myeloid cells were identified in the motif enrichment analysis, 
providing further evidence that the CD11b+ cell purification processing was 
successful. 
 
 
Enrichment FDR cor. P-value
Preganglion parasympathetic nervous system development 3.18 2.37 x 10-41
Parasympathetic nervous system development 2.75 1.41 x 10-36 
Macrophage differentiation 3.6 1.67 x 10-36
Filipodium assembly 2.72 6.31 x 10-32
Glossopharyngeal nerve development 3.6 2.77 x 10-27
Myoblast fate commitment 3.41 5.46 x 10-27
Response to type I interferon 2.26 7.71 x 10-27
Regulation of apoptotic process involved in morphogenesis 4.06 1.18 x 10-25
Glomerular endothelium development 6.68 2.56 x 10-25
Type I interferon-mediated signalling pathway 2.22 4.07 x 10-25
Cellular respone to type I interferon 2.22 4.43 x 10-25
Regulation of myeloid leukocyte mediated immunity 2.65 3.84 x 10-23
Table 4.2. GREAT functional enrichment analysis of human foetal microglial open chromatin regions
Term Name
   FDR cor. P-value (false discovery rate corrected p-value)
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When inspecting the foetal sample peaks tracks (see figure 4.2), similar to adult ex 
vivo and iPSC-derived microglia, there is a clear peak over the SPI1 promoter 
indicating that myeloid specific open chromatin regions can be distinguished in the 
foetal samples. 
 
Rank Motif % of Targets % of Background p-value
1 BORIS 2.97 0.95 1 x 10-1082
2 Zfp161 5.64 2.61 1 x 10-1061
3 Egr1 7.93 4.44 1 x 10-921
4 EGR1 4.77 2.38 1 x 10-747
5 HINFP 8.84 5.85 1 x 10-552
6 Spi1 2.59 1.43 1 x 10-305
7 ZNF189 3.86 2.73 1 x 10-166
8 Rfxdc2 16.46 14.32 1 x 10-140
9 Zfp691 13.83 12.04 1 x 10-115
10 NKX2 1.73 1.13 1 x 10-110
11 NPC 0.74 0.38 1 x 10-106
12 HOXA2 10.13 8.79 1 x 10-85
13 ZNF528 0.04 0.00 1 x 10-82
14 FXR 0.05 0.00 1 x 10-81
15 p53 4.10 3.30 1 x 10-73
16 Smad3 18.22 16.63 1 x 10-70
17 NFIX 0.03 0.00 1 x 10-66
18 bHLH 0.03 0.00 1 x 10-63
19 FOS::JUN 0.03 0.00 1 x 10-63
20 STAT1::STAT2 0.04 0.00 1 x 10-60
Table 4.3. Motif analysis of human foetal microglia OCRs
% of Targets (proportion of microglial open chromatin sites containing specified motif); % of Background 
(proportion of randomly selected background regions containg specified motif); OCR (open chromtin region)
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4.3.2 Principal component analysis 
 
To compare the open chromatin landscape of the foetal microglia to that of the ex 
vivo and in vitro cell lines generated in chapter 3 (see section 3.3.2), the principal 
component analysis described in section 3.2.7 was performed again with the foetal 
sample data added.  
 
The plot for the first two principal components (PCs) is shown in figure 4.3. As in the 
previous analysis (see figure 3.2), the first two principal components explained 85% 
of the total variance in the data. However, when the foetal data was added to the 
analysis PC1 and PC2 captured 78% and 7% of the variance respectively, as 
opposed to 77% and 8% when the foetal data was excluded. As PC2 separates 
cells of myeloid and lymphoid origin at 0.0, the fact that the foetal microglia samples 
cluster with myeloid cells provides additional evidence that the cell purification 
process was successful. Interestingly, on PC2 the foetal samples cluster more with 
the iPSC lines and the SV40 cells than the samples generated from adult microglia 
(Ex-vivo MG and In-vitro MG). This highlights that the open chromatin landscapes of 
foetal and adult microglia differ and suggests that open chromatin sites in human-
Figure 4.2. ATAC-seq peaks in adult ex vivo, foetal, and cell lines of, human 
microglia. Representative genomic tracks showing 27kb surrounding the 
promoter of the myeloid lineage determining transcription factor SPI1. X-axis, 
genomic location; Y-axis, auto-scaled read counts. Adult ex vivo MG (Adult ex vivo
microglia); iPSC_MG (induced pluripotent stem cell derived microglia); 
iPSC_MΩpre (induced pluripotent stem cell derived macrophage precursor);  SV40 
MG (Simian virus 40 immortalised microglia); Foetal MG (cryopreserved 2nd
trimester foetal microglia).
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derived in vitro cell models are a better approximation of foetal microglia than adult 
microglia.  
 
 
 
 
Considering PC1, the foetal microglial samples are the most widely spread of all cell 
types in the analysis. The large variability between the open chromatin landscapes 
of the foetal samples may be explained by the fact that samples derived from 
donors of differing age and sex, or that the tissue for each donor derived from 
different brain hemispheres (see table 4.1), which may have affected microglial 
chromatin accessibility. Other factors such as the post-mortem delay period 
between the extraction of the foetal brain and its arrival for processing (usually 1-2 
days) may also have contributed to this variability. Given that chromatin integrity 
and post-translational modifications have been reported to be stable for >48 hours 
post-mortem (316,317) it is unlikely that chromatin degradation underlies this 
variability. However, changes to the brain microenvironment during brain removal or 
transit may have induced chromatin accessibility changes in microglia, further 
contributing to between-sample variability.  
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Figure 4.3. Principal component analysis plot of open chromatin site read counts derived 
from 11 cell lines. Ex-vivo MG (ex-vivo microglia); In-vitro MG (in-vitro microglia); iPSC_MG
(induced pluripotent stem cell microglia; iPSC_MΩpre (induced pluripotent stem cell 
macrophage precursors); SV40_MG (SV40 immortalised microglia; Foetal_MG (foetal 
microglia); Monocyte (blood monocytes); B cell (B cells); NK cell (Natural Killer cells);. X-axis = 
principal component 1; y-axis = principal component 2. Read counts are log2 normalised.
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4.3.3 Enrichment of bipolar disorder and schizophrenia risk SNPs in 
conserved foetal microglia open chromatin regions 
 
 
GARFIELD was used to test for enrichment of SNPs taken from 7 brain disorder 
GWASs, and a negative control (described in chapter 2.3.2), at 2 GWAS 
significance thresholds, in conserved foetal microglia open chromatin regions. Table 
4.4 shows the GARFIELD output for the 16 SNP enrichment tests carried out.  
 
 
 
 
 
SNPs associated with bipolar disorder at both the P < 1 X 10-8 and P < 1 X 10-5 
GWAS P-value threshold were significantly enriched in conserved foetal microglia 
open chromatin regions (P < 0.05), with the significance of the latter surviving 
Bonferroni correction for 16 tests (odds ratio = 2.97; P = 8.97 X 10-5). SNPs 
associated with schizophrenia at the P < 1 X 10-5 GWAS P-value threshold were 
also enriched at a P-value that survived correction for multiple testing (odds ratio = 
1.67; P = 0.003). While significant enrichment of SNPs associated with major 
depressive disorder at the P < 1 X 10-5 GWAS P-value (P = 0.022) was also 
observed, this did not survive correction for multiple testing. However, it is noted 
that the MDD and BPD SNP enrichment test statistics for SNPs at the P < 1 X 10-8 
threshold may have reduced reliability given that only 2 GWAS-associated SNPs fell 
within conserved foetal microglial open chromatin regions for these tests. 
Conserved foetal microglial open chromatin regions were not enriched for SNPs 
associated with any other trait, including the negative control of wearer of glasses or 
contact lenses (WGL).  
 
GWAS GWAS Thresh OR p-value cor. p-value Beta SE CI95_L CI95_U No. Annot Thesh N. Annot N. Thresh No. of SNPs
ADHD 1 x 10-5 1.62 0.352 1.000 0.483 0.519 -0.535 1.500 4 2,443 138 233,701
ADHD 1 x 10-8 7.41 x 10-8 0.998 1.000 -16.418 6173 -12116 12083 0 2,443 4 233,701
AUTISM 1 x 10-5 0.80 0.822 1.000 -0.229 1.016 -2.219 1.762 1 2,996 103 357,689
AUTISM 1 x 10-8 7.10 x 10-7 0.997 1.000 -14.158 4327 -8494 8466 0 2,996 1 357,689
BPD 1 x 10-5 2.97 8.97 x 10-5 1.43 x 10-3 1.087 0.278 0.543 1.631 15 8,461 227 1,191,616
BPD 1 x 10-8 7.76 0.017 0.268 2.049 0.856 0.371 3.728 2 8,461 8 1,191,616
LOAD 1 x 10-5 2.23 0.063 1.000 0.804 0.433 -0.045 1.652 6 2,874 113 262,885
LOAD 1 x 10-8 5.06 x10-8 0.994 1.000 -16.800 2380 -4680 4647 0 2,874 43 262,885
MDD 1 x 10-5 2.08 0.087 1.000 0.732 0.428 -0.107 1.570 7 8,343 159 1,157,454
MDD 1 x 10-8 6.70 0.022 0.357 1.902 0.832 0.271 3.534 2 8,343 8 1,157,454
NEUROTICISM 1 x 10-5 1.30 0.252 1.000 0.259 0.226 -0.184 0.702 24 8,063 697 907,858
NEUROTICISM 1 x 10-8 1.55 0.402 1.000 0.436 0.520 -0.583 1.455 5 8,063 84 907,858
SCZ 1 x 10-5 1.67 0.003 0.045 0.511 0.171 0.176 0.847 39 2,895 1,042 317,182
SCZ 1 x 10-8 1.68 0.117 1.000 0.520 0.332 -0.131 1.171 10 2,895 232 317,182
WGL 1 x 10-5 1.78 0.570 1.000 0.580 1.022 -1.423 2.583 1 5,389 68 891,538
WGL 1 x 10-8 8.60 x 10-7 0.997 1.000 -13.966 3762 -7387 7359 0 5,389 2 891,538
GWAS Thresh (GWAS significance threshold); OR (Odds ratio); p-value (emprical p-value of the significance of the observed enrichment); cor. p-value (p-value Bonferroni corrected for 16 tests); Beta (effect size from the general 
linear model, equal to log(OR)); SE (standard error from generalised linear model); CI95_L (lower boundary for the 95% CI of the effect size/beta); CI95_U (upper boundary for the 95% CI of the effect size/beta);  No. Annot. 
Thresh (number of annotated variants within annotation passing GWAS thresh); N.Annot (number of variants within given annotation); N.Thresh (number of variants passing GWAS thresh); No. of SNPs (total number of LD 
pruned variants). ADHD (Attention deficit hyperactvity disorder); ASD (Autism spectrum disorder); BPD (Bipolar disorder); LOAD (Late onset Alzheimer's disorder); MDD (Major depressive disorder); SCZ (Schizophrenia); WGL 
(Wearer of glasses or contact lenses).
Garfield Results - Psych GWAS vs. FOETAL hMG Reg. Regions (bulk ext/evo conserved)
   Table 4.4 Enrichment of brain disorder GWAS SNPs in conserved foetal microglia open chromatin regions 
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4.3.4 Evolutionary conservation does not account for bipolar disorder / 
schizophrenia SNP enrichment signals in foetal microglial open 
chromatin regions 
 
As previous studies have reported that GWAS SNPs for a variety of human traits 
are enriched in genomic regions that are highly conserved in mammals (244), it was 
important to test whether the SNP enrichment signals for bipolar disorder and 
schizophrenia reported in section 4.3.3 were driven by open chromatin regions in 
microglia rather than conserved sequence alone. To test this, fastq files for ATAC-
seq data derived from 5 human adult non-brain tissues (oesophagus, colon, heart, 
liver, stomach) were obtained from the ENCODE repository 
(https://www.encodeproject.org). These files were processed in exactly the same 
way as described in section 4.2.9 for the foetal ATAC-seq data, including the foetal 
bulk extraction and evolutionary conserved region intersection steps. GARFIELD 
was run on the on all tissues and GWASs using the same parameters outlined in 
section 4.2.9. 
 
As before, enrichment of SNPs associated with the 8 traits were tested at two 
GWAS significance thresholds: P < 1 X 10-8 and P < 1 X 10-5. In contrast to the 
enrichment observed within conserved foetal microglia open chromatin regions, 
SNPs associated with bipolar disorder were not enriched in conserved open 
chromatin regions in any of the 5 ENCODE tissues at even nominal significance (all 
P > 0.05). SNPs associated with schizophrenia were enriched in conserved open 
chromatin regions from some, but not all, ENCODE tissues, and for colon the 
significance survived Bonferroni correction for 16 tests (GWAS P < 1 x 10-5, OR = 
1.90, P = 2.97 x 10-4; GWAS P < 1 x 10-8, OR = 3.18, P = 5.80 x 10-5; see chapter 
8.1, tables 8.1-8.3). LOAD associated SNPs were also enriched in open chromatin 
sites in 2 of the 5 ENCODE tissues tested, with the test statistic in the liver surviving 
Bonferroni correction (GWAS P < 1 x10-5, OR = 6.26; GWAS P < 1 x 10-5, OR = 
12.24; see chapter 8.1, tables 8.4-8.5); however as only 3 or less LOAD associated 
SNPs were captured in conserved adult non-brain tissue OCRs the validity of these 
test results will have to be independently verified. GWAS-associated SNPs for the 
other brain traits were not significantly enriched in conserved open chromatin 
regions from any ENCODE tissue after multiple testing correction, (see chapter 8.1, 
tables 8.1-8.5), implying that the inclusion of evolutionary conserved regions is not 
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sufficient to drive SNP enrichment signal in open chromatin regions from non-
relevant tissues.  
 
4.3.5 Enrichment of brain disorder risk SNPs in conserved open chromatin 
regions from adult microglia 
 
As it has been widely suggested that microglia have distinct functions in the foetus 
and in the adult (306), I tested whether the bipolar disorder and schizophrenia 
GWAS SNP enrichment seen in the foetal CD11b+ cell regulatory regions were also 
present in conserved open chromatin regions derived from an adult microglia 
dataset.  
 
The adult ex vivo microglia ATAC-seq dataset was generated by Gosselin and 
associates as described in chapter 2.2.1 (236). The data was processed, and 
GARFIELD was run, exactly as described in chapter 4.3.4 with the exception that 
ATAC-seq regions from an adult bulk brain dataset, rather than the foetal bulk brain 
dataset, were used to exclude open chromatin regions shared with other neural 
cells (of the same developmental stage). This adult brain ATAC-seq dataset was 
obtained in peak file format from the CommonMind Consortium repository 
(https://www.synapse.org/#!Synapse:syn18134202).  
 
Table 4.5 shows the GARFIELD results for the enrichment tests with the panel of 
brain disorder GWAS SNPs and the conserved adult ex vivo microglia open 
chromatin regions. Conserved adult microglia open chromatin sites are enriched for 
SNPs associated with several brain traits. For example, as for conserved foetal 
open chromatin sites, conserved adult microglia regulatory regions were also 
enriched for bipolar disorder (OR = 3.74, p = 7.21 x 10-5) and schizophrenia (OR = 
2.54, p = 6.91 x 10-7) GWAS SNPs at the 1 x 10-5 threshold. However, by contrast, 
enrichment of bipolar disorder SNPs also were seen at the 1 x10-8 threshold (OR = 
15.55, p = 1.27 x 10-3) in adult microglia; this was not seen in the foetal CD11b+ cell 
analysis.  
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Furthermore, unique to the adult ex vivo microglia analysis, enrichment of autism 
(OR = 7.71, p = 1.14 x 10-4) and major depressive disorder (OR = 4.80, p = 9.92 x 
10-5) associated SNPs were seen in conserved open chromatin regions at the P < 1 
x 10-5 threshold. Consistent with the stratified linkage disequilibrium score results 
reported in chapter 2.3.2, SNPs associated with Alzheimer’s disease at the P < 1 X 
10-5 threshold were also enriched in open chromatin regions from adult microglia (P 
= 0.032), although the significance of this observation did not survive correction for 
multiple testing. However, the reliability of the autism, Alzheimer’s disease and 
major depressive disorder enrichment results (as well as the BPD result for SNPs at 
the P < 1 x 10-8 threshold) could be questioned due to the low number of SNPs 
located in the conserved foetal open chromatin regions annotation.    
 
These results suggest that some of the SNPs that are most strongly associated with 
bipolar disorder and schizophrenia impact gene regulatory processes in both foetal 
and adult microglia, and that gene regulation in adult microglia may also be affected 
by variants associated with autism and major depressive disorder.  
 
 
4.3.6 Overlap of open chromatin regions in conserved foetal and conserved 
adult microglia 
 
Given that the GARFIELD analyses indicated that bipolar disorder- and 
schizophrenia- associated SNPs were enriched in both conserved foetal and 
conserved adult ex vivo microglial open chromatin regions, I decided to formally test 
the overlap of open chromatin regions of both cell types. Figure 4.4 shows that of 
GWAS GWAS Thresh OR p-value cor. p-value Beta SE CI95_L CI95_U No. Annot Thesh N. Annot N. Thresh No. of SNPs
ADHD 1 x 10-5 1.48 0.587 1.000 0.392 0.721 -1.021 1.805 3 1,270 138 233,701
ADHD 1 x 10-8 7.60 x 10-8 0.999 1.000 -16.392 8767 -17198 17165 0 1,270 4 233,701
AUTISM 1 x 10-5 7.71 1.14 x 10-4 1.82 x 10-3 2.042 0.529 1.005 3.080 4 1,457 103 357,689
AUTISM 1 x 10-8 1.13 x 10-6 0.998 1.000 -13.697 6288 -12338 12310 0 1,457 1 357,689
BPD 1 x 10-5 3.74 7.21 x 10-5 1.15 x 10-3 1.319 0.332 0.668 1.970 10 4,273 227 1,191,616
BPD 1 x 10-8 15.55 1.27 x 10-3 0.020 2.744 0.851 1.075 4.412 2 4,273 8 1,191,616
LOAD 1 x 10-5 3.06 0.032 0.507 1.118 0.520 0.098 2.138 4 1,568 113 262,885
LOAD 1 x 10-8 1.79 0.570 1.000 0.581 1.024 -1.425 2.588 1 1,568 43 262,885
MDD 1 x 10-5 4.74 9.92 x 10-5 1.59 x 10-3 1.556 0.400 0.772 2.339 7 4,240 159 1,157,454
MDD 1 x 10-8 7.98 x 10-8 0.997 1.000 -16.346 4499 -8833 8800 0 4,240 8 1,157,454
NEUROTICISM 1 x 10-5 1.28 0.421 1.000 0.248 0.308 -0.356 0.852 14 4,176 697 907,858
NEUROTICISM 1 x 10-8 2.24 0.174 1.000 0.808 0.594 -0.356 1.973 4 4,176 84 907,858
SCZ 1 x 10-5 2.54 6.91 x 10-7 1.11 x 10-5 0.931 0.188 0.563 1.299 33 1,544 1,042 317,182
SCZ 1 x 10-8 2.41 0.017 0.272 0.878 0.369 0.155 1.602 9 1,544 232 317,182
WGL 1 x 10-5 9.88 x 10-6 0.974 1.000 -11.525 356 -708 685 0 2,625 68 891,538
WGL 1 x 10-8 6.90 x 10-7 0.998 1.000 -14.186 5639 -11066 11038 0 2,625 2 891,538
GWAS Thresh (GWAS significance threshold); OR (Odds ratio); p-value (emprical p-value of the significance of the observed enrichment); cor. p-value (p-value Bonferroni corrected for 16 tests); Beta (effect size from the general 
linear model, equal to log(OR)); SE (standard error from generalised linear model); CI95_L (lower boundary for the 95% CI of the effect size/beta); CI95_U (upper boundary for the 95% CI of the effect size/beta);  No. Annot. 
Thresh (number of annotated variants within annotation passing GWAS thresh); N.Annot (number of variants within given annotation); N.Thresh (number of variants passing GWAS thresh); No. of SNPs (total number of LD 
pruned variants). ADHD (Attention deficit hyperactvity disorder); ASD (Autism spectrum disorder); BPD (Bipolar disorder); LOAD (Late onset Alzheimer's disorder); MDD (Major depressive disorder); SCZ (Schizophrenia); WGL 
(Wearer of glasses or contact lenses).
Garfield Results - Psych GWAS vs. ADULT hMG Reg. Regions (bulk ext/evo conserved)
   Table 4.5 Enrichment of brain disorder GWAS SNPs in conserved adult microglia open chromatin regions 
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the 35,137 and the 13,301 peaks contained in the conserved foetal and conserved 
adult ex vivo microglia peak files respectively, 2,206 peaks overlapped both peak 
sets. This overlap is more than expected by chance given the genomic coverage of 
the peak intervals (P < 0.0001, Fishers Exact Test). However, there are also many 
peaks that are only identified in one cell type; these may reflect genuine 
physiological differences between foetal and adult microglia, differences in sample 
processing or experimental noise. 
 
 
 
 
 
4.4 Discussion 
 
Establishing which brain cell types mediate genetic risk is an important step in 
improving our understanding of causal mechanisms for complex brain disorders. 
The evidence presented in section 4.3.2. suggests that a significant proportion of 
common genetic variants associated with schizophrenia and bipolar disorder 
plausibly operate through CD11b+ cells - the vast majority of which are likely to be 
microglia (318,319) - during prenatal brain development.  
 
Microglia display a broad spectrum of phenotypes throughout life and, as such, 
modulate their gene expression profile according to the stimuli they perceive in their 
local microenvironment. Transcriptomic studies in mice suggest that microglia alter 
their gene expression profile, and presumably open chromatin landscape, in a 
temporally sequential manner, expressing proliferative genes during the embryonic 
phase, genes involved in synaptic pruning during the foetal phase, before settling 
into the adult-like, homeostatic, gene expression profile soon after birth (141). Given 
2,206 11,09532,931
Conserved 
Foetal
Microglia
Conserved
Adult ex-vivo
Microglia
Figure 4.4. Overlap of open chromatin regions in foetal and adult ex-vivo microglia. Foetal microglia (conserved 
foetal microglia open chromatin regions with foetal bulk regions removed); Adult ex-vivo microglia (conserved adult ex-
vivo microglia open chromatin regions with adult bulk regions removed). 
 79 
that the putative biological cause of many psychiatric disorders is aberrant neural 
wiring or connectivity (320,321), microglia’s role during the foetal period in 
regulating neuronal and synaptic maturation is of particular interest as (A) it 
provides plausible mechanism through which a non-neuronal cell can contribute to 
neuron pathology and (B) suggests that timing of exposure to genetic and/or 
environmental insults may be critical for increasing liability for these disorders.  
 
Evidence from epidemiological and animal studies support the hypothesis that peri-
natal perturbation of microglia environment is a risk factor for psychiatric brain 
disorders. For example, environmental insults such as pre-natal maternal stress or 
immune activation (i.e. caused by infection) have been shown to increase the risk 
for psychiatric disorders such as schizophrenia, autism and ADHD (230–234) in 
offspring. Furthermore peri-natal maternal stresses have been shown to have long 
term effects on microglial morphology (322), gene expression profile, phagocytic 
activity (323,324), and perturb the maturation process of microglia in progeny 
(141,322). The data presented here provide additional, functional evidence, 
suggesting that genetic factors in microglial-specific open chromatin regions, which 
are likely to impact the regulation of gene expression, also contribute to disease risk 
during this critical period in neurodevelopment. Moreover, given that the open 
chromatin sites overlap between foetal CD11b+ cells and adult ex vivo microglia 
(reported in section 4.3.6), and the fact that GWAS risk SNP enrichment was seen 
in adult microglia open chromatin regions for several brain disorder traits, these 
data suggest that genetic risk factors for neuropsychiatric disorders may operate in 
microglia throughout life.  
 
Although this study provides novel functional genomic information from human 
foetal immune cells, providing better cellular resolution than similar studies carried 
out using bulk brain tissue (307,308,325), it does not resolve distinct, or niche, 
populations of myeloid cells that exist in the brain. While microglia are by far the 
largest population of myeloid cells in the brain, additional myeloid cell populations 
expressing CD11b exist near blood vessels, the choroid plexus and subarachnoid 
space (326). Due to this, many groups use a dual antibody FACS strategy to isolate 
microglia by gating using CD11b and CD45, where low and high expression of 
CD45 is used to differentiate microglia and from other myeloid cells respectively 
(327). I did initially attempt to use CD45 in my gating strategy (see figure 4.5) but 
had to abandon this due to the extremely low cellular yields. 
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As I optimised the FACS protocol, it became clear that the proportion of foetal 
microglia in the human foetal brain (<0.1%) was considerably lower than that 
reported in adult human brain samples (5-10%). The lower proportion of foetal 
microglia compared to adult microglia has been corroborated recently in a single 
cell analysis (328) and should be considered in future attempts to isolate microglia 
from mixed foetal cell suspensions. Moreover, it has been suggested that distinct, 
brain region-specific, populations of microglia exist that differ in gene expression 
(329) and gene enhancer profiles (139,236,330). Indeed, a recent single cell 
transcriptomic study suggested that microglia heterogeneity may be most marked in 
the developing brain (331). These distinctions could not be resolved in this study as 
CD11b+ cells were extracted from whole brain hemispheres.  
 
Another limitation of the study is that the cell isolation methods used to isolate 
‘microglia’ in the foetal brain tissue described here and in adult brain tissue 
described in the Gosselin et al. study were different (236). For example, Gosselin 
and colleagues added a cell enrichment step, based on cellular mass, using a 
viscosity gradient and used 4 cell surface markers (CD11b+, CD45low, CD64+, 
Figure 4.3. FACS image showing 
dual antibody gating strategy. X-
axis, PE fluorescence indicative of 
level CD45 cell surface expression 
(CD45 PE-A); Y-axis, FITC 
fluorescence indicative of level 
CD11b cell surface expression 
(CD11b FITC-A). Q1, FOTC positive 
cells; Q2, FITC and PC double 
positive cells; Q3, FITC and PC 
double negative cells; Q4, PE 
positive cells.
Figure 4.5. FACS image showing dual 
antibody gating strategy. X-axis = PE 
fluorescence indicative of CD45 cell surface 
expression level (CD45 PE-A); Y-axis = FITC 
fluorescence  indicative of CD11b cell surface 
expression level (CD11b FITC-A). Q1, FITC 
positive cells; Q2, FITC and PC double positive 
cells; Q3, FITC and PC double negative cells; 
Q4, PE positive cells.
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CX3CR1High) for their FACS isolation. Given the issue, discussed above, regarding 
the relatively lower number of CD11b+ cells in the foetal brain compared with the 
adult, these additional steps were not possible in this analysis.  
 
Unlike the sLDSC (see section 2.4), no basement threshold for SNPs coverage 
within a functional annotation of interest is stated in the GARFIELD documentation. 
Indeed, as GARFIELD tests statistical significance of SNP enrichment by running 
10,000 permutations on randomly generated SNPs that have been matched in 
number and by feature (minor allele frequency, distance to the nearest gene and 
local LD), SNP coverage is accounted for in this test (332). Despite this, compared 
to sLDSC, GARFIELD is relatively new methodology and has not been yet been 
rigorously tested in the field. As such, the enrichment results reported here require 
independent validation.  
 
 
4.4.1 Future Work 
 
Following on from the work outlined above, the next logical step would be to attempt 
to characterise individual microglial cell populations in the 2nd trimester brain based 
on their transcriptomic, or epigenomic, profiles using single cell sequencing. This 
could be done by brain region, at different post-conception stages. Single cell 
approaches would be well suited for characterising foetal microglia as they require a 
relatively low cell input number. Furthermore, it is now possible to perform ATAC-
Seq at the single cell level (333), enabling insight into gene regulatory mechanisms 
at play in distinct subpopulations of microglia, and their potential role in complex 
brain disorders.  
 
 
4.4.2 Concluding remarks 
 
Using ATAC-seq, I have generated novel epigenomic data derived from  
CD11b+ cells extracted from human 2nd trimester foetal brain. I found that GWAS 
risk SNPs associated with bipolar disorder and schizophrenia are enriched in 
conserved open chromatin sites within these cells, suggesting that foetal microglia 
mediate some of the genetic risk for these disorders.  
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5 Electromobility mobility shift assay (EMSA) on 
candidate risk variants for Alzheimer’s disease 
 
5.1 Introduction 
 
As the vast majority of common psychiatric risk associated loci are located outside 
regions that encode genes, determining the functional impact any mutation has at a 
molecular level is challenging (334). This is exacerbated by the fact that most risk 
associated loci contain thousands of SNPs that are in linkage disequilibrium making 
it difficult to ascertain causal, from associated, SNPs. Unlike coding mutations which 
directly affect protein formation, conformation or enzymatic activity, non-coding 
variants are most likely to impact risk by altering the molecular processes that 
modulate gene expression (90).  
 
A fundamental process that facilitates gene expression, and one of the key drivers of 
phenotypic variation, is the binding of transcription factors to regulatory elements in 
euchromatic regions of the genome (116). As discussed in chapter 1.3, at regulatory 
elements such as enhancers, DNA binding transcription factors interact with short 
sections of DNA sequence called motifs and, once bound to DNA, recruit other 
regulatory proteins to drive or repress gene expression. Through chromatin looping, 
distal regulatory elements are brought into close spatial proximity with the promoters 
of their target genes and the transcription factors bound to each regulatory element 
interact to alter gene expression. One mechanism by which non-coding SNPs could 
increase genetic susceptibility for a psychiatric disorder is by altering the consensus 
sequence of a transcription factor motif (335) . For example, considering a motif 
located within an enhancer, a single base pair change from A to G could alter the 
consensus sequence of the binding site such that transcription factor binding is more 
or less likely (or prevented altogether), with consequent effects on gene expression.  
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5.1.1 Aims 
 
Having shown in chapter 1 that >50% of common variant LOAD heritability was 
contained in open chromatin sites of ex vivo microglia, the aim of this chapter was to 
attempt to characterise how LOAD associated variants impact microglial function at 
the molecular level. Based on the rationale that non-coding risk alleles are likely to 
alter the consensus sequence of transcription factor binding sites (90), a set of 
candidate LOAD risk alleles that fell within (A) an adult microglial open chromatin site 
and (B) a transcription factor motif relevant to microglial function, were identified. 
Computational analysis was then used to prioritise the alleles that were predicted to 
have the most deleterious impact on motif binding. By designing DNA 
oligonucleotides containing risk or alternate alleles at each prioritised locus, and 
incubating these oligonucleotides separately with microglial nuclear extracts, 
electrophoretic mobility shift assays (EMSAs) were carried out to assess DNA-protein 
interactions at each locus. This made it possible to assess whether nuclear protein 
binding is differentially affected in a cellular system carrying the LOAD risk allele 
compared with the alternate allele, and to potentially identify cell relevant transcription 
factors that may be impacted. Functional experiments such as this are important as 
they provide insight into the molecular basis of genetic risk, and also provide a means 
to prioritise the risk SNPs that are most relevant to disease risk in the post-GWAS 
era. 
 
 
5.2 Materials and Methods 
 
5.2.1 Prioritising LOAD risk SNPs located in microglial regulatory regions 
using MotifbreakR 
 
To prioritise candidate SNPs located in microglial regulatory regions for functional 
analysis, a list of LOAD genome-wide significant index SNPs from the IGAP GWAS 
(80) and correlated SNPs in LD (R2 ³ 0.8) were collated, numbering 390 SNPs. As 
the SNP location information was obtained in Chr:Start:Stop format, BiomaRt (336) 
was used to map SNP locations to rsIDs. Next, Bedtools intersect (310) was used to 
select the SNPs that fell within adult ex vivo microglia open chromatin regions. A 
description of how the chromatin accessibility data were processed can be found in 
Chapter 1 and in the Tansey et al. study (235). This identified 29 SNPs, from 11 LOAD 
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genome wide significant loci, that overlapped putative regulatory regions in adult 
microglia.  
 
MotifBreakR is a bioinformatics tool that annotates any list of SNPs to known 
transcription factor motifs genome-wide (337). Moreover, if any SNP falls within a 
motif, MotifbreakR reports the name of the motif and a score describing how strongly 
each allelic variant modifies the binding potential of the factor/s that putatively interact 
at the motif. MotifbreakR was chosen for this task as it has been previously used for 
functional annotation of GWAS data (338), it is easier to automate, and it queries 
more transcription factor motif repositories than similar online annotation tools such 
as RSAT (339). 
 
The MotifbreakR pipeline was a three-stage process. First, the rsIDs for the LOAD 
index SNPs overlapping microglial regulatory regions were annotated with location 
and allelic information using the dbSNP142 (340) and these locations used to query 
build hg19 of the human reference genome for sequence information surrounding the 
variant sites. Second, the sequence information identified for each locus was cross 
referenced with 4 transcription factor motif repositories (ENCODE (341), Factorbook 
(342), HOCOMOCO (343), Homer (121)) to identify motifs containing the risk SNPs 
that we wish to query for potential disruption of transcription factor binding. Finally, a 
position probability matrix was produced for each motif putatively disrupted, which 
models the relative affinity, and the probability of occupancy, of a transcription factor 
for a consensus sequence (344). By summing the probability scores for the most 
frequently occurring base at each position along the motif, MotifbreakR derives an 
optimal motif score for each motif. It then generates two further motif scores (i.e. it 
substitutes each allelic variant from the SNP of interest into the optimal motif), which 
makes it possible to compare each allele-specific motif score to the optimal motif 
score. This allows MotifbreakR to model the level of disruption caused by each allele 
at that motif. The allelic motif scores were scaled from 1-0, and any allele with a score 
of  ³0.85 was reported. A p-value threshold of 1 X 10-4 was set and 370 potentially 
disruptive motifs, each of which contained one of the original 29 GWAS SNPs, 
reported. For each of the 390 entries, the ratio of the motif scores for the reference 
and alternate alleles was taken, and the SNP/motif at each extreme was selected 
after sorting entries by score ratio. These SNPs were deemed the best candidates to 
take forward as their alleles had the largest differences between their motif scores 
and thus the most likely to have a detectable difference in the EMSA assay. 
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5.2.2 Validation of prioritised SNPs using data from public repositories 
 
In order to corroborate whether the SNPs that had been prioritised by the MotifbreakR 
analysis were suitable for experimental follow up, two public repositories were 
accessed.  
 
Haploreg v4.1 is a repository used for assigning functional annotations to non-coding 
genetic loci. By combining LD information from the 1000 genomes project with 
chromatin state and protein binding information generated by the Roadmap 
Epigenomics and ENCODE projects, Haploreg allows researchers to generate 
hypotheses about how non-coding variation impacts phenotype (345). Haploreg was 
used to corroborate the MotifbreakeR results for both rs2883470 and rs938152  
(https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php accessed 
01.04.19). 
 
Cistrome is a public database containing over 20,000 ChIP-seq and chromatin 
accessibility datasets that can be exploited for gene regulatory analysis (346,347). 
As, at the time of writing, the only human microglia chromatin based study available 
was that produced by Gosselin and colleagues (236), Cistrome was used to access 
chromatin state data in human macrophages, a cell type of the same lineage. These 
data were accessed on 01.04.19 (http://cistrome.org/db/#/). 
 
 
5.2.3 Nuclear protein extraction and quantification  
 
To harvest enough BV2 nuclear protein for multiple EMSAs, three ~80-90% confluent 
T125 flasks of BV2 cells were harvested as described in chapter 2. Ice-cold NE-PER 
nuclear and cytoplasmic extraction reagents (Thermo Fisher – 78833) were used to 
extract the BV2 nuclear protein. BV2 cells were first centrifuged at 16,000g for 5 
minutes to dry the cells as much as possible and transferred to a 1.6ml Eppendorf 
tube. Next, 1ml of CER I was added to the cell pellet. The pellet was vortexed on the 
highest setting for 15 seconds to ensure it was thoroughly resuspended and then it 
was incubated on ice for 10 minutes. Then, 55µl of CER II was added, the nuclei were 
vortexed for 15 seconds, and then centrifuged at 16,000g for 5 minutes. The 
supernatant, which was the BV2 cytoplasmic extract was discarded. The nuclear 
pellet was suspended in 250µl of NER, half the recommended volume, then vortexed 
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for 15 seconds every 10 minutes for a total of 40 minutes. The sample was then 
centrifuged at 16,000g for 10 minutes and the supernatant, which was the BV2 
nuclear protein extract, was transferred to a clean Eppendorf. The protein extract was 
quantified using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) and the 
nuclear extract was aliquoted into 150µg batches and snap frozen at -80oC. 
 
 
5.2.4 Designing and annealing oligonucleotides 
 
For each selected SNP (rs9381562 and rs28834970), complementary 50 nucleotide 
base biotinylated DNA oligonucleotides were synthesised along with unlabelled 
competitor oligonucelotides incorporating either the reference or alternate allele. In 
total, 16 oligonucelotides were created, see table 5.1 (only 8 shown). 
 
 
 
 
 
For annealing, equimolar complimentary oligonucleotides were heated in a 
thermocycler to 95oC for 5 minutes then cooled 1oC every 5 minutes until they 
reached room temperature. Annealed oligonucleotides were diluted to a final 
concentration of 1pmol/µl in 18.2Ω H2O.  
 
 
5.2.5 Electrophoresis mobility shift assay 
 
SNP Motif Allele Oligonucleotide
rs9381562 ETS C - Ref AGTGTCAATGGTGGAACTGGGCTTCCTGGCTTCAGGAGTTCAGTCCAAGTG
CACTTGGACTGAACTCCTGAAGCCAGGAAGCCCAGTTCCACCATTGACACT
A - Alt AGTGTCAATGGTGGAACTGGGCTTCATGGCTTCAGGAGTTCAGTCCAAGTG
CACTTGGACTGAACTCCTGAAGCCATGAAGCCCAGTTCCACCATTGACACT
rs28834970 C/EBP T - Ref TGGTCATTCCATATAAGTGGAATTGTACAACACTGTGGCCTTTCGCGACGG
CCGTCGCGAAAGGCCACAGTGTTGTACAATTCCACTTATATGGAATGACCA
C - Alt TGGTCATTCCATATAAGTGGAATTGCACAACACTGTGGCCTTTCGCGACGG
CCGTCGCGAAAGGCCACAGTGTTGTGCAATTCCACTTATATGGAATGACCA
Table 5.1 Oligonucleotides designed for electrophoresis mobility shift assay
DNA sequences for 50bp oligonucleotides designed for the LOAD associated SNPs rs9381562 and rs28834970. Reference and alternate 
alleles are shown in red. Oligonucleotides were either biotinylated or unlabelled at the 5’ end (not shown).
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The EMSA detects DNA-protein interactions based on the fact that DNA-protein 
complexes migrate more slowly than unbound DNA in a polyacrylamide gel, resulting 
in a shift in migration of labelled, protein-bound, oligonucleotide. The LightShift® 
Chemiluminescent EMSA Kit (Thermo Fisher Scientific) was used for the DNA-protein 
binding reactions and visualisation steps of the EMSA procedure. 
 
A 10 well, 5% Mini-PROTEAN® TBE precast DNA gel (Bio-Rad) was placed in an 
electrophoresis unit filled with 0.5X TBE. The 30µl wells were flushed thoroughly and 
100V was passed through the gel for 30 minutes. Next, 5µl of 5X loading dye was 
added to each sample followed by gentle mixing by pipetting, the wells were flushed, 
and 20µl of each sample was loaded into separate wells of the gel. Again, 100V was 
passed through the gel until the bromophenol blue dye had migrated ¾ the length of 
the gel (approximately 45 minutes). Meanwhile a positively charged Biodyne B Nylon 
Membrane (Thermo Fisher Scientific) was soaked in 0.5X TBE for 10 minutes. Once 
migration was complete, the gel was floated off carefully from its plastic casing in a 
bath of 0.5X TBE. The gel was then placed on top of the nylon membrane, and blotting 
paper applied to each side. Bubbles were removed using a roller and the sandwich 
was placed into a mesh lined cassette. The cassette was placed into a clean 
electrophoresis unit filled with 0.5X TBE (chilled to ~10oC) and 100V was applied for 
30 minutes. When transfer had occurred, the excess TBE was removed from the 
membrane using a paper towel and the DNA was crosslinked to the membrane using 
a UV-light set to 120mJ/cm2 for 1 minute. 
 
 
5.2.6 Chemiluminescence reaction and visualisation 
 
Blocking and wash buffers were heated to ~37oC until particulates had completely 
dissolved. The membrane was then passed through a series of incubation/wash steps 
all of which included gentle shaking on a plate shaker. These included a 15-minute 
incubation in blocking buffer followed by a further 15-minute incubation in stabilised 
streptavidin-horseradish peroxidase conjugate diluted 1:300 in blocking buffer. The 
membrane was then rinsed briefly in 1X wash buffer and placed in 1X wash buffer for 
five minutes. This five-minute wash was repeated three times. Next, the membrane 
was bathed in substrate equilibration buffer (SEB) for 5 minutes. In the final step, 
excess SEB was drained from the membrane before it was incubated, without 
shaking, with substrate working solution (Luminal/Enhancer Solution and Stable 
Peroxide Solution mixed at a 1:1 ratio) for five minutes.   
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The chemiluminescence on the membrane was detected and visualised using the 
Syngene G-Box Chemi XX9 system.  
 
 
5.2.7 Quantification of DNA  
 
Image J was used to quantify DNA captured during imaging. For standardisation, 
images were first transformed to the 16-bit format (Image > Type > 16-bit), then 
calibration measurements were taken from the least and most saturated regions 
respectively. A separate calibration curve was generated for each image (Analyse > 
Calibrate > straight line) and arbitrary units for intensity maxima and minima were set 
from 0 to 100. The rectangle tool was used to measure DNA quantity by capturing the 
relative intensity of each band. Two-sample t-tests were performed to compare band 
intensities between reference and alternate alleles for each SNP. 
 
 
5.2.8 Optimisation of EMSA  
 
To optimise the EMSA a total of eight 20µl samples were set up as shown in table 
5.2 and figure 5.1. The first three reactions included a DNA only control, containing 
biotinylated DNA but no nuclear protein extract or unlabelled competitor DNA, a DNA-
protein reaction containing biotinylated oligonucleotide and nuclear extract, and an 
unlabelled competitor reaction containing biotinylated oligonucelotide, nuclear extract 
and unlabelled target DNA. The latter acted as a competitive inhibitor to the 
biotinylated DNA. For comparison, an additional five DNA-protein reactions were set 
up, each containing a single optimisation reagent, to assess if one or more of these 
reagents improved the DNA-protein interaction in this system. As indicated in table 
5.2, 4pmols of unlabelled target oligonucelotide, 10µg of nuclear protein extract and 
20fmol of Biotin labelled oligonucelotide where added to the appropriate reactions. 
This optimisation step was carried out for risk and non-risk alleles for both SNPs (4 
optimisation experiments in total).  
 
Representative, DNA-protein interactions for the ALT allele at rs9381562 and ALT 
allele at rs28834970 are shown in figure 5.1, marked with arrows. These images 
demonstrate that the EMSA can effectively detect DNA-protein interactions at these 
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loci. In both cases, the interaction was reduced markedly by the addition of unlabelled 
competitor oligonucleotide (lane 3) indicating the specificity of the interaction at each 
locus. Regarding the 5 optimisation reagents, it was decided that the clearest banding 
was evident when NP40 was added (lane 5), particularly for reactions involving 
rs9381562. Henceforth, 1µl of NP40 was added to all reactions. 
 
 
 
 
 
Reagent  Amount
H2O (18.2Ω) Make up to 20µl
10X Binding Buffer 2µl
Poly (dl•dC) 1µg/µl 1µl
Glycerol (50%) * 1µl
NP-40 (1%) * 1µl
KCL (1M) * 1µl
MgCl2 (100mM) * 1µl
EDTA (200mM) * 1µl
Unlabelled DNA (1pmol/µl) 4µl
BV2 nuclear protein extract 10µg
Biotin labelled DNA 20fmol
Table 5.2. Reagents for EMSA optimisation
* optional  
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The optimised EMSA was performed on reference and alternate alleles for both 
rs9381562 and rs28834970 and three technical replicates were obtained for each 
individual allele.  
 
 
A
B
Unlab DNA
Nuc. Ext
Glycerol
NP40
KCl
MgCl2
EDTA
Lane
-
-
-
-
-
-
-
1
-
+
-
-
-
-
-
2
+
+
-
-
-
-
-
3
-
+
+
-
-
-
-
4
-
+
-
+
-
-
-
5
-
+
-
-
+
-
-
6
-
+
-
-
-
+
-
7
-
+
-
-
-
-
+
8
Figure 5.1. EMSA optimisation in BV2 
cells. DNA-protein interactions involving 
oligonucleotides containing rs9381562 (A) 
and rs28834970 (B) ALT alleles. 
Oligonucleotides in all wells are dsDNA 
except those marked with * which are 
ssDNA. 
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5.2.9 Supershift assay 
 
In addition to the normal EMSA procedure, a series of supershift assays were 
included for oligos containing rs9381562 alleles. During the supershift assay, an 
antibody targeting a protein of interest is added to the EMSA reaction. If the target 
protein is present in the protein network bound to the biotinylated oligonucelotides, 
the complex would migrate more slowly through the membrane due to the additional 
mass of the bound antibody. This would lead to a supershift of the DNA-protein band 
in lanes containing the antibody compared to lanes containing control antibodies. The 
supershift assays were initially carried out following the EMSA procedure outlined 
above, however, after the 20-minute protein binding incubation, 2µg of either PU.1 
antibody (Santa Cruz – sc352) or the control IgG antibody (inhouse rabbit polyclonal) 
were added to appropriate wells and incubated for a further 30 minutes. The water 
content of the affected wells was adjusted to keep the total volume constant across 
all wells. The remainder of the EMSA procedure was carried out as normal. 
 
 
5.3 Results 
 
5.3.1 Prioritisation of LOAD associated risk SNPs for molecular analysis 
using MotifbreakR 
 
The motifbreakR analysis identified 390 motifs that were putatively disrupted by the 
29 LOAD risk SNPs included in the analysis. To identify the SNPs that were the 
best candidates to take forward for further analysis, a ratio of the motif scores for 
each allele at each motif were taken. The rationale for this was that, as the motif 
score is a proxy for the binding potential of each putative motif, motifs with the 
largest difference in their allele-specific motif scores would represent the best 
candidates to take forward for EMSA as they would be the most likely candidates to 
have observable allelic differences in DNA-protein binding. Table 5.3. shows the 
MotifbreakR output for the SNPs rs9381562 on chromosome 8 and rs28834970 on 
chromosome 6. Motifs at the extremes of table 5.3 contain the largest differences in 
their allele-specific motif scores. 
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The variant rs9381562 (GWAS p-value = 7.83 x 10-8) lies in a non-coding region of 
chromosome 6 and is in perfect LD (r2 = 1) with the LOAD genome wide significant 
SNP rs10948363 (GWAS p-value 5.20 x 10-11). At rs9381562, the most significantly 
disrupted motif that was proposed was the ETS1 motif which was contained within a 
9bp sequence on the negative strand, see table 5.3.  With a motif score of 5.75 (P = 
5.34 x 10-5), the AALT allele was more disruptive to the motif than the CREF allele which 
scored 7.68 (P = 1.61 x 10-2) representing a 25% reduction in binding potential. 
Notably, 3 of the top 4 most disrupted motifs identified at this SNP affect an ETS 
domain binding site. 
 
rsID Chr REF ALT Motif Sequence Ref score Alt score Ratio Effect
rs28834970 chr8 T C CEBPB gaattgTacaacac              5.68 7.32 0.78 strong
CEBPD aattgTacaaca                       5.75 7.39 0.78 strong
CEBPA attgTacaac                        5.17 6.56 0.79 strong
EP300 aattgTacaacactg                    6.04 7.63 0.79 strong
NA agtggaattgTacaa                         6.19 7.80 0.79 strong
CEBPB attgTacaac                        7.57 9.38 0.81 strong
DDIT3::CEBPA ggaattgTacaa                         6.91 8.38 0.82 strong
DDIT3::CEBPA tggaattgTacaa                         6.93 8.40 0.82 strong
NA aattgTacaacact                     7.71 9.35 0.82 strong
CEBPE ggaattgTacaa                         6.58 7.88 0.84 strong
CEBPG attgTacaac                        8.59 10.01 0.86 strong
STAT3 attgTacaa                         10.45 12.09 0.86 strong
DBP aattgTacaac                        5.55 6.39 0.87 strong
DDIT3 tggaattgTacaa                         7.49 8.62 0.87 strong
CEBPD attgTacaaca                       6.27 7.16 0.87 strong
CEBPG attgTacaac                        8.45 9.63 0.88 strong
CEBPG ggaattgTacaac                        7.26 8.21 0.88 strong
CEBPB attgTacaac                        7.71 8.65 0.89 strong
CEBPE attgTacaac                        7.13 7.85 0.91 strong
BPTF ttgTacaacactgt                   4.51 4.80 0.94 weak
CEBPA gaattgTacaacac                      4.56 4.84 0.94 weak
CEBP gaattgTacaacac                      4.60 4.81 0.96 weak
NFAT5 gtggaattgTacaa                         12.13 11.13 1.09 strong
ETS1 ggaattgT                             5.07 4.59 1.10 weak
ZNF143 tggaattgTa                            11.42 9.78 1.17 strong
rs9381562 chr6 C A NR2F2 gggcttcCtggcttca                     8.79 10.43 0.84 strong
EGR1 actgggcttcCtggcttcaggagtt               15.72 15.40 1.02 weak
NA gcttcCtggcttcaggagttc              14.08 13.68 1.03 weak
RAD21 cCtggcttcaggag                 5.02 4.52 1.11 weak
STAT3 ttcCtggct                        10.97 9.86 1.11 strong
ELF2 gaactgggcttcCtggct                        12.62 10.99 1.15 strong
ELF2 ctgggcttcCtggct                        8.05 6.70 1.20 strong
ELF3 gcttcCtggcttca                     9.02 7.49 1.20 strong
ERG ggcttcCtgg                          9.02 7.40 1.22 strong
ETV4 gcttcCtg                           6.08 4.99 1.22 strong
ELK3 gggcttcCtggc                         6.77 5.54 1.22 strong
GRHL2 gaactgggcttcCtggcttc                      7.69 6.22 1.24 strong
ETS gcttcCtg                           6.49 5.18 1.25 strong
ELF1 ggcttcCtgg                          8.90 7.02 1.27 strong
ETS ctgggcttcCtg                           7.43 5.79 1.28 strong
ETS1 gcttcCtgg                          7.68 5.75 1.34 strong
Table 5.3 Abridged MotifbreakR output showing putatively disrupted motifs identified for the LOAD 
associated risk SNPs rs28834970 and rs9381562.
Chr (chromosome); REF (reference allele) ALT (alternate allele);  Sequence (DNA sequence considered in analysis with SNP 
capitalised); Ref score (Ref motif score); Alt score (Alt motif score); Ratio (ratio of absolute Alt/Ref scores); 
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Considering rs28834970, this variant falls within an intron of protein kinase 2 beta 
(PTK2b) and is a LOAD genome-wide significant SNP (GWAS p-value = 7 x 10-14; 
80). The motif highlighted as being the most significantly disrupted at this locus was 
the C/EBP-b domain located within a 14bp sequence on the negative strand (see 
table 5.2). The predicted direction of effect was opposite to that seen in rs9381562 
with the TREF allele being more detrimental to the binding potential of the motif than 
the CALT allele, with motif scores of 5.68 (P = 7.65 x 10-3) and 7.31 (P = 6.17 x 10-6) 
respectively. This corresponds to a 22% reduction in binding potential when the TREF 
allele is substituted for the CALT allele. Interestingly, 15 of the 25 putatively disrupted 
motifs identified by MotifbreakR for rs28834970 impact motifs of the C/EBP family. 
 
These results provide statistical evidence that rs9381562 and rs28834970 are 
suitable candidates to take forward for molecular analysis. Further biological evidence 
for their suitability from the literature will be discussed in subsequent sections. 
 
 
5.3.2 Publicly available data suggests rs9381562 and rs28834970 fall within 
active regulatory regions in cells of a myeloid lineage  
 
Given that a bioinformatics tool has been used thus far to prioritise SNPs for further 
analysis, it was important to find supporting evidence in the literature for the 
suitability of these SNPs for molecular analysis (348).  
 
Chromatin accessibility and ChIP-seq data from the Glass et al. adult ex vivo 
microglia study (236) suggest that both rs9381562 and rs28834970 are located in 
enhancer regions in microglia. In figure 5.2 A, rs9381562 is situated within a 
chromatin accessibility peak (ATAC) implying that this SNP falls within an active, or 
poised, regulatory element in microglia. Moreover, as the rs9381562 is also located 
at the edge of peaks associated with the histone modifications H3K4Me2 and 
H3K27ac, it is inferred that that this regulatory element is an active enhancer. 
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Regarding rs28834970, figure 5.2 B, a chromatin accessibility peak, as well as 
H3K4Me2 and H3K27ac associated ChIP-seq peaks derived from human ex vivo 
microglia surrounding the SNP, suggest that this SNP is located in an enhancer 
region with regulatory potential in microglia. Moreover, rs28834970 is surrounded by 
a peak derived from a C/EBP-b transcription factor ChIP-seq study in macrophages 
(349), suggesting that C/EBP-b binds at this locus in myeloid cells. Similarly, the 
Haploreg v4.1 database provides evidence that rs28834970 is located in an active 
regulatory region in cells of myeloid lineage as it is associated with the histone marks 
H3K4Me1, H3K4Me3 and H3K427ac in primary myeloid cells from peripheral blood 
A
B
Figure 5.2. Chromatin accessibility and chip-seq data from publicly available 
sources. Representative genomic tracks showing approximately 3kb surrounding the 
LOAD associated SNPs rs9381562 (A) and rs28834970 (B). X-axis is genomic 
location and Y-axis auto-scaled read counts. Peak height corresponds to the 
frequency with which each annotation occurs at a particular locus. Chromatin 
accessibility data (ATAC) and chip-seq data (H3K4Me2, H327ac and Pu.1) from 
human ex vivo microglia taken from Glass et al. 5.22017 (236). Chip-seq data for 
CEBP taken (347) from a study in macrophages. 
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(see figure 5.3). The Haploreg v4.1 output also suggests that the binding potential of 
C/EPB-b motifs are disrupted by rs28834970 in an allele-specific manner, with the 
motif scores for the for the TREF allele being consistently lower than the CALT allele for 
all 4 C/EBP-b entries. This provides independent evidence that the TREF allele at 
rs28834970 is more disruptive to the binding potential of the C/EPB-b motif than the 
CALT allele. 
 
These results suggest that both rs9381562 and rs28834970 are located in active 
enhancer regions in microglia and suitable candidates for molecular analysis. 
 
 
 
 
Figure 5.3. Haploreg v4.1 output for region surrounding rs28834970 in blood and immune 
cell types. Functional chromatin annotations associated with rs28834970, providing evidence that 
histone modifications indicative of active regulatory elements are found in myeloid cells from 
peripheral blood (E029 – primary monocytes). 7_Enh, H3K4Me1_Enh indicate enhancers, whilst 
H3K4Me3_Pro is indicative of promoters and H3K27ac_Enh is indicative of regulatory element 
activation. Output also shows that binding potential of the C/EBP-b motif is consistently lower for 
TREF allele compared with  CALT allele.
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5.3.3 EMSA indicates that DNA-protein interactions at rs9381562 and 
rs28834970 are impacted in an allele-specific manner in BV2 cells 
 
Incubation of BV2 nuclear extracts with biotinylated oligonucleotides containing either 
allele of rs9381562 produced two distinct bands that had significant allelic differences 
in the intensity of bound DNA (see figure 5.4 A). Considering the upper band, 
indicated by the upper arrow, the strong band seen in well 5 is partially eliminated in 
well 6 by the inclusion of 200-fold excess unlabelled competitor oligonucleotides. This 
indicates that the DNA-protein interaction seen here is specific to this DNA sequence. 
When testing differences in band intensity between reactions containing the AALT and 
CREF alleles at rs9381562 (lanes 2 and 5 respectively), oligonucleotides 
encompassing the LOAD associated AALT allele bound, on average, 50% less nuclear 
protein(s) than oligonucleotides containing the CREF allele (p < 6.2 x 10-4, t-test, figure 
5.4 B). By contrast, the lower band, indicated by the lower arrow, had a significant 
allelic difference in band intensity in the opposite direction to the upper band, with 
DNA containing the AALT allele (lane 2) binding 22% more nuclear protein than 
oligonucleotides incorporating the CREF allele (lane 5; p < 0.02, t-test). 
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Similarly, two candidate bands, suggesting allele specific differences in DNA-protein 
binding, were seen in experiments involving rs22834790, see figure 5.4 B. The DNA-
protein interaction depicted by the intensity of the lower band (lane 5, lower arrow) is 
abolished when excess unlabelled competitor oligonucleotide is added (lane 6, lower 
arrow), again indicating the sequence specificity of this interaction. Significant allelic 
differences were measured between the CALT and TREF alleles when comparing band 
intensity (lanes 2 and 5 respectively), with the TREF allele binding 58% less protein on 
average compared to the C allele (p < 0.003, t-test, figure 5.5 D). 
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Figure 5.4. EMSA incubating oligonucleotides containing either rs9381562 (A) or 
rs28834970 (B) in BV2 cell nuclear extract. DNA-protein interactions involving 
oligonucleotides containing alleles from either rs9381562 (A) or rs28834970 (B) and 
nuclear factors from BV2 cells. All wells contain oligonucleotides that were biotin 
labelled. Unlab-DNA (Unlabelled DNA; added in 200-fold excess); Nuc. Ext. (Nuclear 
extract). DNA in all wells is dsDNA. 
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When testing allelic differences in DNA-protein binding in the upper band, although 
there was a trend in the same direction as seen in the lower band (i.e. DNA containing 
the CALT allele bound more protein than DNA incorporating the TREF allele), this 
interaction was non-significant between the alleles (p = 0.17, t-test; figure 5.5 C). 
 
These results suggest allele-specific DNA-protein interactions occur at both 
rs9381562 and rs28834970. 
 
 
5.3.4 EMSA indicates that PU.1 may be present at rs9381562 
 
Given the finding reported in chapter 1 that LOAD risk SNPs were localised in 
microglial open chromatin regions containing the transcription factor PU.1, and the 
fact that the MotifbreakR analysis highlighted that variation at rs9381562 putatively 
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Figure 5.5. Quantification of binding of nuclear factors from BV2 cells to DNA 
oligonucleotides containing either rs9381562, or rs28834090, alleles. Y axis = relative intensity 
of DNA protein band, x axis = allele at each SNP locus. ** P <  0.01 , *** P < 0.001, **** P < 
0.0001. 
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impacted an ETS domain motif, of which PU.1 is known to bind to, I decided to carry 
out a EMSA supershift assay using the rs9381562 alleles.  
 
Figure 5.6, shows a representative EMSA supershift reaction. Notably, when the 
antibody targeting PU.1 was added to reactions containing oligos with either the CREF 
or AALT allele at rs9381562, lanes 7 and 9 respectively, no supershift banding pattern 
was seen, implying that PU.1 was not present within the DNA protein complex bound 
at this locus.  
 
 
 
 
 
However, when considering the upper band (upper arrow) in figure 5.6, identical 
reactions containing C allele oligos incubated either with (lane 7) or without (lane 2) 
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Figure 5.6. EMSA supershift assay incubating 
oligonucleotide containing rs9381562 alleles with 
nuclear factors from BV2 cells and either PU.1 or 
IgG antibodies. Allele-specific interactions indicated 
by arrows. DNA-protein interactions involving 
oligonucleotides containing rs9381562 and nuclear 
extract from BV2 cells. All wells contain 
oligonucleotides that were biotinylated. Unlab-DNA 
(Unlabelled DNA; added in 200-fold excess); Nuc. Ext. 
(Nuclear extract). DNA in all wells is dsDNA. 
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the PU.1 antibody, indicate that band intensity is lessened when the PU.1 antibody is 
present. Moreover, when the IgG antibody is substituted for the antibody targeting 
PU.1, lane 8, band intensity recovers to a level similar to that seen in lane 2. This 
could suggest that PU.1 is present in the bound protein network, but that the antibody 
attaches to the protein in such a way that it prevents PU.1 interacting with either the 
DNA or the entire network.  
 
5.4 Discussion 
 
The aim of this chapter was to investigate how LOAD-associated polymorphisms 
impacted transcription factor binding in microglia. Establishing how individual cell 
types in the brain contribute to pathology is an important step in improving our 
understanding of the causal mechanisms of complex brain disorders. In particular, 
pinpointing the molecular events, within individual cell types, that are perturbed as 
these disorders progress is critical, both to the process of characterising reliable 
biomarkers for diagnosis and, ultimately, to identify credible molecular targets for 
therapeutic intervention. As outlined in chapter 1.4.4, GWAS have now identified 
many variants associated with risk for psychiatric disorders. However, there is now 
a significant bottleneck for researchers in terms of translating these genetic findings 
into clinical outcomes. For example, as most risk loci reside in poorly characterised 
non-coding regions, it is a challenge for researchers to ascertain exactly how risk is 
conferred by these loci. Furthermore, with linkage disequilibrium making it difficult to 
isolate causal from associated variants, and with the spread, and volume, of 
associated loci across the genome, the financial and practical reserves required to 
examine every genetic lead individually would be astronomical. For these reasons, 
prioritisation of the genetic risk loci that are most likely to confer risk is essential. 
 
From an initial list of 390 LOAD common variants, representing all the genome-wide 
significant index SNPs from the IGAP GWAS (80) and associated SNPs with an R2 ³ 
0.8, 29 SNPs were found to overlap microglial open chromatin regions. Both 
rs9381562 and rs28834970 were prioritised over the other 29 LOAD common 
variants for several reasons: (A) they had the largest allele-specific effects on motif 
binding potential, (B) evidence in the literature suggested that they were located in 
active regulatory regions in microglia, and (C) the motifs that were predicted to be 
disrupted at both loci had phenotypic relevance in microglia.  As (A) and (B) were 
 101 
covered in earlier sections, they will be discussed only briefly here; the majority of the 
following discussion will focus on (C).  
 
The MotifbreakR analysis (Table 5.3) predicted that alleles at rs9381562 and 
rs28834970 were most disruptive to the DNA binding potential. Whilst this finding 
alone may be considered justification enough for prioritising these two SNPs, the fact 
that alleles at these loci disrupted motifs known to bind microglial lineage-determining 
transcription factors, and that these factors have also been linked with LOAD risk, 
suggested that these SNPs were excellent candidates for the EMSA.  
 
For example, protein C-ets-1 (ETS1), is a member of the ETS family of transcription 
factors that bind to the 5’ – GGA(A/T) – 3’ motif, which was predicted to be disrupted 
by rs9381562. There are 28 transcription factors known to bind to the ETS domain 
which can be subdivided into 4 subgroups based on common, preferential 
interactions between the TF amino acids and nucleotides at position 4 of the motif 
(A/T), or at nucleotides directly flanking the motif (350). At the molecular level, ETS 
factors can inhibit or enhance DNA binding of cofactors to regulate transcription. In 
the brain, ETS binding factors have been implicated in neuronal pathfinding and 
differentiation, but these factors influence a wide range of biological processes across 
several tissue types including the skin and reproductive organs (351,352). One family 
that bind to the ETS domain are the SPI subfamily of proteins that includes the 
myeloid lineage determining transcription factor PU.1. Moreover, whilst over half the 
ETS family of transcription factors are ubiquitously expressed over several cell types, 
high expression of SPI1, which is the gene that encodes PU.1, is specific to myeloid 
cells (352). With regard to LOAD, a recent genome-wide study reported that a 
protective genome-wide significant LOAD risk SNP located in the 3’ untranslated 
region of the SPI1 gene lowered the expression of SP1 in myeloid cells, and 
suggested that reduction of SPI1 expression levels could lead to partial amelioration 
of AD risk through modulation of myeloid cell gene expression (250). 
 
The CCAAT/enhancer binding protein (C/EPB) family of transcription factors have 6 
isoforms that bind to the consensus sequence 5’-CCAAT-3’, predicted to be disrupted 
by rs28834970. The best characterised isoforms are C/EBP-a and C/EBP-b,  which 
are ubiquitously expressed throughout the body and are primarily involved with 
cellular proliferation and differentiation (353). In the brain, CEBP-b has been 
implicated in neuroinflammatory regulation, where it has been shown to be 
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upregulated in activated microglia and astrocytes (354). Moreover, C/EBP-b is 
significantly increased in the cortex of LOAD patients compared with non-demented 
controls (355), and over-expression of C/EBP-b in LOAD mouse models accelerates 
LOAD-like symptoms, such as cognitive impairment, via modulation of delta-
secretase transcription (356). 
 
The case for selecting rs9381562 and rs28834970 was further strengthened by data 
from publicly available sources in section 5.3.2. (see figures 5.2 and 5.3) which 
demonstrated that loci encompassing either rs9381562 or rs28834970 associate with 
chromatin annotations that correlate with the presence of active enhancers in 
microglia. Clarifying that non-coding variants lie in genomic regions that are 
functionally relevant in a particular cell type is important as the chromatin landscape 
of every cell type is unique. So, for example, whilst an individual’s genotype may show 
that they carry the LOAD risk allele at rs9381562, if rs9381562 is located in a 
microglial heterochromatic region, a region where chromatin is closed, any risk 
conferred by this SNP could not be mediated via this cell type. In effect, the region 
containing the SNP would, in terms of gene regulation, be silent. Regardless of 
whether the relevant transcription factors were expressed in microglia or not, the 
tightly packed histones at this site would sterically impede transcription factors, 
preventing them from accessing the underlying motifs that they bind to. Presented 
with the evidence described above, rs9381562 and rs28834970 were deemed 
suitable candidates for the EMSA assay. 
 
By showing in section 5.3.3. figure 5.4, that oligonucleotides designed to include 
rs9381562 and rs28834970 alleles were capable of forming DNA-protein complexes 
with factors from BV2 nuclear extracts, I have established that the regions 
encompassing both SNPs are likely to be regulatory elements. Whilst the EMSA 
cannot directly indicate the nature of these putative regulatory elements (i.e. by 
identifying the elements’ nature and/or status), these results do concord with 
evidence from the literature (see section 5.3.2) that these SNPs fall within active, 
enhancer regions. Moreover, as the DNA-protein interactions at each polymorphism 
can be distinguished in an allele-specific manner (see figure 5.4), it is inferred that 
allelic variants at these loci have functional relevance to the binding of transcription 
factors expressed by microglia. With regard to LOAD, this allele-specific effect could 
mediate all, or part, of the genetic association reported in the LOAD GWAS studies 
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for these loci, but further, more detailed, experiments will be required to determine 
this (see section 5.4.1).  
 
In the PU.1 supershift assay (Figure 5.6), there was no evidence of a supershifted 
banding pattern; however, the allele specific change in band intensity between lanes 
containing the PU.1 antibody and IgG antibody may imply that PU.1 is present, if not 
directly detectable via EMSA, within this complex. It is plausible that if PU.1 is the 
critical DNA-binding factor that underpins the interaction of the entire protein complex, 
then the inclusion of the antibody may interfere with biotinylated DNA molecules 
forming DNA-protein interactions. This could explain why there is reduction in band 
intensity in well 7 compared with well 2, rather than a supershifted banding pattern. 
However, further experiments will be required to confirm this.  
 
Although position weight matrices (PWMs) are used extensively to explore 
consensus sequence variation in humans, they do have limitations. First, PWMs 
assume that the binding energy of each nucleotide within a given motif is 
independent. Whilst, generally, this does appear to be a good model, as it models 
the hydrogen bonding that occurs between individual nucleotides and the amino 
acid side chains of transcription factors (357), it has been shown to be an over-
simplification. For example, the orientation of the minor groove of the DNA 
backbone also influences transcription factor binding. Conformational changes in 
DNA structure can alter the electrostatic environment surrounding a protein complex 
and the DNA it binds to. This, in turn, can impact of the binding efficiency of the 
individual factors of the complex (358). As such, a point change in one motif can 
alter the electrostatic potential of the base, and surrounding environment, potentially 
altering DNA conformation. This could have a non-independent effect on the binding 
efficiency of factors elsewhere in the network (115). Interestingly, it has been 
suggested that DNA conformation is a genomic chromatin feature under 
evolutionary constraint in certain genomic regions, and that these regions correlated 
strongly with enhancer elements (359). Moreover, PWMs do not capture the binding 
characteristics of multiple identical TFs binding at a motif as a regulatory unit (i.e. 
dimers or trimers) as they only consider each transcription factors binding efficiency 
in isolation. Understanding the complexity of the gene regulatory machinery is a 
major challenge for the field of functional genomics, as is accurately modelling a 
poorly understood system. 
 
 104
Although the EMSA is inexpensive, relatively quick to perform, and provides a robust 
method to identify allele-specific effects impacting DNA-protein binding, it is an 
artificial system. The EMSA cannot identify the individual proteins forming the 
transcription factor complexes that bind to DNA, or provide information on exactly 
where along the oligonucleotide these complexes are bound (360,361).  Moreover, 
as the DNA input for the assay is a synthetic, relatively short oligonucleotide, the 
chromatin environment that the DNA-protein interactions would take place within, in 
vivo, has not been properly modelled. As mentioned in chapter 1.3.2., in vivo, DNA is 
intertwined with histone proteins to form chromatin, and the conformation and post-
translational modification of chromatin can influence context dependent transcription 
factor binding. As no histones have been added in the assay, any potential effects 
that chromatin conformation (or modification) would have on protein interactions have 
not been measured. That said, the EMSAs utility is in its simplicity as it provides a 
means to identify functional SNPs relatively quickly without the need for complicated, 
and expensive, genetic or cellular manipulation.  
 
 
5.4.1 Future Work 
 
Given the inconclusive result of the supershift assay, and the fact that transcription 
factors rarely bind to regulatory elements in isolation, future experiments should aim 
to characterise the proteins that form the complexes at both loci. One method that 
could be used for this is the DNA-affinity precipitation assay (DAPA). In this assay, 
oligonucleotides containing LOAD risk alleles are incubated with nuclear lysates to 
capture both DNA bound factors, and factors that associate with them, and the DNA-
protein complexes are precipitated from the lysate using microbeads (362). These 
complexes are then profiled by mass spectrometry to identify the proteins present 
and compared to assess if any allele-specific differences can be detected.  
 
Considering that there were clear allele-specific differences in DNA-protein binding at 
both loci, assessing the impact, if any, that variation at these sites has on gene 
expression is important. The gene editing technology CRISPR/Cas9 could be used 
to genetically modify microglial cell lines such that separate stable lines are generated 
for both allelic variants at each locus. CRISPR/Cas9 uses an RNA guidance system 
to target specific regions of DNA and then recruit DNA editing enzymes to modify the 
nucleotide sequence (363,364). Once stable lines are created, it would be possible 
to use a number of techniques to assess the degree to which differential binding of 
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nuclear factors impacts gene expression. For example, chromatin capture 
technologies, such as 3C and Hi-C, could be employed to assess any differences in 
promoter-enhancer interactions caused by allelic variation. This would also be a 
means to identify the target genes of each regulatory element (365). Furthermore, 
RNA-seq could be used to assess any effect allelic variation has on the expression 
of the putative regulated gene as well as on downstream gene expression.  
 
Whilst a bioinformatics approach was used here for SNP prioritisation other methods 
exist such as expression quantitative trait loci (eQTL) analysis, which leverages 
genotypic and transcriptomic data to test for association of genetic loci with alterations 
in the levels of tissue specific gene expression (a locus associated with an alteration 
of gene expression is termed an eQTL). As such, this method provides the additional 
benefit of mapping non-coding genetic variants to the gene/s they putatively 
influence. The Genotype-Tissue Expression (GTEx) project is large-scale eQTL 
initiative which, to date, has assessed the association of genetic loci with gene 
expression in 54 adult human tissues (366), including several brain regions, and 
provides an open access repository to query eQTL in these tissues 
(https://www.gtexportal.org/home/). Interestingly, when querying these datasets, 
rs28834970 was reported to modify PTK2b gene expression in five tissues with the 
top hit in whole blood (P = 1.2 x 10-16), but not in brain, whilst rs9381562 was an eQTL 
in 26 human tissues, including 6 brain regions, the majority of which correlated with 
an alteration in expression of RP11-385F7.1. As these analyses were carried out in 
bulk tissue, it is not possible to assess how individual cell types contribute to the eQTL 
signal. Proportionally, microglia constitute 0.5-16% of the total glial population in the 
brain depending on the brain region considered (136), so it is likely that microglial 
specific eQTL signals are modified in bulk brain studies by competing or 
complimentary signals deriving from other brain cell-types. As such, there is a need 
for single cell eQTL studies which focus on individual cell types of the brain. At the 
time of writing, no microglial-specific eQTL analyses exist in the literature. 
 
 
5.4.2 Concluding remarks 
 
Using EMSA, I have investigated the functional consequences of two LOAD 
associated polymorphisms and shown that DNA-protein interactions associated with 
rs9381562 and rs22834970 are impacted in an allele-specific manner. This adds to 
the growing body of evidence that LOAD associated variants have functional 
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relevance in microglial cell lines, and that microglial dysfunction contributes to LOAD 
risk.  
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6 General Discussion 
 
The primary aim of my thesis was to investigate whether gene regulatory processes 
in human microglia contribute to genetic risk for complex brain disorders. With this in 
mind, I was seeking to answer several questions (A) Could common variant 
associations with complex brain disorders be attributed to gene regulatory 
mechanisms in a specific cell type of the brain (i.e. microglia)? (B) If so, does the 
developmental time point at which primary microglia were isolated have an impact on 
this risk attribution? (C) If cell-specific gene regulatory mechanisms are impacted by 
brain disorder common risk variants, is it possible to discriminate causal, from 
associated, SNPs and identify genuine molecular perturbations that are caused by 
allelic variation? (D) Could microglial human-derived cell models recapitulate the 
open chromatin landscape of primary microglia? 
 
In chapter 2, using stratified linkage disequilibrium regression analysis, I tested 
whether human adult ex vivo microglia open chromatin regions (OCRs) were enriched 
for SNP heritability associated with 7 complex brain disorders. I then repeated this 
test using adult neuronal OCRs derived from the ventrolateral pre-frontal cortex to 
test whether brain disorder SNP heritability was generic across two brain cell types 
or could be attributed more specifically to microglia. Of the 7 disorders tested, adult 
microglia OCRs were enriched for LOAD SNP heritability, capturing >50% of the total 
common variant component of the disorder, whilst adult neuronal OCRs were not 
significantly enriched. These data imply that LOAD-associated common variants 
operate in adult microglial OCRs and that a proportion the LOAD risk signal is 
mediated by immune cells. Due to the extensive overlap of the chromatin, and gene 
expression, profiles of microglia and peripheral myeloid cells (251) it was not possible 
to definitively rule out the involvement of peripheral immune cells, or to rule out 
involvement of other brain cell types, in LOAD common variant risk. Further evidence 
implicating microglial function in LOAD genetic risk was provided in chapter 4, when, 
using GARFIELD, I tested adult ex vivo microglial OCRs for enrichment of SNPs at 
two GWAS significance thresholds. Similar to the sLDSC analysis, LOAD-associated 
SNPs that were significant at the P < 1 x 10-5 threshold were enriched in adult MG 
OCRs, suggesting that the LOAD SNP enrichment signal is robust as it is replicable 
using independent statistical methodologies. Overall, these data indicate that 
substantial proportion of common variant risk for LOAD operates via gene regulatory 
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processes in adult microglia. These data are therefore consistent with other recent 
epigenomic studies supporting a primary role for microglia in this disease (367,368).   
 
Having demonstrated that microglial-specific regulatory regions were implicated in 
LOAD common variant risk I next explored whether it was possible to partition LOAD 
SNP heritability further and test if it colocalised within OCRs containing specific 
transcription factor (TF) motifs. In chapter 2.3.4, by showing that LOAD SNP 
heritability was localised in OCRs containing motifs of key regulators of cell identity 
(SPI1, RUNX1 and C/EBP; 143,145,282,362), this strongly implies that immune cell-
specific regulatory networks mediate LOAD common variant risk.  
 
Pioneer factors such as PU.1 (encoded by SPI1) and CEBP-a, have been shown to 
act in collaboration to establish a core suite of myeloid cell enhancers, and their 
associated histone modifications, in macrophages (255,370). It is hypothesised that 
macrophages differentially activate specific subsets of these core enhancers in a 
tissue- and context- specific manner and that this is driven by environmental signals. 
These signals activate signal-dependant transcription factors which, in turn, interact 
with pioneer factors at selected enhancers to modulate gene expression. In microglia, 
TGFb signalling and the transcription factor SMAD3 contribute to microglial-specific 
enhancer selection (139). Establishing whether there are brain-specific microglia 
enhancer patterns will be important to assess whether microglia-specific enhancers 
are uniquely enriched for LOAD risk SNPs. As such, it will be necessary to integrate 
open chromatin data with ChIP-seq data to determine whether core enhancers in 
microglia are inactive, active or poised (368). However, given that microglial 
chromatin features are likely to be altered by context-specific stimuli, functional data 
obtained from microglia in specific activation states and/or from specific brain regions 
is required to explore this fully. With regard to the cooperative binding of PU.1 or 
CEBP-a, it has been reported that mutations within the motifs of either of these factors 
result in the loss of binding of both transcription factors indicating that pioneer factor 
collaboration is critical for enhancer selection (370). Therefore, LOAD risk variants 
altering the DNA template in microglia OCRs containing these key factors, as 
reported here, have the potential to directly, and/or indirectly, disrupt the binding of 
pioneer factors and signal dependent transcription factors (370). As, SPI1 has been 
identified as a LOAD risk gene these data provide further evidence of this gene’s 
involvement in the disorder (208).  
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The purpose in annotating the genome for integration with GWAS data is to identify 
and prioritise the cell-types, regulatory processes and risk variants that drive the 
pathophysiology of brain disorders. Having shown that LOAD risk variants plausibly 
operate in microglial regulatory regions I next attempted to identify putatively causal 
LOAD risk SNPs, that overlapped microglial OCRs, to assess how these variants 
impacted transcription factor binding at the molecular level. As described in chapter 
5, I prioritised 2 LOAD risk SNPs (rs9381562 and rs28834970) that overlapped adult 
ex vivo microglial open chromatin sites for molecular analysis based on allele-specific 
disruption of transcription factor binding potential at these loci. Using electrophoresis 
mobility shift assays (EMSAs), I demonstrated that DNA-protein binding was 
disrupted in an allele-specific manner at both loci, and that allele-specific effects at 
these loci resulted in >50% differences in DNA-protein binding (see table 5.4). These 
data demonstrate the benefit in functionally annotating GWAS data before 
experimental interrogation. When analysed separately, GWAS and chromatin 
accessibility data provide a holistic view of individual aspects of the genome (i.e. 
genomic loci that are implicated in brain disorder risk or regions that are involved in 
cell-specific gene regulation, respectively). In isolation these data are informative; 
however, when these datasets were combined, it was possible to focus global 
measures of LOAD risk to implicate specific cell types and specific molecular 
processes in risk burden.  
 
Having measured enrichment of common risk variants in adult microglial regulatory 
regions, I next explored whether foetal microglial regulatory sites were similarly 
enriched (see chapter 4.3.3). Of the 8 traits tested, bipolar disorder (BPD) and 
schizophrenia (SCZ) associated SNPs (at the P < 1 x10-5 GWAS threshold) were 
enriched in foetal microglial OCRs. Interestingly, it has been widely reported that 
there is significant genetic (and neurobiological) comorbidity between BPD and SCZ 
(371–375), so although additional work would be required to assess whether similar 
regulatory process were perturbed by disease-specific risk SNPs in foetal microglia, 
these data suggest that mechanisms underlying genetic risk for both disorders may 
operate in microglia during pre-natal neurodevelopment. It has long been theorised 
that schizophrenia has a neurodevelopmental component (2–5,376). However, as the 
GARFIELD analysis of brain disorder GWAS SNP enrichment in adult ex vivo 
microglia demonstrated (see chapter 4.3.5) that SCZ and BPD risk SNPs were also 
enriched in adult microglia, this implies that these variants have the potential to impact 
microglial function throughout life. An intriguing hypotheses that could explain these 
findings with regard to schizophrenia, is the ‘2-hit’ model which proposes that 
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schizophrenia symptoms are caused by two brain insults occurring during discrete 
critical periods of vulnerability (before birth and during adolescence when extensive 
neuronal rewiring is occurring; 4,368,369). In this model, abnormal neuronal growth 
is hypothesised to occur in specific neuronal networks before birth that elicit the 
premorbid cognitive deficits seen in pre-psychotic individuals. Then, during the brain 
maturation process in adolescence, excessive synaptic elimination occurs and this 
interacts cumulatively with the mechanisms perturbed earlier in life to induce 
psychosis. As microglia are involved in both in promoting neuronal growth and 
synapse elimination (379,380), it is possible that genetic perturbations to microglial 
gene regulatory processes during key periods of vulnerability could increase liability 
to this condition.  
 
Given the need for reliable human cell models of microglia for brain disorder research, 
it is important to confirm how well in vitro cell lines recapitulate the regulatory profile 
of primary, or in vivo, cells. In chapter 3, I reported that iPSC-derived microglia 
(iPSC_MG) and iPSC-derived macrophage precursor (IPSC_MΩpre) OCRs were 
enriched for motifs recognised by the myeloid-specific transcription factors Spi1, 
C/EBP-a and IRF8 (144,146,285,369). As these were similar to the motifs found to 
be enriched in adult ex vivo microglial OCRs (see section 2.3.1), these results 
indicated that both iPSC lines had a myeloid-like transcription factor motif profile that 
was similar to adult ex vivo microglia. However, it was not possible to distinguish 
between the iPSC lines using this measure. In the principal component analysis 
(PCA; see figure 3.2) the distinctive separation of myeloid and lymphoid cells at 0.0 
on the y-axis, suggested that the open chromatin landscapes of all in vitro cell lines 
were myeloid-like. However, as the iPSC line samples were clustered more closely 
with samples from blood monocytes than adult ex vivo microglia on PC2, this implied 
that the addition of IL-34 during the final stage of iPSC differentiation protocol was 
not sufficient to skew the chromatin landscape of iPSC_MΩpres toward that of adult 
ex vivo microglia. Interestingly, when adding the foetal microglial ATAC-seq data to 
the PCA (see figure 4.3), samples from both iPSC lines clustered more closely with 
the foetal microglial samples on PC2 than samples from either adult ex vivo microglia 
or the peripheral blood monocytes. Relating chromatin features in iPSC-derived 
microglia to that of primary foetal cells may be a better means of assessing how well 
the chromatin landscape of the iPSC lines recapitulate the in vivo state than using 
primary adult cells. Indeed, all groups that have produced iPSC-derived microglial 
protocols recently use gene expression in human foetal microglia as their gold 
standard (268,277–279,295). However, regardless of the primary cell type used, 
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these data imply that there is no clear global distinction in the chromatin profile 
between the iPSC_MΩpres and the iPSC_MG, at least sufficient enough to claim that 
the IPSC_MG are more ‘microglial-like' than the iPSC_MΩpre.   
 
The generation of iPSC-derived microglia is still a relatively new methodology and 
there is, as yet, no standardised protocol for this procedure. For example, in 2017, 4 
groups released bespoke protocols that used differing cell seeds (embryonic stem 
cells and or iPSCs), surface markers for cell isolation, differentiation factors and 
incubation periods to generate microglia-like cells. As such, it is necessary to 
thoroughly validate these methods and determine which, if any, most reliably models 
the in vivo state (as it is unlikely that multiple methods will be sustainable due to 
potential confounds that arise when comparing results using alternate approaches). 
Although the use of iPSC-derived microglia for brain disorder research does provide 
enticing benefits when compared to using primary microglia (i.e. they are accessible, 
abundant, easy to produce and can be patient-derived), several key issues have still 
to be addressed before they are widely accepted as an appropriate model. For 
example, it is not yet known how to maintain an in vivo like gene expression signature 
in cultured cells (265,266,280,381). Some progress has been made which has 
informed iPSC protocols recently; for example, it has been reported that the 
application of CSF1 and TGFb partially rescues the in vivo gene expression signature 
of microglia in vitro (382), but full recapitulation has yet to be realised. Moreover, as 
iPSC-derived microglia are created in vitro, and have never been exposed to the brain 
microenvironment, it is unclear whether they can ever fully recapitulate the 
phenotype/s of microglia in vivo (270). Questions remain about whether the 
ontological derivation of microglia intrinsically impacts the range of functions that fully 
differentiated cells are capable of (266,383) and whether iPSC protocols that mimic 
mouse microglial differentiation apply to human microglial development (268). On a 
positive note, it has been shown that when ex vivo microglia placed (and manipulated) 
in culture are reintroduced to the brain they swiftly regain their homeostatic in vivo 
gene expression profile (236,266). This has promising implications for microglial cell-
based therapy as it suggests that ex vivo (and potentially patient-derived iPSC) 
microglia can be cultured, modified and transplanted, and that the brain is already 
equipped to rescue the microglial phenotype. However, the success of such therapies 
will be predicated on identifying the differentiation factors that are required to fully 
induce homeostatic microglial phenotypes in culture. If a reliable iPSC-derived 
microglial model can be obtained, it’s use in combination with functional data such as 
that presented here (i.e. the identification of a functional GWAS risk SNP in a 
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microglial specific OCR) paves the way for accurate modelling of molecular risk 
mechanisms in vitro using gene editing techniques such as CRISPR (363,364).  
 
It is an exciting time for brain disorder research as advances in single cell analyses 
make it possible to discriminate between individual cell types of the brain, including 
heterogeneous cellular subtypes that may have distinct transcriptomic and 
epigenomic profiles in discrete brain regions (384,385). Indeed, microglia 
heterogeneity, and any relevance this has to health and disease, is a current interest 
in the field. Brain region dependent differences have been reported in microglia 
morphology (386), density (386) gene expression (387) and cell surface marker 
density (388) that are perhaps indicative of non-uniform brain microenvironments in 
which each distinct cell population resides (387). Measures of microglia longevity and 
turnover have also been reported as brain region dependent (389). In a recent 
microglial single cell analysis comparing the RNA-seq profile of cells extracted from 
3 brain regions (dorsolateral pre-frontal cortex, hippocampus and temporal cortex) in 
15 individuals, 14 microglial clusters were identified which showed differential 
expression of homeostatic, proliferative and interferon response genes (390). 
Microglia have also been reported as being sexually dysmorphic with morphological, 
functional and brain region dependant microglial sex differences being reported in 
mice (391). This has led to speculation that sex-specific microglial dysfunction may 
explain the sexual dimorphism seen in brain disorders such as LOAD and ASD 
(202,392). The identification of niche populations of microglia leads to important 
questions regarding their role in the aetiology of complex brain disorders. For 
example, in Alzheimer’s disease, where pathology develops in the hippocampus 
before spreading more widely in the brain, do specific populations of hippocampal 
microglia have unique vulnerabilities which influence disease onset and progression 
(393)? The role that specific populations of microglia have in the brain, and how this 
relates to complex brain disorders, is still an open question.  
 
Another interesting aspect of microglial biology which may impact the aetiologies of 
complex brain disorders is the role of systemic immune processes that influence 
microglial phenotype. For example, acute and chronic systemic infections, as indexed 
by a serum increase in the proinflammatory cytokine tumour necrosis factor a, have 
been reported to cause a 2-10 fold rate of increase of cognitive decline in patients 
with LOAD respectively (394). It is proposed that this process is driven by a 
phenomenon called microglial ‘priming’ where, after an initial immune insult, long-
term epigenetic changes occur in microglia which make them more sensitive, and 
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react more aggressively, to a second immune insult (395,396). Primed microglia 
upregulate genes associated with increased phagocytosis, antigen presentation and 
lysosomal activity (397) and several processes have been reported to induce 
microglial priming in humans such as aging, stress, amyloid-b protein aggregates and 
degenerating neurons (the latter due to the loss of neuronal ligands that inhibit 
microglial activation; 384). In LOAD it is hypothesised that either progressive increase 
of Amyloid-b, degenerating neurons or local ischaemia leads to microglia becoming 
permanently primed such that they swiftly become fully activated during a systemic 
infection thereby contributing to the progression of LOAD through increased 
production of reactive oxygen species (398,399). Indeed as chronic systemic 
disorders with a proinflammatory phenotype such as heart disease (400), obesity 
(401) and diabetes (402) are risk factors for LOAD, some investigators propose that 
culminative insults affecting primed microglia over time may be a causative factor in 
LOAD (394,403).  
 
While epigenomic methods such as ATAC-Seq can be exploited to better understand 
the cellular basis of complex traits, it does not necessarily indicate which genes are 
functionally impacted by risk variation and how they are altered. In recent years, 
chromosome conformation capture (3C) -based methods have been developed in 
order to map distal interactions between enhancers and their regulated genes 
(404,405). Moreover, with sufficient sample sizes, it is possible to perform expression 
quantitative trait loci (eQTL) mapping studies, which identify genetic effects on gene 
expression on a genome-wide scale. While current eQTL studies are typically carried 
out in bulk tissue, it will be necessary for future investigations to focus on discrete cell 
populations, including microglia.    
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8 Appendix 
 
8.1 Garfield SNP enrichment tests 
 
 
 
 
 
 
 
 
 
GWAS GWAS Thresh OR p-value cor. p-value Beta SE CI95_L CI95_U No. Annot Thesh N. Annot N. Thresh No. of SNPs
ADHD 1 x 10-5 1.02 0.975 1.000 0.018 0.593 -1.144 1.181 5 2,816 138 233,701
ADHD 1 x 10-8 7.67 x 10-8 0.998 1.000 -16.384 5872 -11525 11492 0 2,816 4 233,701
AUTISM 1 x 10-5 2.26 0.175 1.000 0.817 0.602 -0.363 1.998 3 3,330 103 357,689
AUTISM 1 x 10-8 1.07 x 10 -6 0.997 1.000 -13.745 4108 -8066 8039 0 3,330 1 357,689
BPD 1 x 10-5 1.35 0.415 1.000 0.299 0.367 -0.420 1.018 8 9,942 227 1,191,616
BPD 1 x 10-8 1.07 x 10-7 0.996 1.000 -16.052 2973 -5844 5812 0 9,942 8 1,191,616
LOAD 1 x 10-5 2.71 0.014 0.224 0.996 0.403 0.206 1.786 7 3,400 113 262,885
LOAD 1 x 10-8 1.81 0.423 1.000 0.592 0.739 -0.856 2.040 2 3,400 43 262,885
MDD 1 x 10-5 1.55 0.345 1.000 0.438 0.464 -0.471 1.347 5 9,708 159 1,157,454
MDD 1 x 10-8 2.51 0.392 1.000 0.921 1.077 -1.190 3.033 1 9,708 8 1,157,454
NEUROTICISM 1 x 10-5 1.18 0.445 1.000 0.169 0.221 -0.264 0.602 26 9,336 697 907,858
NEUROTICISM 1 x 10-8 0.65 0.554 1.000 -0.426 0.721 -1.839 0.986 3 9,336 84 907,858
SCZ 1 x 10-5 1.45 0.031 0.488 0.374 0.173 0.035 0.714 40 3,305 1,042 317,182
SCZ 1 x 10-8 1.73 0.085 1.000 0.547 0.318 -0.075 1.170 13 3,305 232 317,182
WGL 1 x 10-5 1.53 0.675 1.000 0.428 1.021 -1.574 2.429 1 6,197 68 891,538
WGL 1 x 10-8 7.20 x 10-7 0.997 1.000 -14.144 3630 -7129 7100 0 6,197 2 891,538
Garfield Results - Psych GWAS vs.ENCODE ESOPHAGUS Reg. Regions (foetal bulk ext/evo conserved)
   Table 8.1. Enrichment of brain disorder GWAS SNPs in conserved ENCODE esophageal bulk cell open chromatin regions 
GWAS Thresh (GWAS significance threshold); OR (Odds ratio); p-value (emprical p-value of the significance of the observed enrichment); cor. p-value (p-value Bonferroni corrected for 16 tests); Beta (effect size from the general 
linear model, equal to log(OR)); SE (standard error from generalised linear model); CI95_L (lower boundary for the 95% CI of the effect size/beta); CI95_U (upper boundary for the 95% CI of the effect size/beta);  No. Annot. Thresh 
(number of annotated variants within annotation passing GWAS thresh); N.Annot (number of variants within given annotation); N.Thresh (number of variants passing GWAS thresh); No. of SNPs (total number of LD pruned 
variants). ADHD (Attention deficit hyperactvity disorder); ASD (Autism spectrum disorder); BPD (Bipolar disorder); LOAD (Late onset Alzheimer's disorder); MDD (Major depressive disorder); SCZ (Schizophrenia); WGL (Wearer of 
glasses or contact lenses).
GWAS GWAS Thresh OR p-value cor. p-value Beta SE CI95_L CI95_U No. Annot Thesh N. Annot N. Thresh No. of SNPs
ADHD 1 x 10-5 0.92 0.908 1.000 -0.083 0.719 -1.494 1.328 5 2,159 138 233,701
ADHD 1 x 10-8 8.13 x 10-8 0.998 1.000 -16.325 6786 -13318 13285 0 2,159 4 233,701
AUTISM 1 x 10-5 1.01 0.996 1.000 0.006 1.014 -1.983 1.994 1 2,461 103 357,689
AUTISM 1 x 10-8 7.86 x 10-7 0.998 1.000 -14.056 4800 -9422 9394 0 2,461 1 357,689
BPD 1 x 10-5 1.11 0.810 1.000 0.110 0.458 -0.787 1.007 5 7,417 227 1,191,616
BPD 1 x 10-8 1.11 x 10-7 0.996 1.000 -16.015 3476 -6829 6797 0 7,417 8 1,191,616
LOAD 1 x 10-5 1.94 0.202 1.000 0.663 0.519 -0.354 1.679 4 2,667 113 262,885
LOAD 1 x 10-8 6.40 x 10-8 0.995 1.000 -16.564 2516 -4949 4916 0 2,667 43 262,885
MDD 1 x 10-5 1.21 0.750 1.000 0.188 0.59 -0.969 1.344 3 7,241 159 1,157,454
MDD 1 x 10-8 9.54 x 10-8 0.996 1.000 -16.165 3445 -6768 6736 0 7,241 8 1,157,454
NEUROTICISM 1 x 10-5 1.08 0.779 1.000 0.074 0.265 -0.445 0.594 17 7,085 697 907,858
NEUROTICISM 1 x 10-8 1.87 0.230 1.000 0.624 0.519 -0.394 1.641 5 7,085 84 907,858
SCZ 1 x 10-5 1.90 2.97 x 10-5 4.75 x 10-4 0.644 0.178 0.295 0.994 40 2,527 1,042 317182
SCZ 1 x 10-8 3.16 5.80 x 10-5 9.28 x 10-4 1.150 0.286 0.589 1.710 16 2,527 232 317,182
WGL 1 x 10-5 3.71 x 10-6 0.978 1.000 -12.503 443 -881 856 0 4,595 68 891,538
WGL 1 x 10-8 6.32 x 10-7 0.997 1.000 -14.274 4261 -8366 8338 0 4,595 2 891,538
Garfield Results - Psych GWAS vs. ENCODE Colon Reg. Regions (bulk ext/evo conserved)
   Table 8.2. Enrichment of brain disorder GWAS SNPs in conserved ENCODE colon bulk cell chromatin regions 
GWAS Thresh (GWAS significance threshold); OR (Odds ratio); p-value (emprical p-value of the significance of the observed enrichment); cor. p-value (p-value Bonferroni corrected for 16 tests); Beta (effect size from the general 
linear model, equal to log(OR)); SE (standard error from generalised linear model); CI95_L (lower boundary for the 95% CI of the effect size/beta); CI95_U (upper boundary for the 95% CI of the effect size/beta);  No. Annot. Thresh 
(number of annotated variants within annotation passing GWAS thresh); N.Annot (number of variants within given annotation); N.Thresh (number of variants passing GWAS thresh); No. of SNPs (total number of LD pruned 
variants). ADHD (Attention deficit hyperactvity disorder); ASD (Autism spectrum disorder); BPD (Bipolar disorder); LOAD (Late onset Alzheimer's disorder); MDD (Major depressive disorder); SCZ (Schizophrenia); WGL (Wearer of 
glasses or contact lenses).
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GWAS GWAS Thresh OR p-value cor. p-value Beta SE CI95_L CI95_U No. Annot Thesh N. Annot N. Thresh No. of SNPs
ADHD 1 x 10-5 2.58 0.189 1.000 0.948 0.721 -0.466 2.362 2 768 138 233,701
ADHD 1 x 10-8 8.50 x10-8 0.999 1.000 -16.280 11208 -21984 21952 0 768 4 233,701
AUTISM 1 x 10-5 2.8 0.310 1.000 1.031 1.015 -0.959 3.020 1 880 103 357,689
AUTISM 1 x 10-8 1.70 x 10-6 0.999 1.000 -13.284 7832 -15363 15337 0 880 1 357,689
BPD 1 x 10-5 0.63 0.639 1.000 -0.471 1.005 -2.441 1.499 1 2,653 227 1,191,616
BPD 1 x 10-8 1.18 x 10-7 0.998 1.000 -15.946 5700 -11187 11155 0 2,653 8 1,191,616
LOAD 1 x 10-5 2.83 0.150 1.000 1.040 0.722 -0.375 2.455 2 862 113 262,885
LOAD 1 x 10-8 3.52 0.220 1.000 1.257 1.024 -0.750 3.264 1 862 43 262,885
MDD 1 x 10-5 3.69 x 10-6 0.970 1.000 -12.509 329 -658 633 0 2,543 159 1,157,454
MDD 1 x 10-8 9.27 x 10-8 0.998 1.000 -16.193 5705 -11197.713 11165.326 0 2,543 8 1,157,454
NEUROTICISM 1 x 10-5 1.42 0.362 1.000 0.350 0.385 -0.404 1.104 9 2,449 697 907,858
NEUROTICISM 1 x 10-8 1.13 x 10-8 0.998 1.000 -18.303 6357 -12478 12441 0 2449 84 907,858
SCZ 1 x 10-5 1.67 0.084 1.000 0.514 0.298 -0.070 1.097 14 917 1,042 317,182
SCZ 1 x 10-8 3.31 0.005 0.076 1.197 0.427 0.367 2.027 7 917 232 317,182
WGL 1 x 10-5 1.00 x 10-5 0.980 1.000 -11.510 463 -918 895 0 1,540 68 891,538
WGL 1 x 10-8 6.47 x 10-7 0.998 1.000 -14.251 7347 -14413 14385 0 1,540 2 891,538
Garfield Results - Psych GWAS vs. ENCODE Heart Reg. Regions (bulk ext/evo conserved)
   Table 8.3. Enrichment of brain disorder GWAS SNPs in conserved ENCODE heart bulk cell open chromatin regions 
GWAS Thresh (GWAS significance threshold); OR (Odds ratio); p-value (emprical p-value of the significance of the observed enrichment); cor. p-value (p-value Bonferroni corrected for 16 tests); Beta (effect size from the general 
linear model, equal to log(OR)); SE (standard error from generalised linear model); CI95_L (lower boundary for the 95% CI of the effect size/beta); CI95_U (upper boundary for the 95% CI of the effect size/beta);  No. Annot. Thresh 
(number of annotated variants within annotation passing GWAS thresh); N.Annot (number of variants within given annotation); N.Thresh (number of variants passing GWAS thresh); No. of SNPs (total number of LD pruned 
variants). ADHD (Attention deficit hyperactvity disorder); ASD (Autism spectrum disorder); BPD (Bipolar disorder); LOAD (Late onset Alzheimer's disorder); MDD (Major depressive disorder); SCZ (Schizophrenia); WGL (Wearer of 
glasses or contact lenses).
GWAS GWAS Thresh OR p-value cor. p-value Beta SE CI95_L CI95_U No. Annot Thesh N. Annot N. Thresh No. of SNPs
ADHD 1 x 10-5 5.48 x 10-8 0.996 1.000 -16.720 3664 -7198 7165 0 457 138 233,701
ADHD 1 x 10-8 7.54 x 10-8 0.999 1.000 -16.400 14616 -28665 28632 0 457 4 233,701
AUTISM 1 x 10-5 4.38 0.146 1.000 1.477 1.017 -0.516 3.470 1 553 103 357,689
AUTISM 1 x 10-8 1.55 x 10-6 0.999 1.000 -13.376 10050 -19713 19686 0 553 1 357,689
BPD 1 x 10-5 6.29 x 10-6 0.960 1.000 -11.976 236 -474 450 0 1,778 227 1,191,616
BPD 1 x 10-8 1.17 x 10-7 0.998 1.000 -15.959 7099 -13930 13898 0 1,778 8 1,191,616
LOAD 1 x 10-5 6.26 0.002 0.035 1.833 0.598 0.661 3.006 3 570 113 262,885
LOAD 1 x 10-8 5.93 x 10-8 0.998 1.000 -16.641 5440 -10680 10646 0 570 43 262,885
MDD 1 x 10-5 9.67 x 10-6 0.963 1.000 -11.543 2456 -493 470 0 1,730 159 1,157,454
MDD 1 x 10-8 8.72 x 10-8 0.998 1.000 -16.255 7060 -13853 13820 0 1,730 8 1,157,454
NEUROTICISM 1 x 10-5 1.12 0.821 1.000 0.114 0.506 -0.878 1.106 6 1,700 697 907,858
NEUROTICISM 1 x 10-8 1.78 0.569 1.000 0.576 1.011 -1.406 2.558 1 1,700 84 907,858
SCZ 1 x 10-5 1.57 0.245 1.000 0.450 0.387 -0.309 1.209 8 577 1,042 317,182
SCZ 1 x 10-8 2.63 0.101 1.000 0.968 0.590 -0.188 2.124 3 577 232 317,182
WGL 1 x 10-5 2.67 x 10-5 0.975 1.000 -10.530 336 -670 649 0 1,056 68 891,538
WGL 1 x 10-8 6.94 x 10-7 0.999 1.000 -14.181 8801 -17265 17237 0 1,056 2 891,538
Garfield Results - Psych GWAS vs. ENCODE Liver Reg. Regions (bulk ext/evo conserved)
   Table 8.4. Enrichment of brain disorder GWAS SNPs in conserved ENCODE liver bulk cell open chromatin regions 
GWAS Thresh (GWAS significance threshold); OR (Odds ratio); p-value (emprical p-value of the significance of the observed enrichment); cor. p-value (p-value Bonferroni corrected for 16 tests); Beta (effect size from the general 
linear model, equal to log(OR)); SE (standard error from generalised linear model); CI95_L (lower boundary for the 95% CI of the effect size/beta); CI95_U (upper boundary for the 95% CI of the effect size/beta);  No. Annot. 
Thresh (number of annotated variants within annotation passing GWAS thresh); N.Annot (number of variants within given annotation); N.Thresh (number of variants passing GWAS thresh); No. of SNPs (total number of LD 
pruned variants). ADHD (Attention deficit hyperactvity disorder); ASD (Autism spectrum disorder); BPD (Bipolar disorder); LOAD (Late onset Alzheimer's disorder); MDD (Major depressive disorder); SCZ (Schizophrenia); WGL 
(Wearer of glasses or contact lenses).
GWAS GWAS Thresh OR p-value cor. p-value Beta SE CI95_L CI95_U No. Annot Thesh N. Annot N. Thresh No. of SNPs
ADHD 1 x 10-5 5.10 x 10-8 0.999 1.000 -16.792 9928 -19476 19442 0 62 138 233,701
ADHD 1 x 10-8 6.27 x 10-8 1.000 1.000 -16.585 39128 -76709 76676 0 62 4 233,701
AUTISM 1 x 10-5 4.73 x10-5 0.982 1.000 -9.959 436 -865 845 0 88 103 357,689
AUTISM 1 x 10-8 0.387 1.000 1.000 -0.948 31137 -61030 61028 0 88 1 357,689
BPD 1 x 10-5 4.49 x 10-5 0.965 1.000 -10.011 225 -451 431 0 262 227 1,191,616
BPD 1 x 10-8 1.19 x 10-7 0.999 1.000 -15.947 18556 -36386 36354 0 262 8 1191616
LOAD 1 x 10-5 12.24 0.014 0.228 2.505 1.022 0.502 4.508 1 94 113 262,885
LOAD 1 x 10-8 5.48 0.999 1.000 -16.719 13653 -26776 26743 0 94 43 262,885
MDD 1 x 10-5 11.01 0.018 0.296 2.398 1.018 0.403 4.394 1 265 159 1,157,454
MDD 1 x 10-8 7.46 x 10-8 0.999 1.000 -16.412 18115 -35523 35490 0 265 8 1,157,454
NEUROTICISM 1 x 10-5 2.07 0.475 1.000 0.726 1.015 -1.264 2.715 1 241 697 907,858
NEUROTICISM 1 x 10-8 1.10 x 10-8 0.999 1.000 -18.326 20223 -39656 39619 0 241 84 907,858
SCZ 1 x 10-5 1.42 0.731 1.000 0.349 1.016 -1.641 2.340 1 100 1,042 317,182
SCZ 1 x 10-8 5.41 0.098 1.000 1.689 1.021 -0.312 3.690 1 100 232 317,182
WGL 1 x 10-5 7.82 x 10-5 0.986 1.000 -9.457 521 -1029 1010 0 165 68 891,538
WGL 1 x 10-8 6.51 x 10-7 0.999 1.000 -14.244 22364 -43848 43819 0 165 2 891,538
Garfield Results - Psych GWAS vs. ENCODE Stomach Reg. Regions (bulk ext/evo conserved)
   Table 8.5. Enrichment of brain disorder GWAS SNPs in conserved ENCODE stomach bulk cell open chromatin regions 
GWAS Thresh (GWAS significance threshold); OR (Odds ratio); p-value (emprical p-value of the significance of the observed enrichment); cor. p-value (p-value Bonferroni corrected for 16 tests); Beta (effect size from the general 
linear model, equal to log(OR)); SE (standard error from generalised linear model); CI95_L (lower boundary for the 95% CI of the effect size/beta); CI95_U (upper boundary for the 95% CI of the effect size/beta);  No. Annot. 
Thresh (number of annotated variants within annotation passing GWAS thresh); N.Annot (number of variants within given annotation); N.Thresh (number of variants passing GWAS thresh); No. of SNPs (total number of LD 
pruned variants). ADHD (Attention deficit hyperactvity disorder); ASD (Autism spectrum disorder); BPD (Bipolar disorder); LOAD (Late onset Alzheimer's disorder); MDD (Major depressive disorder); SCZ (Schizophrenia); WGL 
(Wearer of glasses or contact lenses).
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